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ABSTRACT 
 
The paralogous multi-functional adaptor proteins YAP and TAZ are nuclear effectors of 
the Hippo pathway, a central regulator of developmental organ size control, tissue 
homeostasis and tumour suppression. YAP/TAZ target the TEAD transcription factor 
family to promote cell survival and inhibit apoptosis. TEAD proteins contain a DNA-
binding domain and a YAP/TAZ interaction domain. PCR analysis of medaka fish 
TEAD cDNA revealed the presence of alternative TEAD splice-forms with variations at 
the C-terminus of the DNA-binding domain. Structural analysis indicated the YAP-
binding domain of TEAD proteins is folded and globular. NMR spectroscopy showed 
that the TEAD binding domain of YAP does not contain secondary structure. YAP and 
TAZ both contain WW domains, which are small protein-protein interaction modules. 
Two YAP isoforms are known, YAP1 and YAP2 that contain one and two WW 
domains, respectively. To date, only a single WW isoform of TAZ has been described. 
PCR analysis of medaka TAZ cDNA identified both single WW and tandem WW 
isoforms of TAZ. NMR spectroscopy was used to characterise structural, 
conformational, and peptide binding features of the tandem WW domains from YAP 
and TAZ. The YAP WW2 solution structure confirms that the domain has the canonical 
anti-parallel β-sheet WW fold. WW1 of YAP and both WW domains of TAZ undergo 
conformational exchange. The region linking the two WW domains is flexible and 
allows interaction of both WW domains with peptides containing single and dual PPxY 
binding motifs. In addition to YAP and TAZ, tandem WW domains are also present in 
the core and upstream Hippo pathway proteins Salvador and Kibra. Both proteins 
contain one atypical WW domain; the tandem WW domains of these two proteins are 
unstable. Understanding structure and function of Hippo pathway components could 
contribute to drug development and will also contribute to knowledge of protein folding 
and interactions. 
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ABBREVIATIONS 
(l) Long variant/construct 
(s) Short variant/construct 
APS Ammonium peroxodisulphate/persulphate 
cDNA Complementary DNA 
CK1 Casein kinase 1 
CKIP1 Casein kinase 2-interacting protein 1 
Crb Crumbs 
DBD DNA-binding domain  
Dco Discs overgrown  
DNA Deoxyribonucleic acid 
Ds Dachsous 
DSS 4,4-dimethyl-4-silapentane-1-sulfonic acid 
dSTRIPAK Drosophila Striatin-interacting phosphatase and kinase 
DTT Dithiothreitol 
Dvl Dishevelled 
EDTA Ethylenediaminetetraacetic acid 
EMT Epithelial to mesenchymal transition 
Ex Expanded 
FBP21 Formin-binding protein 21 
FRMD6 FERM domain-containing protein 6 
GST Glutathione-S-transferase 
HLH Helix-loop-helix 
Hpo Hippo  
HSQC Heteronuclear single quantum coherence (spectrum) 
IPTG Isopropyl-1-thio-ß-galactopyranoside 
LATS Large tumour suppressor  
LB Luria-Bertani bacterial growth medium 
Lft Low-fat 
Lgl Lethal giant larvae  
MAD Multi-wavelength anomalous dispersion 
Mats Mob as tumour suppressor 
Mer Merlin 
MIR Multiple isomorphous replacement  
MOB1 Mps1 binder 1  
Mps 1 Monopolar spindle-1 kinase 
	   iv	  
MST Mammalian Ste20-like kinase 
NLS Nuclear localisation signal  
NMR Nuclear magnetic resonance (spectroscopy) 
OPPF Oxford Protein Production Facility 
PATJ PALS1-associated tight junction protein 
PCR Polymerase chain reaction 
PDB Protein data bank 
PKC Protein kinase C 
PNK Polynucleotide kinase 
RASSF Ras-association domain family 
Rb Retinoblastoma 
RMSD Root mean squared deviation 
RNA Ribonucleic acid 
SAD Single-wavelength anomalous dispersion 
Sav Salvador 
SCRA Sveinssons’ chorioretinal atrophy 
Sd Scalloped 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
Shh Sonic hedgehog 
SIR Single isomorphous replacement 
Su(dx) Suppressor of deltex 
TAD Transactivation domain 
TAZ Transcriptional co-activator with PDZ binding motif 
TBD TEAD-binding domain 
TEA Transcription enhancer activation (domain) 
TEAD TEA domain containing transcription factor 
TEF Transcription enhancer factor 
TEMED N,N,N’,N’-Tetramethylenediamine 
TF Transcription factor 
Wts Warts 
WW Protein domain containing two conserved tryptophan residues 
YAP Yes-associated protein 
YBD YAP-binding domain  
Yki Yorkie 
ZO Zonula occludens proteins 
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CHAPTER 1: INTRODUCTION  
1.1 Introduction to this thesis 
The body of work contained in this thesis comprises cloning, expression, purification 
and biophysical characterisation of protein domains that are involved in the Hippo 
signalling pathway. The Hippo pathway plays a vital role in development, regulating 
cell growth and organ size. Disruption of the pathway often leads to malignant 
tumourigenesis. Dividing key proteins from the pathway into putative domains allows 
for structural characterisation using biophysical techniques such as nuclear magnetic 
resonance (NMR) spectroscopy and X-ray crystallography. Splitting proteins into 
smaller functional units also enables detailed analysis of protein-protein interactions.  
In this chapter the Hippo pathway will be introduced and the proteins that were 
studied described in more detail. Chapter 2 outlines the general materials and methods 
used throughout the project. The interaction domains of the nuclear effector of the 
Hippo pathway, YAP, and its target transcription factor, TEAD are described in Chapter 
3. The results presented in Chapter 4 were published in Biochemistry (Webb et al. 
2011); the work characterises the WW domains from YAP and its homologue TAZ, and 
the WW domains’ interactions with peptides containing the consensus binding-motif 
PPxY. Chapter 5 continues the thread of WW domains in the Hippo pathway, with 
NMR studies of tandem WW domains from the cytoplasmic proteins Salvador (Sav) 
and Kibra. The work is brought together in Chapter 6, a final discussion of the results 
and conclusions from the three preceding chapters. 
 
1.2 An introduction to Hippo pathway proteins 
1.2.1 Importance of the Hippo pathway 
The Hippo pathway has emerged over the last decade as a key player in organ size 
regulation during development and tissue homeostasis throughout adult life. The 
signalling pathway also, perhaps unsurprisingly, plays a role in tumour suppression. 
Hippo pathway components were identified through loss of function genetic screens in 
Drosophila melanogaster; the Hpo gene, after which the pathway has been called, was 
named for the mutant overgrown head phenotype that resembled hippopotamus hide 
(Udan et al. 2003) (Figure 1.1).  
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Figure 1.1. SEM images of (A) Hpo mutant with overgrown head phenotype and (B) wild type 
Drosophila heads. Arrows indicate the ocelli (eyes), which have developed normally. Image 
from Udan et al (2003). 
The pathway has been shown to regulate organ growth in a coordinated manner such 
that when the nuclear effector YAP was upregulated in studies involving mice, the 
overall size of the liver increased significantly (Figure 1.2). Furthermore, after 8 weeks 
of YAP over-expression, tumourigenesis was observed and by 12 weeks the liver was 
riddled with hepatocellular carcinoma (HCC) (Dong et al. 2007). Makoto Furutani-Seiki 
(University of Bath) has shown that YAP is essential for the proper formation of organs 
in development of Oryzias latipes (medaka fish) embryos. The hirame mutant medaka 
embryos contain a null YAP mutation, with a distinctive phenotype characterised by a 
flat body, flattened neural tube and collapsed epithelial organs (Figure 1.3). Mutations 
in Hippo pathway components have also been observed in clinical cancer cases as well 
as in vitro cell lines. Therefore this signalling pathway is of interest both for potential 
regenerative medicine and cancer therapy uses, as well as elucidation of developmental 
control mechanisms. 
 
Figure 1.2. Transgenic mouse livers after (A) no YAP over-expression; (B) 4 weeks, (C) 8 
weeks (with arrows indicating tumours) and (D) 12 weeks of YAP overexpression. Figure 
adapted from Dong et al (2007). 
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Figure 1.3 The YAP (hir) mutant vs wild-type medaka embryo phenotypes. (A, B) Lateral view 
of live embryos. (C, D) Frontal section of fixed embryos.  (A, C) Wild type and (B, D) mutant 
embryos. The neural tube and somites are flat and the dorsal aorta and intestine are missing in 
the YAP mutant medaka embryos. Image provided by Makoto Furutani-Seiki (University of 
Bath). 
 
1.2.2 Canonical Hippo pathway in Drosophila  
The canonical Hippo pathway (Figure 1.4) is initiated in response to cell contact and 
extracellular matrix-induced tension (Dupont et al. 2011) through as yet unidentified 
receptors. In Drosophila, the most upstream component identified is the large atypical 
cadherin Fat, which is located at the sub-apical region of the plasma membrane during 
Hippo pathway activation and is associated with Dachsous (Ds) on neighbouring cells. 
The subsequent cellular signalling from Fat to the core kinase cassette requires 
phosphorylation of Fat by Discs overgrown (Dco) and interaction of Fat with Low-fat 
(Lft) in order to inhibit Dachs, an atypical myosin that inactivates the core kinase Warts 
(Wts). Fat also appears to activate the protein Expanded (Ex), but the exact process of 
this signal transduction is currently unclear (Badouel et al. 2009; Kango-Singh et al. 
2009; Luo 2010; Sudol et al. 2010; Zhao et al. 2010; Zhao et al. 2010; Bao et al. 2011; 
Halder et al. 2011). 
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Figure 1.4 Representation of the Hippo pathway in Drosophila. Kinases and arrows that 
promote Hippo pathway activation are coloured orange; the core conserved Hippo kinase 
cascade is located within the orange box; proteins and arrows that inhibit the Hippo pathway are 
coloured in dark grey and black.  
 
Another upstream regulator is the Crumbs (Crb) complex that is also located in the 
sub-apical region of the cell membrane (reviewed in (Parsons et al. 2010)). Crb recruits 
Ex to the plasma membrane, Ex then associates with Merlin (Mer), and the interaction 
is stabilised by binding to Kibra. This complex then binds to the core Hippo pathway 
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components Hpo and Sav through multiple interactions (Ex-Hpo, Mer-Sav, Kibra-Sav) 
and activates the core kinase cascade. Hpo is a kinase that autophosphorylates it’s 
activation loop, then phosphorylates and forms an active complex with Sav. Hpo is then 
able to phosphorylate the kinase Wts and co-activator Mats (Mob as tumour 
suppressor). Wts subsequently phosphorylates the most downstream target of the Hippo 
pathway, Yorkie (Yki), at three sites, one of which enables 14-3-3 proteins to bind Yki 
and anchor it in the cytoplasm (Figure 1.4). When located in the nucleus Yki interacts 
with various transcription factors and acts as a transcriptional co-activator; therefore 
cytoplasmic sequestration renders Yki inactive (Badouel et al. 2009; Kango-Singh et al. 
2009; Luo 2010; Sudol et al. 2010; Zhao et al. 2010; Zhao et al. 2010; Bao et al. 2011; 
Halder et al. 2011). 
Inhibition of the Hippo pathway results in nuclear localisation of Yki, which enables 
Yki to co-activate the transcription factor Scalloped (Sd). Cell proliferation and survival 
genes are transcribed upon Yki-mediated activation of Sd. A negative feedback loop 
that leads to upregulated transcription of the Hippo pathway components Ex, Mer and 
Kibra is also initiated by Yki-Sd.  One known mechanism of Hippo pathway inhibition 
is the formation of a complex between the Drosophila Ras-association domain family 
protein dRASSF ( and Hpo, which competitively inhibits interactions between Hpo and 
Sav. dRASSF also associates with the phosphatase complex dSTRIPAK-PP2A that 
counteracts Hpo autophosphorylation (Ribeiro et al. 2010). dRASSF-mediated 
inhibition of the Hippo pathway appears to be under the control of atypical protein 
kinase C (aPKC) and Lethal giant larvae (Lgl) but the exact mechanism is not 
completely understood (reviewed in (Parsons et al. 2010)).  
 
 
1.2.3 Hippo pathway in vertebrates 
The downstream and core Hippo pathway proteins are conserved in vertebrates, 
though with more complexity (Figure 1.5). Many mammalian homologues of 
Drosophila Hippo pathway components have been shown to rescue mutant fly 
phenotypes providing evidence that the functionality of the pathway is conserved. The 
vertebrate orthologues of Sd are the Transcription enhancer activation domain (TEAD) 
transcription factors, TEAD1-TEAD4, which are also known as transcription enhancer 
factors (TEFs). The conserved TEA domain is a DNA binding region of around 70 
residues, which is described in detail in section 1.2.4. The vertebrate orthologues of Yki 
are Yes-associated protein (YAP) and Transcriptional co-activator with PDZ binding 
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motif (TAZ). YAP was first discovered through its interaction with the SH3 domain of 
the c-Yes Src tyrosine kinase (Sudol 1994); however the role of YAP in Yes-signalling 
has not been extensively studied since the identification of this interaction. YAP and 
TAZ are highly similar in structure and function but can play different functional roles 
depending on cellular circumstances.  
 
Figure 1.5 Representation of the Hippo pathway in vertebrates. Kinases and arrows that 
promote Hippo pathway activation are coloured orange; the core conserved Hippo kinase 
cascade is located within the orange box; proteins and arrows that inhibit the Hippo pathway are 
coloured in dark grey and black; proteins that contain WW domains are coloured or labelled in 
various shades of pink/purple. 
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The other vertebrate homologues of the Hippo pathway core kinase cassette are 
Mps1 (Monopolar spindle protein 1) binder-1 (MOB1) A and MOB1B (Mats in 
Drosophila), Large tumour suppressor (LATS) 1 and LATS2 (Wts in Drosophila), Sav1 
(Sav in Drosophila), and Mammalian Ste20-like kinase (MST) 1 and MST2 (Hpo in 
Drosophila). Phosphorylation of YAP by LATS occurs at five sites bearing the HxRxxS 
motif resulting in the inhibitory interaction with 14-3-3. In mammals the YAP-14-3-3 
complex is stabilised by α-catenin (Schlegelmilch et al. 2011). YAP phosphorylation by 
LATS can also lead to YAP degradation through CK1δ/ε mediated 
hyperphosphorylation and ubiquitination by the E3 ligase SCFβTRCP (Bao et al. 2011; 
Halder et al. 2011). 
Most of the upstream Drosophila Hippo pathway proteins also appear to have 
counterparts in vertebrates (Figure 1.4) but the functional transmission of signals is less 
clear than in Drosophila. Mammalian Kibra cannot bind the apparent Ex homologue 
FERM domain-containing protein 6 (FRMD6), though there is some speculation as to 
whether this protein is a true homologue due to structural and functional differences 
(Genevet et al. 2010). Kibra is however able to interact with vertebrate Mer (a.k.a. NF2) 
(Genevet et al. 2010), and in addition to this it can bind directly to the LATS kinases, 
thereby regulating YAP phosphorylation (Xiao et al. 2011). The effect of mammalian 
Mer on MST1 and MST2 (Hpo homologues) has yielded conflicting data and so is also 
unclear. Crumbs (Crb), Fat4 (Fat) and Dachsous1 (Ds) localise in cell membranes in a 
similar manner to their Drosophila counterparts but have not yet been shown to affect 
FRMD6 (Ex), and a Dachs substitute has not been found. CD44, which can interact 
with Mer, has been suggested as another membrane bound regulator of the mammalian 
Hippo pathway (reviewed in (Bao et al. 2011)). 
Mammalian PP2A antagonises the mammalian Hippo pathway by dephosphorylating 
YAP and acting in direct competition with the α-catenin-14-3-3 complex 
(Schlegelmilch et al. 2011). The relationship between MST (Hpo) and PP2A is more 
complex in mammals than in Drosophila. The mammalian MST seems to contribute to 
the stabilisation of PP2Ac rather than being inhibited by the phosphatase as occurs in 
Drosophila (Kilili et al. 2010). Mammalian RASSF proteins have been found to interact 
with MST, however the role of RASSF within the Hippo pathway is not clear (Avruch 
et al. 2011). Recently, other negative regulators of LATS have been elucidated, 
including the cilia-associated protein NPHP4 (Habbig et al. 2011) and the Ajuba LIM 
adaptor proteins (Das Thakur et al. 2010). The Drosophila counterpart of the Ajuba 
LIM proteins, djub, interacts genetically with the Hippo pathway. In addition to the 
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complexities regarding the function of upstream Hippo pathway components, several 
examples of crosstalk with other signalling pathways have been demonstrated (Table 
1.1). 
 
Table 1.1 Cross-talk between Hippo pathway proteins and other signalling pathways  
Effect of Hippo 
signalling   
Hippo pathway protein interaction 
The Hippo pathway 
inhibits Wnt/β-
catenin signalling    
(Varelas et al. 2010) 
Direct interaction of TAZ with Dvl2 inhibits phosphorylation 
of Dvl2 by CK1δ/ε thereby preventing formation of the β-
catenin destruction complex and resulting in β-catenin 
nuclear localisation and expression of Wnt target genes. 
Hippo pathway 
inhibits 
BMP/TGFβ  signallin
g (Alarcon et al. 2009; 
Varelas et al. 2010) 
Direct interaction of YAP with phospho-Smad1 and 
YAP/TAZ with phospho-Smad2/3 retains Smads in the 
nucleus and leads to transcription of TGFβ/Smad target 
genes. 
The Hippo pathway 
inhibits JAK/STAT 
signalling  
(Karpowicz et al. 
2010) 
Nuclear Yki induces transcription of cytokines that promote 
JAK/STAT signalling in response to injury. 
The Hippo pathway  
inhibits Notch 
signalling 
(Reddy et al. 2010) 
Active Yki inhibits the Notch ligand Delta which leads to 
Notch activation. 
Sonic hedgehog (Shh) 
signalling inhibits the 
Hippo pathway 
(Fernandez et al. 2009) 
Shh signalling up-regulates expression of YAP1 mRNA, and 
stabilises IRS1 (insulin receptor substrate 1) which acts as a 
nuclear retention factor for YAP. Shh signalling also results 
in decreased levels of phospho-LATS. 
The Hippo pathway 
promotes FoxO 
signalling  
(Choi et al. 2009) 
MST1 phosphorylates FoxO proteins leading to nuclear 
localisation and transcription of FoxO target genes. 
PI3 kinase 
(PI3K)/Akt signalling 
inhibits the Hippo 
pathway 
 (Yuan et al. 2010) 
Akt phosphorylates MST1 (at T120), thereby preventing the 
kinase activity of MST1. 
Retinoblastoma (Rb)  
(Nicolay et al. 2011; 
Tschop et al. 2011) 
The transcription factor E2F is negatively regulated by Rb. 
E2F interacts with the Yki-Sd complex; therefore Rb inhibits 
E2F-Yki-Sd mediated transcription. In humans, LATS 
phosphorylates DYRK (dual-specificity tyrosine 
phosphorylation-regulated kinases), which leads to activation 
of the ‘DREAM’ complex and inhibition of E2F.    
EGF-receptor 
signalling   
(Zhang et al. 2009) 
YAP mediates transcription of the EGF-R ligand 
amphiregulin, leading to proliferation and migration of 
neighbouring cells.  
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1.2.4 TEAD transcription factors (the nuclear targets of YAP/TAZ) 
The Hippo pathway monitors and controls the interaction of YAP and TEAD. The 
TEAD transcription factors are ubiquitously expressed, though each TEAD protein 
(TEAD1-TEAD4) occupies a slightly different niche with respect to tissue expression 
and developmental stage (Kaneko et al. 1997). TEADs induce transcription of genes 
that regulate cell proliferation, morphogenesis and differentiation, and so are crucial 
during development and tissue homeostasis (Chen et al. 2010). TEAD proteins have two 
discrete domains (Figure 1.6), the N-terminal DNA-binding domain (DBD) and the C-
terminal YAP-binding domain (YBD). YAP is more complex, with several domains 
that mediate protein-protein interactions (Figure 1.6). The TEAD-binding domain 
(TBD) is located at the N-terminus of YAP. This domain of YAP seems to bind TEAD 
with high fidelity; to date no other protein interactions have been found to occur in the 
region. 
 
 
Figure 1.6 Representation of TEAD and YAP protein domains. The domain and linker lengths 
are to relative scales. The DNA binding region of TEAD TFs (blue) is approx 65-70 residues; 
the YAP-TEAD interaction domains of TEAD and YAP (green) are around 230 and 50 residues 
respectively; the WW domains of YAP are approx 40 residues and the inter-WW linker is 
around 20 residues. LATS phosphorylation sites (HxRxxS) (Hao et al. 2008) are highlighted in 
orange. The SH3 binding motif (maroon) is phosphorylated by Tyr kinases such as c-Yes. 
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The nuclear localisation signal (NLS) within the DBD of TEAD is vital to the 
activity of the TEAD-YAP or TEAD-TAZ complex. Sd is known to transport Yki into 
the nucleus as Yki/YAP lacks a NLS (Goulev et al. 2008). TEADs were also found to 
be responsible for the nuclear transport and retention of the YAP paralogue TAZ (Chan 
et al. 2009). The TEAD DBD can bind to a variety of M-CAT-like DNA sequences (the 
M-CAT motif is 5′-TCATTCCT-3′) in a fairly promiscuous manner (Anbanandam et al. 
2006). M-CAT elements specifically bind TEF family proteins and are located in 
promoter-enhancer regions of various muscle-specific genes where they play important 
roles in muscle development (Yoshida 2008). There is no single mechanism of 
transcriptional activation by TEAD proteins; transcription is regulated by 
phosphorylation of TEAD, the presence of co-factors, interactions with other 
transcription factors and DNA binding proteins, accessibility of the M-CAT sequences 
to TEADs, and alternative splicing of TEFs (Yoshida 2008). 
The solution structure of the human TEAD1 (TEF-1) A49S mutant DBD (which is 
also known as the TEA domain) (Figure 1.7) comprises a three-helix bundle in a 
homeodomain-like fold (Anbanandam et al. 2006). The first two helices are almost anti-
parallel and the third helix lies across them both. The A49S mutation was made in the 
α1-helix (based on the Drosophila Sd DBD sequence) to improve solubility of the 
protein for use in NMR experiments. In a similar manner to homeodomain proteins, 
DNA binding is mediated by the third α-helix (H3) and the loop preceding it (L2); H1 
and L1 do not bind directly but are necessary for full strength binding of TEAD to 
tandem M-CAT sites (Anbanandam et al. 2006).  
YAP and TAZ are not the only nuclear co-factors of the TEAD transcription factors; 
gene specific transcription seems to be dependent on the interactions of TEAD with 
particular coactivators that presumably act to recruit the relevant transcriptional 
machinery. YAP and TEAD co-evolved, placing selection pressure on maintaining the 
interaction between the two proteins (Hilman et al. 2011). TEAD orthologues can be 
traced back to the ancient eukaryotic yeast Saccharomyces cerevisiae. YAP appeared 
later, the earliest example was found in the metazoan Trichoplax adherens; YAP was 
not identified in plants or yeasts (Hilman et al. 2011).  
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Figure 1.7 The TEAD1 A49S DNA-binding domain, with the N-terminus in blue and the C-
terminus in orange (PDB ID: 2HZD (Anbanandam et al. 2006)). The image was made using 
PyMol (MacPyMOL 2009-2010). 
 
The crystal structures of TEAD and YAP interaction domains from human TEAD2 
(Tian et al. 2010), human TEAD1-YAP (Li et al. 2010), and mouse TEAD4-YAP 
(Chen et al. 2010) were published in 2010.  The YAP-TEAD complex has been 
described as a hybrid transcription factor (Luo 2010) because individually the two 
proteins have no transcriptional activation capabilities. The Y421H mutation in TEAD1 
that is present in human Sveinsson’s chorioretinal atrophy (SCRA) was previously 
found to abrogate interactions with YAP and TAZ (Kitagawa 2007). As anticipated this 
residue is located in the TEAD-YAP interface where it forms a hydrogen bond with a 
Ser residue in YAP (S94 in human YAP, S79 in mouse YAP) (Fig 1.8e) (Chen et al. 
2010; Li et al. 2010).  
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Figure 1.8 Crystal structures of (A) human TEAD2 (YBD) (PDB ID: 3L15), (B) human 
TEAD1 (YBD)-YAP (TBD) (PDB ID: 3KYS), and (C) mouse TEAD4 (YBD)-YAP (TBD) 
(PDB ID: 3JUA). YAP fragments are shown in (B, D, E) blue and (C) red. (D) The essential 
TEAD-binding helices of YAP comprise a longer helix that fits into a binding pocket within 
TEAD and two short helices C-terminal to a flexible loop that wraps around TEAD. (E) An 
essential H-bond forms between S94 of YAP (yellow) and Y421 of TEAD1 (orange). The 
images were made using PyMol (MacPyMOL 2009-2010). 
The crystal structures of human TEAD2, human TEAD1-YAP and mouse TEAD4-
YAP (Figure 1.8) show that the YAP-binding domains (YBD) of the TEAD proteins 
adopt an immunoglobulin-like β-sandwich conformation with the addition of two helix-
turn-helix motifs. The TBD of YAP is natively unfolded but gains secondary structure 
upon interaction with TEAD (Fig. 1.8b,c). The TEAD structure is relatively unaffected 
by the interaction and YAP wraps around TEAD forming contacts in several places. 
The longer YAP peptide used in the human TEAD1-YAP structure (Fig. 1.8b) contains 
an N-terminal β-strand that is missing from the mouse TEAD 4-YAP structure; this 
strand does form contacts with TEAD but is not essential for the interaction. The 3 
helices present in both structures (Fig 1.8) are all necessary for the interaction.  
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1.2.5 The many faces of YAP and TAZ 
YAP and TAZ are multifaceted in both structure and function. The proteins are made 
up of modular domains that allow for interactions with many partners leading to a 
variety of, at times conflicting, functional roles. The modular structure of YAP is 
illustrated in Figure 1.6. TAZ is similar in structure to YAP, however TAZ lacks a 
proline rich region present at the N-terminus of human YAP and to date only a single 
WW domain isoform of TAZ has been described. The role of YAP/TAZ in cell 
proliferation was described in section 1.2.4, in addition to this function the proteins are 
also involved in epithelial to mesenchymal transition (EMT), differentiation, cell 
polarity, stem cell pluripotency, and apoptosis.  
Although YAP was shown to require TEAD for nuclear localisation, YAP and TAZ 
are also known to interact with various other transcription factors including the pro-
apoptotic p73 protein. In the case of p73, the PDZ binding motif at the C-terminus of 
YAP was shown to be essential for nuclear localisation and p73-YAP mediated 
transcription (Oka et al. 2009). Subsequent studies indicate this requirement is linked to 
interactions with the PDZ domain containing Zonula Occludens 1 and 2 (ZO) tight 
junction proteins (Oka et al. 2010; Remue et al. 2010). The PDZ-binding motif is also 
necessary for stabilising the YAP-p73 interaction (Oka et al. 2009). Although ZO 
proteins promote YAP-p73 activity, ZO2 was found to inhibit the transactivation 
activity of TAZ (Remue et al. 2010). This inhibition may be due to the formation of a 
ternary complex with an unidentified molecule.  
In addition to the PDZ binding motif, the WW domains of YAP/TAZ (described in 
section 1.2.6) are also indispensable for the interaction with the consensus PPxY 
sequence of p73. The WW domains also mediate many interactions between YAP/TAZ 
and other binding proteins (Table 1.2) including the upstream Hippo pathway 
components LATS, Ex and Crb. The two isoforms of YAP (YAP1 and YAP2) contain 
one and two WW domains, respectively. The functional differences between isoforms 
are not completely clear but the presence of the second WW domain does appear to 
enhance the interaction of LATS1, which contains two PPxY motifs, with YAP (Zhang 
et al. 2008) and TAZ (Lei et al. 2008).  
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Table 1.2 Binding partners of YAP and TAZ 
Binding 
protein 
Description of binding 
protein 
YAP/TAZ domain 
involved 
Reference 
HNRNPU Heterogenous nuclear 
ribonuclear protein U binds 
to YAP and p73 
Proline-rich region 
at N-terminus of 
YAP 
(Howell et al. 2004) 
TEAD Transcription factor TBD (Vassilev et al. 2001) 
14-3-3 Dimeric proteins that 
sequester YAP to the 
cytoplasm 
Phosphorylated 14-
3-3-binding motif 
(Kanai et al. 2000; Basu et 
al. 2003) 
Ex Upstream Hippo pathway 
FERM-domain protein 
WW domain (Badouel et al. 2009) 
LATS1/2 Hippo pathway Ser-kinase WW domains (Lei et al. 2008; Zhang et al. 
2008) 
p73 Pro-apoptotic transcription 
factor 
WW domain and 
PDZ-binding motif 
(Strano et al. 2001; Oka et 
al. 2009) 
WBP1/2 WW domain-binding 
proteins 
WW domain (Chen et al. 1995) 
ASPP1/2 
(p53BP) 
Apoptosis-stimulating 
protein of p53 protein family 
WW domain (Espanel et al. 2001; Liu et 
al. 2011) 
Runx1/2 Transcription factors with 
Runt DNA-binding domain 
WW domain (Yagi et al. 1999; Zaidi et 
al. 2004; Hong et al. 2005) 
Smad1/7 Transcription factors 
regulated by the TGFβ BMP 
signalling pathway 
WW domains (Ferrigno et al. 2002; 
Alarcon et al. 2009) 
ErbB4 Receptor Tyr-kinase that 
contains a cleavable 
cytoplasmic fragment 
WW domains (Komuro et al. 2003) 
Dvl2 Dishevelled polarity protein 
involved in Wnt signalling 
WW domain (Varelas et al. 2010) 
AMOT Angiomotin part of the 
Crumbs complex 
WW domains (Chan et al. 2011) 
PRGP2 Proline rich membrane Gla 
protein 
WW domain (Kulman et al. 2007) 
PEBP2 Polyoma enhancer binding 
protein 2 transcription factor 
WW domain (Yagi et al. 1999) 
NFE2 
(p45) 
Haemopoietic transcription 
factor-2 
WW domains (Gavva et al. 1997) 
c-Yes Tyr-kinase SH3-binding motif (Sudol et al. 1995) 
NHERF 
(EPB50) 
Recruits YAP and TAZ to 
plasma membrane 
PDZ-binding motif (Mohler et al. 1999; Kanai 
et al. 2000) 
ZO1/2 Zonula occludens tight 
junction proteins 
PDZ-binding motif (Oka et al. 2010; Remue et 
al. 2010) 
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It is tempting to conclude that the nuclear activity of YAP is wholly dictated within 
the cytoplasm. Just as cytoplasmic proteins negatively regulate YAP/TAZ by 
phosphorylation and sequestration, evidence suggests that YAP and TAZ are 
transported from the cytoplasm into the nucleus by the transcription factors and co-
factors that complete the active complexes. However, given the sheer number of 
identified (and potentially unidentified) binding partners of YAP/TAZ (some of which 
are in Table 1.2) the process is likely to be more complex. Therefore it is important to 
understand the structure of YAP/TAZ domains and how the domains behave during 
protein-protein interactions, both individually and together. 
 
1.2.6 WW domains within the Hippo pathway and beyond  
WW domains are the smallest known protein-protein interaction modules at around 
35-40 residues long and are so named because of two conserved tryptophans (Trp) 20-
22 residues apart. The domains also contain a conserved proline (Pro) two residues C-
terminal to the second Trp. WW domains typically fold into a twisted three-stranded β-
sheet. The first Trp is essential for domain folding and is located on the first β-strand 
within the hydrophobic core (Koepf et al. 1999). The second Trp contributes to ligand 
interactions and is located in the aromatic binding pocket. WW domains are categorised 
into five groups (I-V) according to their cognate ligand (Ball et al. 2005); all WW 
domains bind Pro-rich motifs (Table 1.3). 
 
Table 1.3 WW domain groups and binding motifs. Adapted from Ball et al (2005) 
Classification Consensus binding motif Example WW domain protein 
Group I PPxY YAP 
Group II PPLP FBP-11 
Group IIIa (p/φ)P(p/g)PPpR FE65 
Group IIIb (p/φ)PP(R/K)gpPp FBP-21 
Group IV (Sp/Tp)P PIN1 
Group V (p/φ)PPPPP PRP40 
x any residue; p residue is phosphorylated; lower case letters signify favoured but not 
conserved residues; φ hydrophobic residues. 
 
The Hippo pathway is rich in WW domains. YAP contains 1 or 2 WW domains that 
are used during interactions with many binding partners (Table 1.2) that contain 1 or 2 
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PPxY motifs. The upstream Hippo pathway proteins Sav and Kibra contain two WW 
domains each. ITCH E3 ubiquitin ligase, that was recently found to induce proteasomal 
degradation of LATS, also contains multiple WW domains (Salah et al. 2011). The 
functionality of WW domains extends far beyond the Hippo pathway. To date, almost 
100 WW domains and around 1900 PPxY motifs have been identified within the human 
proteome (Sudol et al. 2010). Several diseases have been attributed to aberrant WW 
domain function including Liddle’s syndrome (Nedd4-EnAC interaction) (Staub et al. 
1996), Alzheimer’s disease  (Pin1-Tau, FE65-APP) (Sudol et al. 2001), and Duchenne’s 
Muscular Dystrophy (dystrophin-β-dystroglycan-caveolin) (Ilsley et al. 2002). 
 
 
Figure 1.9 (A) Average solution structure of a YAP WW1 bound to a peptide (not shown) 
(PDB ID: 1K9R (Pires et al. 2001)). (B) Sequence of human YAP WW1 with locations of β-
strands illustrated with arrows. Residues shown in blue are involved in folding and stability; 
other residues that contribute to the hydrophobic core are shown in (A) grey or (B) underlined. 
Residues involved in peptide binding and binding specificity are highlighted in red.  
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The WW domain was first identified and characterised in YAP1 (previously known 
as YAP65) (Sudol 1994). Subsequently the solution structure of YAP WW1 in complex 
with the peptide GTPPPPYTVG was published (Macias et al. 1996); this structural 
characterisation also showed that an Ile N-terminal to the core WW domain was 
necessary to stabilise the fold (Figure 1.9). Since the structure of YAP WW1 was 
revealed as the first example of a WW domain fold, it has been the subject of several 
other structural studies. 
The previously mentioned property of stability being attributed to the first W and 
binding to the second W in WW domains was studied using YAP WW1 (Koepf et al. 
1999). Espanel and Sudol (1999) showed that mutating the Leu and His in the second β-
strand of the group I YAP WW1 domain to Trp and Ile switched the ligand binding 
preference of the domain to that of the group II WW domain-containing protein FE65. 
These residues (L and H in the β2 strand) are known to interact with the Y of the PPxY 
motif favoured by group I WW domains. Pires et al (2001) mutated residues of YAP 
WW1 that lead to formation of a more stable WW-PPxY complex. As observed in the 
group I to group II WW domain study, it was mutation of the β2 Leu (to Lys in this 
instance) that resulted in altered peptide-binding affinity. In the same study (Pires et al. 
2001) a minimal peptide ligand consisting of acetyl-PLPPY was identified. A molecular 
dynamics simulation study supported previous observations that YAP WW1 requires 
the unstructured regions N- and C- terminal to the core β-sheet to maintain the WW 
domain fold and that ligand binding further stabilises the structure (Ibragimova et al. 
1999). Figure 1.9 illustrates the WW domain fold of YAP WW1 and highlights the key 
residues involved in folding and binding. 
YAP WW1 was the first of many WW domains to be studied using NMR 
spectroscopy; each published WW domain solution structure contains the common 
three-stranded β-sheet fold, however not all WW domains are natively folded. For 
example the WW3-WW4 tandem WW repeat from the E3 ubiquitin ligase Nedd4 
family protein Suppressor of deltex (Su(dx)) is partially unfolded, and requires the 
interaction between WW3 and PPxY peptide to stabilise the structure of both WW3 and 
WW4 (Fedoroff et al. 2004). Another unusual feature of Su(dx) WW4 is a substitution 
of the second Trp by Phe (so it could be called a WF domain). The ‘WF’ domain of 
Su(dx) cannot bind the PPPY motif that was used in studies of YAP WW1 but is 
capable of binding the PPSY motif present in the Notch protein, though with a lower 
affinity than its typical WW counterparts (Jennings et al. 2007). The E3 ubiquitin ligase 
Smurf2 also contains a ‘WF’ domain (WW3). In the case of Smurf2, the ‘WF’ domain 
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can bind the PPPY motif of Smad7 but it also requires the presence of six residues C-
terminal to the motif that stabilise the complex through additional interactions with the 
WW domain (Chong et al. 2006). As was observed for Su(dx), the Trp to Phe 
substitution in Smurf2 reduces the binding affinity for cognate ligand in comparison to 
a typical WW domain.  
Tandem WW domains are common in Hippo pathway proteins (YAP, TAZ, Sav, 
Kibra, ITCH).  WW domain doublets from a range of other proteins have been 
characterised using NMR spectroscopy. Solution structures of peptide-bound Su(dx) 
WW3-WW4 (PDB ID: 1TK7) (Fedoroff et al. 2004) and unliganded FBP21 (PDB 
ID:2JXW) (Huang et al. 2009) reveal a lack of secondary structure in the inter-domain 
linker. Conversely the linker between WW domains in the yeast splicing factor Prp40 
forms a rigid α-helix that fixes the orientation of the WW domains (Wiesner et al. 
2002). The inter-domain linker is a key factor in the regulation of interaction specificity 
for the Smurf ubiquitin ligases. The linker length varies between different isoforms of 
Smurf1/2; the isoforms with shorter linkers have higher affinity with peptide ligand due 
to cooperation between WW domains (Chong et al. 2010). The solution structure of 
Smurf1 WW1-WW2 with phospho-Smad1 peptide reveals a linker consisting of helix-
turn-loop that allows for formation of a more stable ternary complex with CKIP1 
(casein-kinase 2-interacting protein 1) (Aragon et al. 2011). 
WW domains are key interaction modules within the Hippo pathway and beyond. 
Although many WW domains have been studied and despite their small size, the exact 
factors that determine folding and interactions are still not completely predictable. 
Tandem WW domains are common in the Hippo pathway and other important cell 
regulatory proteins, and each tandem WW domain to date exhibits different structural 
and functional characteristics. Therefore it is important to understand how the WW 
domain modules fold and function in proteins of the Hippo pathway for potential 
therapeutic modifications and drug targeting in the future. 
 
1.2.7 Salvador, the WW domain-containing core Hippo pathway protein 
Salvador (Sav/Sav1) was first identified in human and mouse in 2000 through an 
EST search for novel WW domain containing proteins; at that time the protein was 
named WW45 (Valverde 2000). As mentioned previously (Section 1.2.2 and 1.2.3), Sav 
is integral to the canonical Hippo pathway. It is a scaffold protein that contributes to 
multi-protein complex formation through its modular interaction domains. The N-
terminus of Sav is not predicted to contain structural elements, two WW domains are 
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present in the middle of the protein, and a coiled-coil region is located at the C-terminus 
(Figure 1.10). The coiled-coil region was later shown to be a novel interaction domain 
common to, and allowing complex formation between, Sav, Rassf and Hpo; it was thus 
called a SARAH domain (Scheel et al. 2003). The solution structure of the SARAH 
domain from human MST1 (Hpo) is in the PDB (2JO8), but the Sav SARAH domain 
remains undetermined. In addition to the defined domains within Sav, a nuclear 
localisation signal (NLS) sequence was identified N-terminal to the WW domains, and 
two endoplasmic reticulum membrane retention signals are present at either end of the 
protein. 
 
 
Figure 1.10 Representation of structured Sav domains. WW1 (pink) is a typical group 1 WW 
domain. WW2 (purple) is an atypical ‘WY’ type WW domain. The C-terminal SARAH domain 
is a coiled coil that can homo- or hetero-dimerise with the SARAH domains of RASSF and 
MST proteins. Inter-domain random coil regions are to relative scales in comparison to the 
structured domains; there is no inter-WW linker. 
 
The first WW domain of Sav belongs to the group I classification; the solution 
structure of mouse Sav WW1 is in the PDB (2YSB). The second WW domain of Sav is 
unusual in that Y replaces the second conserved W (a ‘WY’ domain). Mouse Sav WW2 
is also atypical because it exists as a homodimer in a β-clam like formation with the 
interface obscuring what would normally be considered as the ligand binding site 
(Ohnishi et al. 2007) (Figure 1.11b). Homodimerisation of WW2 may contribute to the 
role of Sav as a scaffold protein, allowing for the formation of larger protein complexes 
through interactions between Sav WW1-LATS and Sav SARAH-Rassf/Hpo SARAH. 
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Figure 1.11 Solution structures of mouse Sav  (A) dimeric WW2 (blue and purple to distinguish 
the monomers) (PDB ID: 2DWV) and (B) monomeric WW1 (magenta) (PDB ID: 2YSB). (A) 
The polar residues Glu and Ser that are located at the N- and C- termini, respectively, of the 
WW2 β1 strand contribute to the dimerisation and are shown in thick lines. The four aromatic 
residues (F,Y,H,Y) that also play a role in dimerisation are shown in thin lines. The equivalent 
residues in (B) WW1 to the Glu and Ser of WW2 (Ser and Thr) are shown in thick lines and 
only two equivalent aromatic residues are present in WW1 (thin lines). The images were made 
in PyMol (MacPyMOL 2009-2010). 
 
1.2.8 Kibra, the upstream WW domain Hippo pathway protein 
Kibra was first described in 2003 (Kremerskothen et al.), after being identified in a 
yeast two hybrid human brain cDNA library screen with a fragment of human Dendrin 
as bait. The protein was named for its predominant expression in kidney and brain. 
Kibra has a molecular weight of 125 kDa and comprises two WW domains at the N-
terminus, followed by a predicted unstructured region that contains a nuclear 
localisation signal, a C2 domain, Glu-rich region, PKCζ-binding domain and a C-
terminal PDZ-binding motif (Figure 1.12). 
Kibra has several known interaction partners outside of the Hippo pathway including 
PKCζ/PKMζ, Dendrin and Synaptopodin, all of which are involved in dendritic 
cytoskeleton organisation. Through these interactions Kibra appears to play a key role 
in cognitive function and memory. Kibra has also been linked to Alzheimer’s disease. 
Another known binding partner is PATJ (PALS1-associated tight junction protein). This 
protein is part of the Crumbs complex that is linked to the Hippo pathway in 
Drosophila, but is better known for regulating cell polarity and migration (reviewed in 
(Schneider et al. 2010)). 
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Figure 1.12 Representation of structured domains from Kibra. WW1 (pink) is a typical group 1 
WW domain and WW2 (purple) is an atypical ‘WY’ type WW domain; there is no inter-domain 
linker. The role of the C2 domain (orange) in the Hippo pathway is currently unknown. The C-
terminal region of Kibra is unstructured but contains a Glu-rich region (salmon pink), a PKCζ 
binding-motif (red) and a PDZ binding-motif (yellow). 
The C-terminal interaction regions consist of short sequence motifs without any 
predicted secondary structure. A crystal structure of the Kibra C2 domain is in the PDB 
(2Z0U) but has not been published as part of a peer reviewed article. C2 domains are 
involved in Ca2+-dependent phospholipid binding and are frequently associated with 
signalling molecules. The Kibra C2 domain is an 8 stranded β-sandwich (Figure 1.13) 
with a structure typical of these domains, one example of which is the first C2 domain 
of synaptotagmin (Sutton et al. 1995). Unlike synaptotagmin, however, the crystal 
structure of Kibra C2 does not contain a Ca2+ or any other metal ion. 
 
Figure 1.13 Crystal structure of the Kibra C2 domain (PDB ID: 2Z0U), the orange colour 
corresponds to the C2 domain representation in Figure 1.12. The image was made using PyMol 
(MacPyMOL 2009-2010). 
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No structural studies have been carried out on the WW domains of Kibra to date. The 
first WW domain of Kibra is predicted to be a typical group I WW domain. The second 
WW domain is unusual in that the second Trp is replaced with an Ile, and as might be 
expected given this substitution, WW2 is incapable of binding to peptides with the 
PPxY motif (Kremerskothen et al. 2003). The WW domains are of particular 
importance for the role of Kibra in the Hippo pathway. Upon deletion of the two WW 
domains the interaction of Kibra with LATS is abrogated, leaving LATS susceptible to 
ubiquitination and subsequent proteasomal degradation (Xiao et al. 2011). 
 
1.3 Aims 
The work described in this thesis is intended to resolve the structural features and 
protein-protein interaction properties of domains from five proteins within the Hippo 
pathway at the atomic level using NMR spectroscopy and X-ray crystallography. The 
key aims are to successfully clone target gene regions into suitable expression vectors 
for bacterial expression, purify sufficient quantities of homogeneous protein, prepare 
high quality protein samples, and produce structural and interaction data using NMR 
spectroscopy and X-ray crystallography. 
The proteins and domains that feature are the TEAD transcription factors (DBD, 
YBD), YAP (TBD, WW domains) and TAZ (WW domains), Sav (WW domains) and 
Kibra (WW domains). Through studying the structure and binding properties (function) 
of these protein domains, better understanding of protein folding in general will be 
gained. Also, structural properties of Hippo pathway components will be revealed that 
may contribute to therapeutic targeting and drug design in the future. 
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CHAPTER 2: GENERAL MATERIALS AND METHODS 
 
This chapter describes the materials and methods that were used throughout the 
project and are relevant to all subsequent results sections. Detailed experimental 
conditions for each construct will be described in the ‘Materials and Methods’ section 
of Chapters 3, 4 and 5 accordingly. 
 
2.1 Chemicals and reagents 
Where specific standard chemicals are not included in Table 2.1 it can be assumed 
that they were purchased from the company (listed next to ‘chemicals’) with the most 
competitive pricing. 
 
Table 2.1 Sources of reagents and chemicals 
REAGENT/ CHEMICAL COMPANY 
13C-labelled D-glucose 99 atom % Isotec 
15N-labelled NH4Cl Isotec 
2-mercaptoethanol Fluka 
2-propanol Sigma Aldrich 
40% 29:1 acrylamide/bis-acrylamide Fisher Scientific 
Agarose Melford 
Antibiotics (kanamycin, ampicillin, 
chloramphenicol) Melford 
Ammonium peroxodisulphate BDH/Sigma Aldrich 
Brilliant blue R250 Fisher Scientific 
Bromophenol blue BDH 
Chemicals (not otherwise mentioned) 
Melford/Sigma Aldrich/Fisher 
Scientific 
‘Complete mini protease inhibitor cocktail’ 
tablets Roche 
D-glucose BDH 
Deuterium oxide 99.9 atom % Goss Scientific Instruments 
Deoxynucleotide triphosphate set, PCR grade Roche 
DL Dithiothreitol Sigma Aldrich 
DNAse I Ambion 
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Ethylenediamine tetraacetic acid (EDTA) Fisher Scientific 
Ethidium bromide (10 mg/ml solution) Fisher Scientific 
Glycerol Fisher Scientific/Sigma Aldrich 
Glycine Sigma Aldich 
HRV 3C protease Novagen 
Imidazole Acros Organics 
Isopropyl-1-thio-ß-galactopyranoside (IPTG) Melford 
KOD Hot Start polymerase Novagen 
Luria Bertani Agar, Miller Fisher Scientific 
MEM Vitamin (100x) solution) Sigma Aldrich 
Miniprep kits Stratagene/Fermentas/Promega 
  
PBS tablets Oxoid 
PCR/Gel clean-up kits Stratagene/Fermentas/Promega 
PEG 4000 Fluka 
Phusion High-fidelity DNA polymerase NEB 
  
Primers MWG/Invitrogen 
Reduced glutathione Acros organics/BDH 
Restriction endonucleases (HF and Fast-digest) NEB 
Sodium citrate Melford 
Sodium dodecyl sulphate BDH 
Solvents (EtOH, MeOH, acetone) Fisher Scientific/Sigma Aldrich 
T4 DNA ligase NEB 
T4 PNK β NEB 
TaKaRa PCR kit  AMV 
Taq DNA Polymerase NEB 
N,N,N’,N’-Tetramethylenediamine (TEMED) Sigma Aldrich 
tris(hydroxymethyl)aminomethane (tris base) Melford 
Triton-X100 Fisher Scientific/Sigma Aldrich 
TRIzol® Invitrogen 
Trypsin from bovine pancreas Sigma Aldrich 
Tryptone Melford 
Yeast extract Melford 	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2.2 Plasmids, cell strains and media 
2.2.1 cDNA plasmids for use as PCR templates 
pBlueScript SK-. These vectors contain an ampicillin resistance gene and inserted 
sequences are under the regulation of the T7 promoter. Makoto Furutani-Seiki 
(University of Bath) was kind enough to provide EcoRV digested pBluescript SK- and a 
plasmid containing medaka K-Cab strain YAP cDNA. 
 
Sav cDNA. Nic Tapon (Cancer Research UK) kindly supplied Drosophila and human 
Salvador cDNA plasmids.  
 
Kibra cDNA. Human Kibra cDNA plasmids were a gift from Joachim 
Kremerskothen (Universität Münster). 	  
2.2.2 Expression plasmids 
Vanderbilt vectors (pSV…/pBG…) were supplied by Vanderbilt University 
Structural Biology Center; these plasmids are derived from pET vectors and are only for 
use in bacterial expression systems. The Oxford Protein Production Facility (OPPF), 
UK (Berrow, Alderton et al. 2007) supplied the pOPIN vectors; these vectors are 
designed for use in E. coli, insect and mammalian expression systems and are based on 
the pTriEX2TM vectors (Novagen). Initially Vanderbilt vectors were used as they have 
been tried and tested within the group and are known to produce high protein yields 
under optimal conditions. The TEAD protein constructs (and YAP TBD) were largely 
insoluble when produced by the Vanderbilt vectors. Various protein domains were re-
cloned into the pOPIN vectors with the intention of testing expression in bacterial, 
insect, and if necessary mammalian cell lines in attempts to improve the protein 
solubility. The Vanderbilt plasmid maps are in Appendix I-f and pOPIN vector details 
are in Appendix I-g. 
 
pSV281 (Vanderbilt University Structural Biology Center). This plasmid contains a 
TEV protease cleavable N-terminal 6His-tag, a kanamycin resistance gene and is under 
the control of the T7 promoter region. 
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pBG100 (Vanderbilt University Structural Biology Center). This plasmid contains a 
3C protease cleavable N-terminal 6His-tag, a kanamycin resistance gene and is under 
the control of the T7 promoter region. 
 
pBG101 (Vanderbilt University Structural Biology Center). This plasmid contains a 
3C protease cleavable N-terminal 6His-GST-tag, a kanamycin resistance gene and is 
under the control of the T7 promoter region. 
pOPIN-E (OPPF). This plasmid contains a non-cleavable C-terminal 6His-tag, an 
ampicillin resistance gene and is under the control of the T7 promoter region.  
 
pOPIN-F. This plasmid contains a 3C-cleavable N-terminal 6His-tag, an ampicillin 
resistance gene and is under the control of the T7 promoter region.  
 
pOPIN-J. This plasmid contains a 3C-cleavable N-terminal 6His-GST-tag, an 
ampicillin resistance gene and is under the control of the T7 promoter region.  	  
 
2.2.3 Cell strains 
E. coli strains used for cloning. Mach1 (T1R) chemically competent cells 
(Invitrogen) were used when cloning full-length TEAD and TAZ cDNA plasmids. XL1-
blue subcloning-grade chemically competent cells (Stratagene) and DH5α cloning 
efficiency chemically competent cells (Invitrogen) were used for cloning procedures 
carried out with constructs in Vanderbilt vectors and TEAD4 pOPIN constructs. 
Omnimax (2 T1 R) chemically competent cells were used for cloning procedures 
carried out at OPPF. 
 
Expression E. coli strains. BL21 (DE3), Arctic Express (DE3)TM RIL/RP, and 
Rosetta (DE3)TM (Stratagene) chemically competent cells were used for protein 
expression. Rosetta (DE3) cells were grown in the presence of 34 µg/ml 
chloramphenicol in addition to antibiotics required for selection of the expression 
vector. 
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2.2.4 Cell growth medium 
Luria-Bertani (LB) medium. LB broth containing 10 g Tryptone, 5 g Yeast extract, 
and 10 g NaCl per 1 L distilled H2O (Milli-Q water purification system, Millipore) was 
sterilised by autoclave and used to grow all strains of E. coli. Stock solutions of 
antibiotic (100 mg/ml ampicillin or 50 mg/ml kanamycin) were added to the medium 
using a dilution factor of 1/1000 prior to culturing the cells. LB agar was made 
according to the manufacturers instructions using distilled water and autoclaved. The 
agar was allowed to cool enough to be handled, the antibiotic was then added and the 
medium poured into 90mm Petri dishes. LB agar plates were stored at 4°C. 
 
M9 minimal medium. M9 medium was used to grow cells producing labelled proteins 
for use in NMR spectroscopy. 1 L 10x M9 stock solution containing 67.82 g Na2HPO4 
(anhydrous), 30 g KH2PO4, 5 g NaCl was prepared and autoclaved. Each 1 L labelled 
M9 medium contained 5 g D-glucose or 2 g 13C-labelled D-glucose, 1 g 15N-labelled 
NH4Cl, 100ml 10x M9 stock, 1 ml 1 M MgSO4, 50 µl CaCl2, 650 µl trace elements 
stock solution (Appendix III-a), and 1 ml MEM Vitamin solution, and was made up to 
volume with autoclaved distilled H2O in a sterile measuring cylinder. The medium was 
then transferred into a sterile 5 L conical flask (> 1 L volume) or 2 L conical flask (0.5-
0.75 L volume).  	  	  
2.3 Cloning 
2.3.1 Polymerase Chain Reaction (PCR) 
An initial temperature screen was carried out to determine the optimal annealing 
temperature for each reaction. A temperature gradient was set up for the annealing step 
of the PCR using an MJ Research PTC-200 Thermocycler. The final volume for each 
reaction was 20-25 µl. Successful reactions were scaled up using the best annealing 
temperature with reaction volumes of > 50 µl. Mini-prepped plasmids (approx. 20 
ng/µl) being used as template DNA were diluted 1/100 in sterile water. PCR products 
from the first round of nested PCR being used as template DNA were not diluted. After 
transformation of competent cells with the insert-containing plasmid (section 2.3.4), 
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colonies were cultured in 200 µl LB medium for at least 5 hours and PCR was used to 
identify positive clones using the cells as template DNA.  
 
KOD polymerase. This enzyme was used to amplify large DNA fragments (> 1 kb) 
for the production of cDNA and some TEAD domains. A typical reaction mixture is 
shown in Table 2.2. The temperature cycle for this enzyme is in Table 2.3. 
 
 
Table 2.2 Components of a 25 µl PCR reaction when using KOD polymerase 
Volume (µl) Reagent 
2.5 10x buffer (supplied with KOD) 
1.5 25 mM MgSO4 (supplied with KOD) 
2.5 2 mM dNTPs (supplied with KOD) 
0.75 Each primer (25 µM working stock) 
1.0 Template DNA  
0.4 KOD polymerase (1 U/µl) 
15.6 Sterile H2O 
 
Table 2.3 Temperature cycle for KOD PCR 
Step Temperature Time 
1. Initialisation 95°C 1-2 min 
2. Denaturation 95°C 20-30 sec 
3. Annealing Range/optimum °C 30 sec 
4. Elongation 68°C 45-60 sec 
5. Amplification Go to step 2 36-38x 
6. Final elongation 68°C 10 min 
7. End 4°C - 
 
Phusion polymerase. This high fidelity enzyme was used to amplify the majority of 
DNA fragments. A typical reaction mixture is shown in Table 2.4. The temperature 
cycle for this enzyme is in Table 2.5. 
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Table 2.4 Components of a 25 µl PCR reaction when using Phusion polymerase 
Volume (µl) Reagent 
5 5x buffer (HF1B) 
0.5 10 mM dNTPs (10 µl each stock dNTP + 60 µl H2O) 
2 Each primer (10 µM working stock) 
0.3 Template DNA 
0.25 Phusion polymerase (2 U/µl) 
18 Sterile H2O 
 
Table 2.5 Temperature cycle for Phusion PCR 
Step Temperature Time 
1. Initialisation 98°C 30 sec 
2. Denaturation 98°C 5 sec 
3. Annealing Range/optimum °C 15 sec 
4. Elongation 72°C 25 sec 
5. Amplification Go to step 2 35x 
6. Final elongation 72°C 10 min 
7. End 4°C - 
 
Taq polymerase. Taq was used to screen transformed cells for the plasmid containing 
the DNA insert. A longer initial step was used to ensure complete cell lysis in order for 
the enzyme to gain access to the DNA. Table 2.6 shows the components of a typical 
reaction and Table 2.7 illustrates a typical temperature cycle. 
 
Table 2.6 Components of a 10 µl PCR reaction when using Taq polymerase 
Volume (µl) Reagent 
1 10x buffer (HF1B) 
0.2 10 mM dNTPs (10 µl each stock dNTP + 60 µl H2O) 
1 Each primer (10 µM working stock) 
1 Template – colony cells 
0.1 Taq polymerase (5 U/µl) 
5.7 Sterile H2O 
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Table 2.7 Temperature cycle for Taq cell screen PCR 
Step Temperature Time 
1. Initialisation 95°C 5 min 
2. Denaturation 95°C 5-30 sec 
3. Annealing Range/optimum °C 15-30 sec 
4. Elongation 68-72°C 35-90 sec 
5. Amplification Go to step 2 30-38x 
6. Final elongation 68-72°C 10 min 
7. End 4°C - 
2.3.2 DNA analysis and purification 
Agarose gel electrophoresis. Agarose gels of 30 ml or 50 ml containing 1% agarose, 
1X TAE buffer (Appendix III-h) and a 1/20000 dilution of a 10 mg/ml ethidium 
bromide solution were used to visualise PCR products. 5 µl PCR product was added to 
1 µl 6x buffer and electrophoresed using a Biorad gel system at a constant voltage of 
110V. For size determination, the DNA ladders (NEB) shown in Figure 2.1 were used. 
Gels were visualised using a Toyobo FAS-I electronic UV transilluminator. 
 
Figure 2.1 Markers used for DNA fragment size determination. (A) NEB 1 kb DNA ladder and 
(B) NEB 100 bp DNA ladder. 
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DNA purification. Nucleic acid purification columns for use with a micro-centrifuge 
(Eppendorf) were purchased as part of various DNA purification kits (PCR/Gel 
purification or miniprep kits,Table 2.1). For PCR products that produced a single band 
on an agarose gel, the PCR product was used directly in the PCR purification kits. For 
those that produced more than one band, the whole PCR reaction mixture was 
electrophoresed, cut out of an agarose gel and then purified. Whole plasmids were 
purified using miniprep kits. Phosphorylated full-length TEAD and TAZ DNA 
fragments were purified using phenol-chloroform extraction. 
 
Phenol-chloroform extraction. All steps were carried out at 4°C. A 10 µl 
phosphorylation reaction mixture was made up to 50 µl with sterile H2O, 50 µl phenol-
chloroform (lower phase) was added to the tube and mixed by inverting the tube several 
times. The tube was centrifuged at 10,000 rpm for 5 min. The top layer was transferred 
to a fresh tube containing 50 µl chloroform and mixed. The tube was centrifuged at 
10,000 rpm for another 5 min. The top layer was transferred to a fresh tube and 
subjected to ethanol precipitation. 
 
Ethanol precipitation. 100 µl cold 100% ethanol and 5 µl 3 M sodium acetate pH 5.2 
were added to 50 µl DNA and frozen at -80°C for at least 15 min. After warming the 
samples (hand temperature) enough to reduce the viscosity, the tube was centrifuged at 
10,000-13,000 rpm at 4°C for 20-30 min. The supernatant was carefully pipetted off and 
150 µl 70% ethanol was added to the DNA pellet. The tube was centrifuged at 4°C for 
20-30 min and the supernatant discarded. The tube was left at room temperature for up 
to an hour or at 4°C overnight to allow the residual ethanol to evaporate. The DNA 
pellet was resuspended in 10 µl TE buffer. 	  
2.3.3 Insertion of DNA fragments into plasmids 
Vanderbilt vectors. DNA fragments and vectors were digested with restriction 
endonucleases in the supplied recommended buffer (a double digest reaction was 
preferentially carried out when buffers were compatible). Typically, 1.5-2 µl enzyme 
(20 U/µl) and 50 µl DNA (~20 ng/µl) were used in each reaction. High-fidelity 
restriction endonucleases were incubated with DNA at 37°C for 2-3 hours, with the 
exception of EcoRI which had a total incubation time of 1 hour. Fast-digest enzymes 
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were incubated with DNA for approximately 1 hour. PCR purification kits were used to 
terminate the reactions. 
 DNA fragments were ligated into the desired vector using T4 DNA ligase with the 
supplied buffer. A 20 µl ligation reaction typically contained 10 µl insert DNA (~10-20 
ng/µl), 2-5 µl vector DNA (20 ng/µl) and 1 µl ligase. Reactions were carried out 
overnight in PCR tubes at 16°C. 
 
pBluescript SK-. Blunt ended full-length (fl) DNA fragments (5 µl) were 
phosphorylated by 1 µl T4 PNK β in a 10 µl reaction containing ATP at 37°C for 30 
min followed by inactivation at 65°C for 10 min. The phosphorylated DNA was 
purified by phenol-chloroform extraction and ethanol precipitation prior to ligation. 
Ligation mixtures containing 5 µl phosphorylated DNA insert, 1 µl dephosphorylated 
EcoRV digested pBluescript SK- vector (50 ng/µl) and 1.5 µl T4 DNA ligase with the 
supplied buffer, were incubated for 3 days (over the weekend) at 18°C. 
 
pOPIN vectors. DNA fragments were inserted into HindIII- or KpnI-cleaved pOPIN 
vectors by ligation independent cloning (see Chapter 3 for details).  
 
2.3.4 Transformation of E. coli cells  
To insert the plasmids into cloning cell strains, 7.5-10 µl ligation mixture was added 
to 10 µl cells on ice and left for 30 minutes. The cells were heat-shocked at 45°C for 45 
sec and returned to ice for 5 min. 300-600 µl room temperature LB medium (or for full-
length TEAD and TAZ plasmids, SOC medium) was added to the cells which were 
immediately incubated at 37°C, shaking for 1-2 hours. At least 100 µl transformation 
mixture was spread onto an LB agar plate containing the appropriate antibiotic.  
When a pure plasmid was used for transformation into expression cell strains, 1 µl 
plasmid was added to 10 µl chemically competent cells. The rest of the procedure was 
carried out as described above. 	  
2.3.5 Sequencing 
GATC biotech carried out sequencing of most plasmids. More recently Source 
Bioscience were used to sequence the plasmids (Sav). DNA sequences were translated 
into protein sequences using the Expasy translate programme and aligned with expected 
sequences using the EBI ClustalW or Align programmes. 
	   33	  
 
2.4 Downstream protocols 
2.4.1 SDS-PAGE analysis  
All protein samples were analysed by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) using 15% bis-acrylamide gels in the Novex gel system 
(Invitrogen). The samples were prepared by mixing with 2X loading buffer (Appendix 
III-c) and boiling for 5-10 min. 5-15 µl samples were loaded onto the gel and 
electrophoresed in a 1X Tris-glycine buffer containing SDS (10X solution is shown in 
Appendix III-d), using a current of 60-100 mA. Gels were incubated with Coomassie 
Blue stain (Appendix III-e) for 30 min after being heated in a microwave for 30 sec. 
Gels were subsequently de-stained (Appendix III-f) and dried (Appendix III-g) in 
cellophane (Invitrogen). Unless otherwise stated, the Fermentas ‘Unstained Protein 
Molecular Weight Marker’ (Figure 2.2) was used to determine the size of proteins. 
 
Figure 2.2 Fermentas ‘Unstained Protein Molecular Weight Marker’ used during SDS-PAGE. 
The marker was supplied in loading buffer; typically 5 µl marker was loaded into the well. 
 
2.4.2 Protein expression and purification  
Initial expression trials. Various domains and combinations of domains from the 
Hippo pathway proteins were initially transformed into chemically competent 
BL21(DE3) cells using standard protocols (section 2.3.4) and spread onto LB agar 
plates containing the appropriate antibiotic (50 µg/ml Kanamycin for Vanderbilt vectors 
or 100 µg/ml ampicillin for pOPIN vectors). Colonies were transferred into 5-10 ml LB 
	   34	  
broth with antibiotic and grown to an OD600 of 0.4-0.6 at which point a glycerol stock 
was made (0.5 ml 50% glycerol and 1 ml culture, frozen on dry ice and stored at -80°C). 
At an OD600 of 0.6-0.9 the cells were induced to express the protein by way of the T7 
promoter using 0.5 mM IPTG at 37°C for up to three hours. 1 ml samples were taken 
pre- and post-induction. The cell samples were centrifuged and resuspended in 100 µl 
water and 100 µl 2X SDS-PAGE buffer. Expression was assessed by SDS-PAGE.  
 
Purification trials. Primary cultures of 1-10 ml (LB and antibiotic) were, unless 
otherwise stated, started from glycerol stocks and grown overnight, shaking at 180-220 
rpm at 37°C before being sub-cultured in volumes of between 100 ml and 1 L. Cells 
were induced as previously described. After induction, cells were centrifuged at 3000-
6000 g and resuspended in His buffer A (Appendix III-i). Cell lysis was carried out on 
ice using a Branson digital sonicator for a total time of 30-60 sec (0.5 sec pulses with 3 
sec between bursts – saved as programme 1) at 60-80% amplitude. The lysate was 
centrifuged at high speed (16000-65000 g) and the supernatant retained. Proteins were 
purified using an ÄKTA Purifier 10 chromatography unit (GE Healthcare) by passing 
the cell lysate through a pre-packed nickel affinity column (HisTrap FF column; GE 
Healthcare). After washing the column with 3-5 column volumes of His buffer A, the 
bound protein was eluted with His Buffer B (Appendix III-i) in an imidazole gradient 
up to a concentration of 500mM.  
 
Expression of labelled protein for use in NMR experiments. Primary cultures of 25-
50 ml LB containing antibiotic were grown as described for purification trials. The cells 
were separated from the LB medium by centrifugation. M9 medium supplemented with 
15N-labelled NH4Cl or 15N-labelled NH4Cl and 13C-labelled glucose was used to 
resuspend the cells, which were then grown in 0.5-2 L M9 medium at 37°C. Subsequent 
induction and protein purifications were carried out as for unlabelled protein. 
 
2.4.3 NMR spectroscopy  
Sample preparation. Proteins were exchanged into NMR buffers by concentration 
and dilution using disposable centrifugal concentrators (Amicon/Sartorius/Millipore) 
with MW cut-offs at least 2-3 times lower than the MW of the protein, or using an 
Amicon stir cell concentrator with a cellulose ultra-filtration membrane (3 kDa cut-off). 
5-10% D2O was added to each sample, which was centrifuged to remove precipitate and 
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then the sample was transferred to a standard NMR tube or Shigemi tube depending on 
the amount of protein. 
  
 Experimental details. Nuclear magnetic resonance (NMR) experiments were 
performed using a Varian Unity INOVA spectrometer operating at the nominal proton 
frequency of 600 MHz, employing a room temperature triple resonance 5 mm probe 
equipped with pulse field gradients (PFG) along the z-axis. Unless otherwise stated, all 
datasets were acquired using Varian BioPack pulse sequences. Spectra were processed 
using NMRPipe/NMRDraw (Delaglio et al. 1995) and analysed with CCPN Analysis 
(Vranken et al. 2005). 1H and 15N chemical shifts were referenced to 4,4-dimethyl-4-
silapentane-1-sulfonic acid (DSS) (Wishart et al. 1995).  
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CHAPTER 3: TEAD PROTEINS AND THEIR 
INTERACTION WITH YAP 
 
 
Figure 3.1 TEAD (blue) and YAP (pink) are located within the nucleus when the Hippo 
pathway is inactive. The two proteins interact to form a transcription factor complex that leads 
to the up-regulation of target genes. 
	   37	  
3.1 Introduction  
TEAD transcription factors bind to the MCAT DNA motif (5’-TCATTCCT-3’) and 
similar DNA sequences through an N-terminal tri-helical DNA-binding domain (DBD) 
(Figures 1.7 and 3.2); the solution structure of a modified form of the TEAD1 (TEF-1) 
DBD was published in 2006 (Anbanandam et al.). TEAD proteins are functional only in 
combination with co-activators, one of which is YAP. The Hippo pathway regulates 
YAP-TEAD interactions by YAP phosphorylation that subsequently leads to 
cytoplasmic sequestration (Figure 3.1). The DBD of TEAD contains a nuclear 
localisation sequence in the third α-helix that allows the YAP-TEAD complex access to 
the nucleus resulting in the transcription of target genes (Goulev et al. 2008).  
 
Figure 3.2 Representation of the TEAD and YAP domains studied in this chapter using the 
colour scheme seen in Figure 1.7. As for Figure 1.7, the domains and linker regions are to 
relative scales. Domains that do not feature in this chapter are not labelled or shown in colour. 
 
The YAP-binding domain (YBD) of TEAD proteins (Figures 1.8 and 3.2) comprises 
the C-terminal region and is approximately 230 residues in length. The YBD binds the 
N-terminal TEAD binding domain (TBD) of YAP. The TBD is 107 amino acids long, 
however smaller fragments within this region are capable of binding TEAD with lower 
affinity than the full length TBD (Vassilev et al. 2001). The C-terminal region of YAP 
is thought to be a transcriptional co-activation domain and has no predicted secondary 
structural elements.  
At the beginning of this project the functional interactions between TEAD (YBD) 
and YAP (TBD) were fairly well characterised but the structural details of the proteins 
were unknown. To really understand how a particular protein works and interacts with 
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binding partners, structural information at the atomic level is needed. Two common 
biophysical techniques that can yield such information are X-ray crystallography and 
NMR spectroscopy.  
X-ray crystallography is used to determine a 3D structural model of proteins that are 
in a crystalline (i.e. solid) state. Proteins of almost any size can be studied using this 
technique but there are several limiting steps including crystallisation, diffraction and 
data analysis. NMR spectroscopy is used to study structural features and biochemical 
properties of proteins in solution. Traditionally, proteins should be 20 kDa or less for 
successful NMR experiments, though with the advent of more powerful spectrometers, 
better NMR pulse sequences (such as TROSY) and data processing/reconstruction, and 
more complex isotope labelling procedures, it is possible to study larger proteins. Both 
X-ray crystallography and NMR spectroscopy require pure, homogeneous, concentrated 
protein samples; therefore careful protein preparation is imperative for obtaining usable 
data.  
The aim of the work described in this chapter was to use biophysical techniques to 
better understand the structural properties of the two discrete TEAD domains (DBD and 
YBD) individually and in complex with YAP, with a long-term goal of studying the 
DNA-TEAD-YAP interactions. Unfortunately setbacks were encountered during 
protein purification, crystallisation and data analysis. Three research articles containing 
crystal structures of TEAD YBD both alone and in complex with the TBD of YAP were 
published before this work could be completed (Chen et al. 2010; Li et al. 2010; Tian et 
al. 2010). 
 
3.2 Materials and methods 
General materials and methods are described in Chapter 2. This section describes the 
production and analysis of relevant individual samples in more detail. 
 
3.2.1 Production of full-length template cDNA 
TEAD1, TEAD2/3 and TEAD4 cDNA plasmid construction. Total RNA was 
extracted from two adult Hd-rR (southern inbred strain) medaka fish using TRIzol® 
reagent.  The isolated RNA was treated with DNAse I and concentrated by phenol-
chloroform extraction followed by ethanol precipitation as described in Chapter 2. A 
cDNA library was synthesised from the purified RNA using the TaKaRa PCR kit. 
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Nested PCR using KOD Hot Start polymerase with standard protocols was used to 
amplify blunt-ended TEAD cDNA as a single round of PCR did not yield sufficient 
quantities of DNA for cloning (i.e. PCR products were barely visible on agarose gels). 
The primers labelled ‘outer’ (Table 3.1) and the cDNA library as template were used for 
the first round of PCR. The primers labelled ‘inner’, and PCR products from the first 
round of PCR as template, were used for the second round of PCR that produced the 
TEAD cDNA used in subsequent procedures.  
The full-length (fl) TEAD DNA fragments were phosphorylated, purified and ligated 
into the pBluescript SK- vector as described in Chapter 2. The resulting plasmids were 
transformed into Mach1 competent E. coli cells and spread onto LB agar plates 
containing 100 µg/ml ampicillin. PCR screens were performed on several colonies of 
each construct for selection of successful clones. Several clones for each TEAD plasmid 
were sequenced (GATC Biotech). 
 
Table 3.1 Primers used for nested PCR amplification of full length TEAD cDNA  
Construct Outer forward Inner forward Inner reverse Outer reverse 
TEAD1 TAGCTTGGAGA
GCCCGACT 
AGAGCCCGACT
GCCAAGAT 
TGTTCATTCTTTA
ACCAGTCTGTAG
AT 
GGTGTTCATTC
TTTAACCAGTC
TGT 
TEAD2/3 CACCATTGCGTC
CAACGA 
GCGTCCAACGA
GTGGAGT 
TCCCTGGCAAGCT
GTTAGTC 
AGAAGCTCCC
TGGCAAGC 
TEAD4 AGAGGTTCCCTC
TCCATCGT 
CATCGTCCCACC
ACGTCT 
TCAGTCTTTGACC
AGCCTGT 
CACCAGTGCC
TCTGTGTCAG 
 
YAP cDNA. Dr Makoto Furutani-Seiki (MFS, University of Bath) generated Kyoto-
Cab inbred medaka strain YAP cDNA prior to the commencement of our collaboration. 
 
3.2.2 Cloning of TEAD and YAP DNA fragments 
Cloning of TEAD DNA into Vanderbilt vectors. All TEAD DNA fragments were 
amplified by KOD Hot Start polymerase using standard protocols (Chapter 2). A 
medaka whole genome cDNA library (produced by Makoto Furutani-Seiki) was used as 
template for the TEAD2/3 (239-462) fragment with an annealing temperature of 54°C 
using the forward and reverse primers ‘mTEAD3_V239f’ and ‘Med_TEAD2-rev’ 
(Appendix I-a). The TEAD4fl (1) cDNA plasmid was used as template for TEAD 4 
(222-470) with annealing temperatures of 54.6°C to 63.8°C, using forward and reverse 
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primers ‘TEAD4_Y222f’ and ‘TEAD4_D470r’ (Appendix I-a). Both of the 
aforementioned TEAD (YBD) DNA fragments as well as the pSV281 (6-His tag, TEV 
cleavable) and pBG101 (6-His GST tag, 3C cleavable) vectors underwent double digest 
reactions with EcoRI and XhoI high-fidelity restriction enzymes (Chapter 2).  
 
Cloning of YAP DNA into Vanderbilt vectors. All YAP DNA fragments were 
amplified using Phusion DNA polymerase using standard protocols (Chapter 2). The 
YAP TBD-WW1 (1-168) construct was amplified using an optimal annealing 
temperature of 64.6°C using forward and reverse primers ‘YAP_M1f’ and 
‘YAP_T168r’ (Appendix I-a). YAP DNA and vectors were subjected to double digest 
reactions using EcoRI and HindIII high-fidelity restriction enzymes (Chapter 2). 
 
High-throughput ligation independent cloning of TEAD and YAP DNA into pOPIN 
vectors (OPPF). TEAD and YAP DNA fragments were amplified using KOD Hot Start 
DNA polymerase with primers designed for ligation independent cloning into pOPIN 
vectors (Appendix I-a). 1.5 µl DNA was cloned into 1 µl vector (pOPIN-E, pOPIN-F or 
pOPIN-J) using the In-Fusion™ cloning enzyme at 42°C for 30 minutes. 40 µl TE 
buffer was used to terminate the reaction (yielding a total volume of 50 µl). The mixture 
was then used to transform Omnimax cells following standard transformation protocols 
(Chapter 2), and the cells were grown in 24 well plates containing 1 ml LB agar, XGal, 
IPTG, and carbenicillin for positive selection. Positive colonies were picked, grown 
overnight in 1 ml LB broth at 37°C and screened by PCR. Plasmids containing the 
insert were mini-prepped and glycerol stocks were made in 96 well plates.  
 
3.2.3 Expression and purification of TEAD and YAP (TBD) protein constructs 
The initial purification trial protocol (Chapter 2) was used for the successful 
purification of YAP (TBD-WW1) in both pSV281 and pBG101 expression vectors. The 
initial expression and purification conditions were not successful for the TEAD protein 
constructs, which tended to be insoluble. The following strategies were used in the 
attempt to optimise TEAD purification conditions: altering (generally lowering) 
induction temperature and time to slow protein production and possibly aid folding; 
adding the detergent Triton-X100; changing expression cell strain including Arctic 
Express with rare codons and Rosetta for use with rare codon strains (see Appendix II 
for rare codon analysis); re-cloning with different boundaries to reduce the effect of 
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flexible termini and into alternative vectors for potential differences in expression and 
effects of different affinity/solubility tags; and co-expression with the chaperone protein 
pREP4-GroESL to aid protein folding (a kind gift from David Cowburn, then New 
York Structural Biology Centre, now at Albert Einstein College of Medicine). The 
TEAD constructs described below were the most successful samples i.e. the TEAD4 
used for X-ray crystallography is different to the TEAD4 used in NMR experiments; 
this is because the Vanderbilt vector construct yielded a 2D NMR spectrum and the 
pOPIN construct yielded protein crystals. 
 
Optimal expression and purification conditions of TEAD2/3 (YBD) for use in NMR 
experiments. BL21 (DE3) chemically competent cells (10 µl) were transformed with the 
TEAD2/3 (239-462) pSV281 plasmid and pREP4-GroESL plasmid (1 µl of each), a 
glycerol stock was made and the primary culture for the NMR sample was started from 
this. A 10 ml primary culture was grown overnight in LB broth at 25°C. The primary 
culture was transferred into 0.5 L LB medium and grown to OD600 of 1.8 at 37°C. The 
cells were centrifuged at low speed (< 3000 g) before being transferred to 1 L pre-
warmed M9 minimal medium supplemented with 15N NH4Cl. 50 µg/ml kanamycin was 
present in all cultures. The cells were induced overnight at 12°C with 0.25 mM IPTG. 
The cells were resuspended in His buffer A with 4% Triton X-100, lysed by sonication 
and purified by affinity chromatography as described for initial expression and 
purification trials (Chapter 2). 
 
Optimal expression and purification conditions of TEAD4 (YBD) used for NMR and 
trypsin digestion. Rosetta (DE3) competent cells (10 µl) were transformed with the 
TEAD4 (222-470) pSV281 plasmid (1 µl) and a glycerol stock was made from which 
all subsequent cultures were started (in the presence of 50 µg/ml kanamycin). Primary 
cultures were grown overnight at 37°C, secondary cultures were grown to an OD600 of 
0.6-0.9 at 37°C in either LB medium or M9 minimal medium supplemented with 15N 
NH4Cl and induced overnight at 12°C with 0.5 mM IPTG. TEAD 4 (YBD) pSV281 was 
purified in the same way as TEAD2/3 (YBD) pSV281. 
 
Optimal expression and purification conditions of TEAD4 (YBD) for crystallisation 
and X-ray crystallography. Chemically competent BL21 (DE3) cells were co-
transformed with the TEAD4 (171-240) pOPIN-F plasmid (ampR) and the pREP4-
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GroESL plasmid (kanR) and a glycerol stock was made from which all subsequent 
cultures were grown (in the presence of 100 µg/ml ampicillin and 50 µg/ml kanamycin). 
Expression and purification conditions of TEAD4 (YBD) pOPIN-F were as described 
for TEAD4 (YBD) pSV281.  
The 6His-tag was cleaved from TEAD4 (YBD) pOPIN-F using 3C preScission 
protease in His-buffer A with 10% glycerol and 1 mM DTT, on a rocking platform at 
room temperature overnight. The protein was concentrated and buffer exchanged into 
50 mM Tris pH 7.5 and 150 mM NaCl, using a disposable centrifugal concentrator with 
a MW cut-off of 10 kDa. 
 
Optimal expression and purification conditions of YAP (TBD-WW1) for NMR 
spectroscopy. BL21 (DE3) competent cells (10 µl) were transformed with the YAP (1-
168) pSV281 plasmid (1 µl) and a glycerol stock was made from which all subsequent 
cultures were started (with 50 µg/ml kanamycin). 50 ml primary cultures were grown at 
37°C overnight, 0.5-1.5 L secondary cultures were grown to an OD600 of 0.6-0.9 at 
37°C in M9 minimal medium supplemented with 15N NH4Cl. Protein expression was 
induced for 3 hours at 37°C with 0.5 mM IPTG. YAP (TBD-WW1) was purified as 
described for the TEAD proteins. 
 
 
3.2.5 Trypsin digestion of TEAD4 (YBD) 
TEAD4 (YBD) pSV281 was concentrated using a 10 kDa cut-off disposable 
centrifugal concentrator and buffer exchanged into trypsin cleavage buffer (50 mM Tris 
pH 8, 20 mM NaCl, 1 mM EDTA, 5 mM DTT) to a final volume of 50 µl at an 
approximate concentration of 6 mg/ml. 10 µg trypsin was added to the protein, half was 
incubated at 37°C and the remaining half was incubated at room temperature. 2 µl 
samples were taken at time points of 15, 30, 60 and 120 mins, 4 hours and overnight; 
the samples were frozen immediately. 2X SDS loading dye was added and the samples 
were analysed by SDS-PAGE.  
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3.2.6 NMR spectroscopy 
Only 2D 1H-15N heteronuclear single-quantum coherence (HSQC) spectra (described 
in the results section of this chapter) were obtained for the TEAD-YAP interaction 
domains. NMR experiments were carried out as described in Chapter 2. Details of 
experimental conditions and parameters relating to data for YAP-binding domains of 
TEAD and TBD-WW1 domains of YAP shown in Chapter 3.3 are in Table 3.2.  
 
Table 3.2 NMR buffer conditions and parameters for HSQC experiments of TEAD and 
YAP interaction domains 
Construct Buffer Temperature 15N SW 15N carrier frequency  
TEAD2/3 
(239-462) 
pSV281  
50 mM Tris, 
pH 7.5 
25°C 1519 Hz 119 ppm 
TEAD4 
(222-470) 
pSV281 
20 mM KH2PO4,  
200 mM NaCl,  
1 mM DTT, 
pH 5.5 
37°C 1519 Hz 119.5 ppm 
YAP  
(1-168) 
pSV281 
50 mM KH2PO4, 
200 mM NaCl,  
2 mM EDTA,  
pH 6.5 
25°C 2000 Hz 118.5 ppm 
 
 
3.2.7 Crystallisation and X-ray crystallography 
Production of protein crystals. High-throughput 96 well crystallisation screens 
(Structure Screen I&II, Molecular Dimensions Ltd) were carried out on TEAD2/3 
(YBD)-6His-tag, TEAD4 (YBD) and TEAD4 (YBD)-YAP (TBD-WW1) using an Art 
Robbins Phoenix nano-dispenser robot. One successful crystal hit occurred for TEAD4 
(YBD) pOPIN-F without affinity tag, in 0.1 M sodium citrate pH 5.6, 20% v/v 2-
propanol, and 20% w/v PEG 4000. This condition was used as a basis for optimisation, 
leading to the final buffer condition: 0.1 M sodium citrate pH 5.6, 2% v/v 2-propanol, 
15% w/v PEG 4000.  
 
	   44	  
X-ray diffraction experiments. Native crystals were frozen in the final buffer 
condition with 25% v/v glycerol. A data set was acquired at the Diamond Light Source 
synchrotron on beam IO2 with X-ray exposures of 0.25 sec at 100% intensity. The data 
were processed using HKL2000 software (Otwinowski et al. 1997). As no similar 
structures were available, molecular replacement could not be used to obtain the phase 
information that would allow the TEAD4 structure to be solved. A number of 
experimental techniques (as described below) were utilised when trying to solve the 
phase problem. 
Selenomethionine labelling of TEAD4 was carried out by culturing the cells in M9 
medium (Chapter 2) with 1 g NH4Cl and 10 g D-glucose, supplemented with 50 mg 
seleno-l-methionine, in an attempt to prepare crystals for multi-wavelength anomalous 
diffraction (MAD) X-ray experiments. 
In an attempt to prepare crystals for multiple isomorphous replacement (MIR) X-ray 
data collection, native crystals were soaked in the well buffer containing various 
concentrations (between 0.5 mM and 5 mM) of either mercury (II) chloride, 
phenylmercuric acetate or potassium tetrachloroplatinate for various amounts of time 
(the shortest being ~ 10 sec).  
Longer wavelength data were collected on native crystals at the ID29 beam-line, 
ESRF, Grenoble, in an attempt to use native sulphur single-wavelength anomalous 
diffraction (SAD). The beam-line contains an adjustable aperture to 50 µm and a mini-
kappa goniometer. 3-4 images were acquired at 6 keV, a resolution of 2 Å with 0.2 sec 
exposures. The MOSFLM programme (CCP4i) was used in the attempt to process, 
index, and predict the mosaicity of the data. The STAC_kappa programme was then 
used to orient the crystal to the best angle for obtaining a symmetrical diffraction 
pattern and another 3 images were acquired. These 3 images were processed and 
indexed as before. The RADDOSE programme (CCP4i) was used to estimate and 
optimise the best parameters for data collection (including resolution, starting angle, 
degrees of rotation, exposure time and number of images). Finally datasets were 
collected and attempts were made to process these data using XDS (Kabsch 2010). 
Molecular replacement was attempted after the publication of the three TEAD 
(YBD) structures. The online programme Balbes (Long et al. 2008) was used to obtain  
an electron density map, and refinement was attempted using CCP4i (Potterton et al. 
2003).  
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3.3 Results 
3.3.1 TEAD cDNA isoforms 
Medaka cDNA for full-length TEADs was cloned into the holding vector pBluescript 
SK- as PCR template for smaller TEAD domains. Several full-length (fl) TEAD cDNA 
plasmids (pBluescript SK-, ampR) were sequenced, revealing the existence of different 
splice forms of medaka TEAD proteins. TEAD1 and TEAD2/3 splice form variants 
both contained an insertion in the DNA binding domain (DBD) (Figure 3.3). The DBD 
from human TEAD1 (a.k.a. TEF-1), which is 92% identical and 99% similar to the 
DBD of medaka TEAD1(s), comprises a bundle of three α-helices which bears close 
resemblance to the typical DNA binding homeodomain fold (Anbanandam et al. 2006). 
Secondary structure prediction using Jpred (Cole et al. 2008) identifies the anticipated 
three helices within the DBD of each non-variant TEAD protein. The insertion in 
TEAD1 and TEAD2/3 was not aligned with any known protein and so were not 
predicted to contain secondary structure.  
TEAD4 was not found to have a DBD variant, however many of the TEAD4 
plasmids contained a stop codon at the beginning of the YBD, in place of the codon for 
W78. It is possible that a TEAD4 protein consisting only of the DBD could be 
translated in vivo. 
 
3.3.2 Protein expression and purification 
Various domains and combinations of domains from TEADs and YAP were 
expressed in BL21 (DE3) E. coli cells. In some cases expression was poor upon 
induction or the protein was insoluble. In such cases alternative expression methods 
were utilised in an attempt to optimise the production of soluble protein, including the 
use of various expression strains of E. coli, co-expression with a plasmid containing the 
chaperone complex GroELS, and re-cloning fragments with altered boundaries and 
different expression vectors. Table 3.3 summarises the final expression and purification 
outcomes; all constructs were tested for purification potential but only the most 
successful constructs are described in detail. The numbering of TEAD4 was different 
for the pSV281 and pOPIN-F constructs because of differences in the predicted start of 
the sequence. The pSV281 primers were ordered first but cloning using genomic DNA 
was initially unsuccessful; subsequently the TEAD4 cDNA was successfully cloned and 
pOPIN primers were designed with the new numbering. Later the pSV281 TEAD4 
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(YBD) cloning was successful but the original numbers were used to identify the 
primers. Both TEAD4 constructs end at the C-terminal Asp. 
 
 
Figure 3.3 Full-length medaka TEAD sequence alignments from cDNA translation (Swiss 
Institure of Bioinformatics Expasy Translate programme). Alignments were made in ClustalW; 
TEAD1fl_short 84-96 and TEAD4 75-81 were manually moved to align with TEAD3fl_short. 
The shading was carried out using Boxshade; Black background represents identical alignments 
and grey backgrounds represent similar alignments. Yellow bars indicate the DNA binding 
domain (DBD), red bars indicate the YAP binding domain (YBD). The insertion in the DBD of 
TEAD1 and TEAD2/3 are at residue numbers 96-117 and 85-106. 
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Table 3.3 Summary of protein expression and purification outcomes for TEAD 
constructs and associated interaction domains of YAP and TAZ. 
Protein Domain Expression Solubility Purification 
TEAD 1  DBD  Good Insoluble Unsuccessful 
TEAD 2/3 DBD Good Insoluble Unsuccessful 
TEAD 1 YBD Poor Insoluble Unsuccessful 
TEAD 2/3 YBD  
(239-462) 
pSV281 
Good 20-50% soluble: 
Co-expressed with 
GroELS in BL21 (DE3) at 
12°C with 0.25 mM IPTG 
Successful: 
Nickel ion 
affinity 
chromatography 
TEAD 4 YBD 
(222-470) 
pSV281 
Good 40-60% soluble: 
Expressed in Rosetta 
(DE3) at 12°C with 0.5 
mM IPTG 
Successful: 
Nickel ion 
affinity 
chromatography 
TEAD4 YBD 
(171-398) 
pOPIN-F 
Good 50-80% soluble: 
Co-expressed with 
GroELS in BL21 (DE3) at 
12°C with 0.5 mM IPTG 
Successful: 
Nickel ion 
affinity 
chromatography 
YAP TBD Good Insoluble Unsuccessful 
YAP TBD + WW1 
(1-168) 
pSV281 
Good Soluble:  
Expressed in BL21 (DE3) 
at 37°C with 0.5 mM 
IPTG 
Successful: 
Nickel ion 
affinity 
chromatography 
Final yields of TEAD2/3 were low (~0.5-1 mg/L), TEAD4 yields were better (~3-6 mg/L), and 
YAP (1-168) yields were reasonable (~5-10 mg/L).  
 
3.3.3 The YAP-binding domain of TEAD is globular and folded 
Purification of TEAD2/3 and TEAD4 (YBD) proteins used in NMR and trypsin 
digestion experiments. The most successful NMR sample from the TEAD proteins was 
from TEAD2/3 (YBD) in pSV281 when co-expressed with pREP4-GroESL (Piserchio 
et al. 2009) in BL21 (DE3) cells. The TEAD4 (YBD) pSV281 construct expressed in 
Rosetta (DE3) also yielded a 2D 1H-15N-HSQC spectrum. The elution profiles are 
shown in Figure 3.4.   
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Figure 3.4 NMR sample purification and SDS-PAGE profiles for (A, B) TEAD 2/3 (YBD in 
pSV281) and (C, D) TEAD4 (YBD in pSV281). Volume (ml) and fractions are shown on the x-
axis. The blue line in the elution profile signifies A280 and the green line represents the 
imidazole gradient. The proteins were purified using a 5 ml His-Trap FF column (GE 
Healthcare). (B, D) The purity of the proteins was verified using Coomassie blue stained SDS-
PAGE gels; the marker is shown on the left hand side with the corresponding MW of each band 
annotated; purified TEAD protein, with an expected size of ~28 kDa, is shown on the right hand 
side of the gel images. 5 µl marker and 10 µl of the pooled peak fractions diluted 1:1 with 
sample buffer were loaded onto the gel. 
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Trypsin digestion of TEAD4 (YBD). The YAP-binding domain of TEAD4 was 
digested with trypsin to gain an indication of whether the domain contains exposed 
unstructured regions that would be susceptible to cleavage. A slight decrease in 
molecular weight was observed and a single distinct band was visible at around 26 kDa 
(Figure 3.5). This band represents a protein population that is resistant to protease 
digestion and is indicative of a globular domain. 
 
Figure 3.5 Trypsin digestion of TEAD4 (YBD), visualised on a Coomassie blue stained SDS-
PAGE gel. Each lane represents a different incubation time of 0 (1), 8 min (2), 15 min (3), 30 
min (4), 1 hr (5), 2 hrs (6), 4 hrs (7), and 20 hrs (8). Lanes labelled as ‘a’ and ‘b’ represent 
incubations at 37°C and room temperature, respectively. 
 
NMR spectroscopy of TEAD2/3 and TEAD4. In order to verify that the TEAD 
transcription factor YBD is a structured domain as implied by trypsin digestion, 1H-15N- 
HSQC experiments were carried out on 15N labelled TEAD2/3 and TEAD4. HSQC 
spectra provide protein ’fingerprints’. Each residue containing an NH within the 
backbone peptide bond is represented by a spot (peak) that comprises a signal (chemical 
shift) from the 1H in one dimension (x-axis in this case) and the 15N in the other 
dimension (y-axis). The chemical environment of the residue determines the location of 
each peak within the spectrum. The pattern and distribution of the peaks can provide 
information about protein structure and conformational stability. 
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The 2D 1H-15N-HSQC spectra (Figure 3.6) show roughly the expected number of 
backbone peaks i.e. number of residues minus proline and the N-terminal amino acid 
(233 expected for TEAD2/3 including His-tag residues, 217 expected for TEAD4). The 
peaks are well dispersed in both the 1H and 15N dimensions, indicating that secondary 
and tertiary structural elements are present. The TEAD2/3 (YBD) peak intensities are 
uniform, suggesting that the YBD adopts a single dominant conformation in solution. 
The TEAD4 (YBD) spectrum exhibits variable peak intensities, which may be 
indicative of conformational exchange or a population of misfolded/unfolded protein. 
 
Figure 3.6 2D 1H-15N-HSQC spectra of (A) 15N TEAD2/3 (YBD) acquired at 25°C with 256 
scans and (B) 15N TEAD4 (YBD) acquired at 37°C with 32 scans. Positive peaks are shown in 
red and negative peaks (arising from out of range folded positive peaks) are shown in green. 
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3.3.4 Purification and crystallisation of TEAD4 (YBD) 
Overview of X-ray crystallography, data collection and processing. NMR 
experiments implied that the YBD of TEAD is folded, so we attempted to solve the 
structure, which at the time remained unknown, using X-ray crystallography. When 
proteins are crystallised and subjected to X-ray radiation diffraction patterns of 
regularly spaced spots (known as reflections) may be obtained; the X-ray scattering is 
caused by the electrons from each atom within the protein and variations in electron 
density cause variations in the intensity of each reflection. If a crystal diffracts to a high 
resolution (ideally at least 3Å) an atomic-level model of the 3D protein structure can, 
given the necessary parameters, be calculated. The protein crystal is rotated through 
180° and a diffraction pattern collected at each rotation.  
During data processing the diffractions must be indexed to identify the unit cell 
dimensions and space group, integrated into a single file, then merged to ensure only 
one of each reflection is present and scaled to make the intensity of each reflection 
consistent. To calculate an electron density map of the protein three pieces of 
information are needed: the wavelength of the X-ray (which is set in the experiment), 
the amplitude of the X-ray wave (which can be determined from the intensity of the 
reflection), and the phase of the X-ray wave (which cannot be directly measured as part 
of a single diffraction experiment). Thus, in order to calculate an electron density map 
on which to base the final structure, the ‘phase problem’ must first be solved. Various 
methods exist to overcome the phase problem, from using the phases from a similar 
structure to incorporating (or using naturally occurring) ‘anomalous scatterers’ e.g. 
heavy atoms, into the crystal and calculating the phase from the known structure of such 
atoms. 
 
Crystallisation of TEAD4. The first limiting step of X-ray crystallography is 
producing protein crystals. Successful crystallisation was achieved with the YBD of 
TEAD4 (171-398) in pOPIN-F when co-expressed with pREP4-GroESL (Piserchio et 
al. 2009), purified using a HisTrap-FF column, and the 6His-tag cleaved (Figures 3.7 
and 3.8). The final crystallisation buffer consisted of 0.1 M sodium citrate pH 5.6, 2% 
isopropanol and 15% PEG4000. The initial ‘hit’ that this buffer was derived from 
contained 0.1 M sodium citrate pH 5.6, 20% isopropanol and 20% PEG4000. Other 
‘hits’ occurred in the Molecular Dimensions Structure screen I+II (HT96) F11 (1.6 M 
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(NH4)2SO4, 0.1 M MES pH6.5 and 10% dioxane) and C9 (0.2 M MgCl, 0.1 M Tris 
pH8.5 and 30% PEG4000). 
 
Figure 3.7 (A) Affinity purification elution profile from a 5 ml His-Trap FF column of TEAD4 
(YBD) pOPIN-F used in successful crystal trials (A280 is represented by the blue line; imidazole 
gradient is shown in pale green). (B) The Coomassie blue stained SDS-PAGE gel shows 1 µl 
concentrated TEAD4 (YBD) with (1) and without (2) the His-tag, at ~ 28 and 26 kDa, used in 
crystallisation trials.   
 
Figure 3.8 TEAD4 crystals at a final magnification of 500X in the optimal crystallisation 
condition 0.1 M sodium citrate pH 5.6, 2% isopropanol and 15% PEG4000. Crystals were 
approximately 125 µM in length. 
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The native crystals in Figure 3.8 diffracted to a resolution of 1.9 Å (Figure 3.9, Table 
3.4) at the Diamond Light Source synchrotron beam (IO2) in Oxford, UK. At the time 
of data collection, there were no similar structures; hence an electron density map could 
not be calculated using phasing information from the molecular replacement method. In 
order to obtain difference data to solve the phase problem by MIR, the crystals were 
soaked in heavy atom-containing solutions, which either cracked the crystals, prevented 
diffraction or produced very mosaic diffraction datasets that were difficult to process 
and impossible to refine. Seleno-methionine labelled protein that could potentially be 
used for MAD did not crystallise. Longer wavelength X-rays were also utilised in the 
attempt to allow phasing by sulphur-SAD, but the data displayed signs of mosaicity and 
could not be properly processed. It was at this point that crystal twinning was first 
suggested (by Christoph Mueller-Dieckmann, ESRF, Grenoble).  
Crystal twinning occurs when crystal domains are not in perfect alignment. There are 
various types of twin (as discussed in section 3.4) including macroscopic, merohedral 
and non-merohedral. Macroscopic twins can often (but not always) be seen under a light 
microscope whereas other types of twin are sub-microscopic and cannot be detected by 
eye. Some useful diagrams to illustrate the different types of twinning can be found in 
pages 388-394 of Biomolecular Crystallography: Principles, Practice, and Application 
to Structural Biology (Rupp 2009), which cannot be reproduced here due to copyright. 
 
Table 3.4 Native TEAD4 (YBD) crystal data processing statistics and parameters 
from data collected at the Diamond Light Source on beam IO2 
Cryo buffer condition 25% glycerol added to: 0.1 M Sodium citrate pH 5.6, 2% 
isopropanol, 15% PEG4000 
Wavelength 0.976 Å 
Resolution Limit 1.86 Å 
Cell dimensions 62.9 Å, 89.5 Å, 109.2 Å,   90.00°, 90.00°, 90.00° 
Unit Cell P 2 2 21 
Total reflections 602085 
Unique reflections 43964 
 50-1.98 Å        2.05-1.98 Å 
Rmerge 0.063                (0.403)     
Completeness 96.4                  (94.5) 
I/σ(I) 22.1                  (3.43) 
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Figure 3.9 (A) Diffraction data for native TEAD4 (YBD) crystal. The data processing (using 
HKL2000 (Otwinowski et al. 1997)) that placed the crystal in the orthorhombic P2221 space 
group is shown in panel B where yellow spots represent partial measurements and red 
represents overlapped spots. Panel C illustrates a diffraction spot beyond the 2 Å marker.  
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Shortly after the phasing attempts, three papers containing various structures of 
TEAD YBDs were published (Chen et al. 2010; Li et al. 2010; Tian et al. 2010). 
Electron density maps were calculated using these structures to model the phases by 
molecular replacement. Unfortunately the R-factors could not be reduced during the 
refinement stage and we returned to the idea that the crystals may be twinned. The 
native dataset was converted to CNS format using CCP4i (Potterton et al. 2003) and 
submitted to the UCLA ‘Merohedral Twin Detector’ programme, which is not affected 
by anisotropy, pseudo-centering or pseudo-non-crystallographic symmetry (Yeates 
1997). The output graph indicates that the crystals were partially twinned (Figure 3.10). 
The difficulty experienced in processing the data at ESRF was also a sign of non-
merohedral twinning. As perfect merohedral twinning did not occur, the twinning factor 
could not be corrected for and the structure of medaka TEAD4 YBD remains unsolved. 
 
Figure 3.10 (A) Reference and (B) native TEAD4 crystal diffraction data output graphs from 
the UCLA ‘Merohedral Twin Detector’ using the Padilla-Yeates algorithm (Yeates 1997). 
Graphs show the local intensity statistics curve, N(|L|) versus |L|, where L = [I(A) - I(B)]/[I(A) 
+ I(B)] and I(A) and I(B) are the intensities of nearby (local) unrelated reflections A and B. 
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3.3.5 YAP (TBD) protein purification and NMR spectroscopy  
The TEAD binding domain of YAP expressed well in BL21 (DE3) cells but was 
insoluble and refolding attempts were unsuccessful. For the NMR sample, 15N labelled 
YAP (TBD-WW1) in pSV281 was used.  The 15N labelled protein was expressed in 
BL21 (DE3) cells for 3 hours at 37°C and purified using standard protocols described in 
Chapter 2 (Figure 3.11). 
 
 
Figure 3.11 (A) Elution profile of 15N YAP (TBD-WW1) from a 5 ml His-Trap FF column (GE 
Healthcare). (B) Coomassie blue stained SDS-PAGE analysis of purified 15N-labelled YAP 
(TBD-WW1) with an expected MW of 20 kDa; 10 µl of the concentrated NMR sample diluted 
1:10 with sample buffer (appendix III-c) (left) and 5 µl marker (right, with band MWs 
indicated) were loaded.  
 
The 2D 1H-15N-HSQC (Figure 3.12) revealed that the N-terminal, TBD of YAP is 
natively unstructured. Most of the peaks are clustered in the centre of the spectrum, 
many of which overlap. The weak peaks that are more widely dispersed arise from the 
folded WW1 residues. In accordance with these results, Tian et al (2010) also found that 
the N-terminus of human YAP is natively unfolded. 
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Figure 3.12 1H-15N YAP (TBD-WW1) HSQC acquired at 25°C with 8 scans. Buffer conditions 
are shown in Table 3.2. The lack of peaks in the 1H 8.5-9.5 ppm region of the spectrum and the 
high proportion of overlapped peaks in the central region suggest that the protein lacks rigid 
secondary structure. 
 
 
3.3.6 TEAD-YAP interaction 
In order to verify that medaka fish YAP and TEAD proteins interact, and to set up 
co-crystal screens, TEAD4 (YBD) pOPIN-F was immobilised on a 5 ml nickel affinity 
column and used to pull-down pure YAP (TBD-WW1). SDS-PAGE analysis of the 
elution peak revealed the presence of both proteins (Figure 3.13) indicating that, as 
expected, they are capable of forming a complex.  
Crystal screens were carried out and although some ‘hits’ occurred, successful 
crystallisation conditions could not be replicated on a larger scale. Following the 
publication of the mouse TEAD4-YAP (Chen et al. 2010) and human TEAD1-YAP (Li 
et al. 2010) interaction domain complex crystal structures in 2010, the decision to focus 
on other Hippo pathway protein domains was taken (Chapters 4 and 5). 
YAP 
TBD-WW1 
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Figure 3.13 (A) Elution profile from a 5 ml His-Trap FF column, the imidazole gradient is 
shown in green and the A280 in blue. (B) Coomassie blue stained SDS-PAGE analysis of His-
tagged TEAD4 (YBD) pull-down of cleaved pure YAP (TBD-WW1) on the left and the marker 
on the right (with band MWs indicated to the right of the gel). The band at approximately 28 
kDa is TEAD4 and the band at 20 kDa is YAP. The affinity tag was removed from YAP prior to 
use in the experiment 
3.4 Discussion  
3.4.1 TEAD cDNA isoforms  
Plasmids containing TEAD cDNA were constructed from medaka fish mRNA with 
the intention of using them as PCR templates. Sequencing the plasmids revealed variant 
full-length (fl) TEAD isoforms. TEAD1 (fl) and TEAD2/3 (fl) each had a primary 
structure close to the expected sequence (that was in the Ensembl database), they also 
both had a splice variant containing an insertion of around 20 amino acids within the 
DNA binding domain (DBD). It took two separate attempts to obtain a useful TEAD4 
(fl) cDNA plasmid as all of the initial plasmids sequenced contained a stop codon in 
place of W78, at the N-terminus of the YBD. 
 The insertion of around 20 amino acids located within the DBD of TEAD1 is 68% 
identical and 84% similar to the predicted third α-helix (H3) (Cole et al. 2008) of the 
shorter non-variant TEAD1 (TEAD1(s)). The insertion in TEAD2/3 DBD has 68% 
identity and 90% similarity with predicted H3 of TEAD2/3(s). Therefore, although the 
lack of a corresponding inserted region in the database for alignment meant that the 
insertion was not predicted to be α-helical, it is likely that the insertion forms a fourth 
α-helix (an alignment of the four regions is shown in Figure 3.14a).  
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According to the original multiple sequence alignments of the full-length medaka 
TEAD proteins (Figure 3.3), the TEAD1(l) variant contains the insertion/theoretical 
helix between H2 and H3 (of TEAD1(s) non-variant), whereas in the TEAD2/3(l) 
variant the insertion/theoretical helix is apparently C-terminal to H3. This was the case 
even when the gap penalties were increased. When the DBDs of TEAD1 and 2/3 are 
aligned with human TEAD1 without the YBD (again using ClustalW2), the theoretical 
helix is C-terminal to H3 in both cases (Figure 3.14b), further highlighting the similarity 
between H3 and the insertion, which will now be called theoretical H4 (tH4). Due to the 
high similarity between H3 and tH4, the alignment in Figure 3.3 was manually edited to 
place the insertion after H3 in both TEAD1 and TEAD2/3. 
As we were unable to successfully purify any DBD proteins, the implications of the 
extra region for DNA binding are currently unclear. In the case of human TEAD1 the 
H3 α-helix is known to be the DNA recognition site (Anbanandam et al. 2006). The 
structure of the TEA domain is similar to that of the homeodomain fold; DNA binding 
is also known to be mediated by H3 in homeodomain-containing proteins (Laughon 
1991). Given the proximity of tH4 in TEADs 1 and 2/3 to H3, tH4 may affect DNA 
binding in some way. The presence of an extra helix might enhance or alter the 
specificity of DNA binding. There are examples of transcription factor DBDs 
comprising four-helix bundles including E47 (a bHLH TF) (Ellenberger et al. 1994) and 
Upstream stimulatory factor (USF, a b/HLH/Z TF) (Ferre-D'Amare et al. 1994), 
however these tend to be dimers of two helix-loop-helix (HLH) structures. Alternatively 
the extra helix might interfere with or prevent interactions with DNA, or have no effect 
on DNA binding at all. 
The TEAD4 variant with a stop codon before the YBD would presumably be 
translated as an isolated DNA binding domain. If this assumption is correct, it might be 
feasible for the non-YAP binding isoform of TEAD4 to competitively inhibit the action 
of full-length TEAD-YAP thereby preventing transcription. A truncated TEAD would 
be able to enter the nucleus as the nuclear localisation signal (NLS), 
“RKQVSSHIQVLARRKAREIQ”, identified in the Drosophila TEAD homologue Sd 
(Srivastava et al. 2002) encompasses H3 of the DNA binding domain. The Sd NLS 
bears between 77% and 94% identity with the medaka TEAD H3 and tH4 helices, so 
enhanced nuclear localisation might be an alternative role of tH4 in TEAD1 and 
TEAD2/3. 
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Figure 3.14 (A) Multiple sequence alignment of TEAD1 (T1) and TEAD2/3 (T3) H3 and tH4. 
The illustration above the alignments highlights the location of residues thought to be located in 
helical regions based on the structure of human TEAD1 A49S mutant (PDB ID: 2HZD) 
(Anbanandam et al. 2006). (B) Alignment of the DBD from human TEAD1 A49S with TEAD1 
(s and l) and TEAD2/3 (s and l). Alignments were made using ClustalW2 and the panels 
generated with Boxshade. 
3.4.2 Practical aspects of TEAD purification 
As TEAD transcription factors are the nuclear target of YAP (and TAZ) regulated by 
the Hippo pathway, our intention was to purify the DBD of one or more medaka TEAD 
proteins in order to study TEAD-DNA interactions more closely. At the beginning of 
the project, the structure of the C-terminal domain of TEAD that interacts with YAP 
was unsolved. Also, as the amino acid sequence of TEAD (YBD) was not similar to any 
other protein in the PDB there was no template available for homology modelling. 
Therefore we intended to study the structure of TEAD and its interaction with YAP.  
Unfortunately, it proved extremely difficult to purify sufficient yields of TEAD DBD 
and YBD protein constructs for biophysical characterisation. Despite using a range of 
expression methods including changing vectors and cell strains, none of the DBD 
fragments provided any useful data. Previously, the human TEAD1 (TEF-1) DBD was 
subjected to site-directed mutagenesis (A49S in the first α-helix based on the 
Drosophila Sd sequence) in order to produce enough protein for structural 
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characterisation (Anbanandam et al. 2006). This avenue was not explored, though it 
may be worth considering for potential future experiments.  
The best quality 1H-15N-HSQC of the YBD from a TEAD protein was that of 
TEAD2/3 (239-462) when expressed in the pSV281 vector alongside the pREP4-
GroESL chaperonins. The proteins used in this study are derived from medaka fish, a 
multicellular, vertebrate organism with more complex molecular machinery than the 
unicellular E. coli strains that were used to express the proteins. The co-expression of 
the bacterial chaperonins GroEL and GroES (on the same plasmid) with proteins from 
higher organisms was previously shown to improve expression and purification of 
properly folded constructs for use in NMR experiments (Piserchio et al. 2009). 
Reproducing a good quality TEAD2/3 NMR sample proved troublesome. Both the 
TEAD2/3 (YBD) and pREP4-GroESL vectors contain kanamycin resistance genes; 
therefore it is possible that the cell line lost the pREP4-GroESL plasmid, thereby 
reducing the ability of the cells to produce well-folded TEAD2/3.  
The TEAD4 (YBD) pSV281 construct used for trypsin digestion and NMR 
experiments was expressed without the assistance of extra chaperones, though as for all 
successful YBDs, the cells were induced at 12°C and lysed in buffer containing 4% 
Triton X-100. Although the concentration of TEAD4 (YBD) pSV281 achieved when 
making the NMR sample was higher than TEAD2/3, the TEAD4 spectrum exhibited 
signs of heterogeneity such as variable peak intensities. This could be attributed to a 
misfolded or unfolded fraction of the protein population. Trypsin treatment would have 
removed unfolded protein but may not have been effective in digesting misfolded 
protein; production of trypsinised 15N-labelled TEAD4 (YBD) was attempted but 
acquisition of an improved 1H-15N-HSQC spectrum was not achieved.  
Co-expression of TEAD4 (YBD) pOPIN-F with pREP4-GroESL (selection of 
colonies was made with ampicillin and kanamycin) was used successfully for 
crystallisation, which suggests the protein was homogeneous. However, this may not 
have been the case. A fraction of the population could have been misfolded, which 
might have lead to the crystal twinning effect that will be discussed in section 3.4.3. 
Again, production of 15N-labelled TEAD4 (YBD) for NMR using this method did not 
result in a good quality spectrum.  
 
3.4.3 Structural characterisation of TEAD and YAP interaction domains 
The trypsin digest of TEAD4 (YBD) gave an initial indication that the domain is 
globular.  The presence of folded secondary structural elements in the YBD of 
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TEAD2/3 and TEAD4 was confirmed by NMR spectroscopy (Figure 3.6). The ability 
of the YBD to crystallise was another indication that the protein possesses a rigid 
secondary structure. NMR data collection was limited due to difficulties in 
concentrating protein, the poor reproducibility of protein preparation and the size of the 
domain. This meant that 15N/13C samples were not made and triple resonance data sets 
that might have led to sequence specific peak assignments could not be acquired. 
Although TEAD4 crystals diffracted well, at the time there were no homologous 
models available for molecular replacement to solve the phase problem and calculate an 
electron density map. Therefore, a host of alternative experimental methods were 
utilised in an attempt to acquire difference data. Initially the standard method of seleno-
methionine labelling was tried in order to obtain phasing data by multi-wavelength 
anomalous dispersion (MAD). Although protein was produced it would not crystallise, 
perhaps because of slight differences in sample preparation. The next method attempted 
was multiple isomorphous replacement phasing (MIR). Various heavy atom salts 
including mercury (II) chloride, phenyl mercuric acetate and potassium 
tetrachloroplatinate were soaked into native crystals. Most of the time the additives 
disrupted the crystal structure to the extent that visible cracks appeared, rendering the 
crystal useless. The few occasions that the crystal was not visibly damaged, diffraction 
did not occur or was mosaic, thus indicating sub-microscopic (i.e. not visible under a 
light microscope) disruption of the crystal lattice. 
The TEAD4 (YBD) contains three Cys and six Met residues that could be detected 
by anomalous sulphur scattering by changing the wavelength of the X-ray beam. Longer 
wavelength X-rays were used at ESRF (Grenoble) on these crystals, however the data 
displayed signs of mosaicity and could not be processed, thus the possibility that the 
crystals were twinned was suggested by one of the course leaders – Christoph Mueller-
Dieckmann. In 2010 three independent TEAD (YBD) structures were published: human 
TEAD2 (Tian et al. 2010), human TEAD1-YAP (Li et al. 2010), and mouse TEAD4-
YAP (Chen et al. 2010). As expected, all three structures are highly similar. The key 
features of the TEAD (YBD) structures are described in Chapter 1. As a native data set 
had previously been acquired, a final attempt was made to solve the medaka TEAD4 
(YBD) structure using molecular replacement with one or more of the published 
structures as a model for obtaining phases.  
Unfortunately it proved impossible to refine the medaka TEAD4 (YBD) structure 
and the possibility that the crystals might be twinned was reconsidered. This theory was 
supported by the fact that although indexing the data indicated that the space group was 
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P2221 (Table 3.4), there was also a high possibility of the unit cell being in the P222 
space group. The UCLA merohedral twin detector software indicated that the TEAD4 
(YBD) crystals were partially twinned. Twinning is the presence of more than one 
crystal lattice within what appears to be a single crystal, which leads to overlapping 
reflections in the diffraction pattern.  Twinning may be described as macroscopic, 
merohedral or non-merohedral. According to CCP4, merohedral twinning gives rise to 
diffraction patterns that can be superimposed, whereas in the case of non-merohedral 
twins the reciprocal lattices are not aligned. Macroscopic twins may be seen under the 
microscope and grow from separate nucleation sites. Not all space groups can form 
merohedral twins and the two most likely space groups for the TEAD4 (YBD) crystals, 
P222 and P2221, unfortunately fall into this group. Orthorhombic crystals (like TEAD4) 
can form ‘pseudo-hemihedral’ twins (similar to merohedral twins) but only if two of the 
cell axes are of similar lengths; the criterion for non-merohedral twins also includes two 
of the cell dimensions being similar. The TEAD4 crystal cell dimensions (Table 3.4) are 
63, 90 and 109 Å so they are clearly not pseudo-hemihedral or non-merohedral twins. 
Therefore, although twinning was not visible at the highest magnification, the TEAD4 
crystals must have been macroscopic twins.  The CCP4 suite contains the ‘DETWIN’ 
programme to correct for merohedral twinning but the software does not currently have 
the means to refine macroscopic, non-merohedrally or partially twinned datasets. The 
medaka TEAD4 YBD structure therefore remains undetermined. 
 
3.4.4 TEAD-YAP interaction 
A pull-down assay between immobilised His-tagged TEAD4 (YBD) on a nickel ion 
affinity column and YAP (TBD-WW1) verified that medaka TEAD and YAP interact. 
Human YAP (TBD) was subsequently shown to bind TEAD2 (YBD) with nanomolar 
affinity (Tian et al. 2010). Given the many functional studies of the YAP-TEAD 
interaction, the crystal structures, and the recently discovered co-evolution of YAP and 
TEAD (Hilman et al. 2011), the results of the pull-down experiment are not unexpected.  
Attempts were made to crystallise the YAP-TEAD complex, initially using 96 well 
high throughput screens and then optimising the conditions in 24 well plates. The 
scaled-up screens were unsuccessful and after the publication of the 2010 TEAD 
structure papers (Chen et al. 2010; Li et al. 2010; Tian et al. 2010) the WW domains of 
YAP and its paralogue, TAZ became the main focus of investigation. 
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CHAPTER 4: WW DOMAINS OF YAP AND TAZ  
(INSIGHTS INTO THE STRUCTURAL, DYNAMIC AND 
BINDING PROPERTIES OF TANDEM WW DOMAINS 
FROM THE NUCLEAR EFFECTORS OF THE HIPPO 
SIGNALLING PATHWAY) 
 
Figure 4.1 Location of YAP and TAZ within the Hippo pathway (highlighted in pink). Core 
Hippo pathway components are located within the orange box. 
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4.1 Introduction 
WW domains are small protein-protein interaction domains, prevalent in signalling 
molecules. There are two isoforms of YAP; the presence of either one or two WW 
domains is the only difference between them. To date only a single WW domain 
isoform of TAZ has been described. The WW domains of YAP and TAZ are central to 
their multi-protein binding capabilities (Table 1.2) including the interaction with the 
LATS kinase that leads to cytoplasmic sequestration of YAP/TAZ by 14-3-3 proteins 
(Fig 4.1). Previous studies on tandem WW domains have described molecules with a 
range of different properties including linkers with different lengths and degrees of 
flexibility, and inter-domain cooperation that leads to significantly enhanced binding 
affinities. All published tandem WW domain structures to date contain shorter inter-
WW linkers (at 12-20 residues) than the inter-WW linker of YAP which is 35 residues. 
Prior to this work, there were no structure-based studies on the second WW domain or 
tandem WW1-WW2 domain of YAP. 
The solution structure of human YAP WW1 in complex with various peptide ligands 
has been published (Macias et al. 1996; Pires et al. 2001; Aragon et al. 2011). There are 
no available solution structures of unliganded YAP WW1 and previous studies have 
implied that YAP WW1 is unstable in comparison with other WW domains 
(Ibragimova et al. 1999). Neither were there any structures of YAP WW2. Since the 
publication of the work in this chapter (Webb et al. 2011), a study of the interaction 
between a Smad1 peptide and YAP individual and tandem WW domains has been 
published (Aragon et al. 2011). However, prior to these recent publications, there were 
no structure-based studies on the WW-pair of YAP or TAZ. 
The WW domains of YAP and TAZ are small enough to be characterised by NMR 
spectroscopy. In addition to gaining insight as to whether a protein is folded (by 
inspecting the 2D 1H-15N-HSQC spectrum), this technique can be used to generate a 
model of the 3D structure, study the dynamic properties of a protein and determine 
which residues are affected by interactions between proteins.  
The aims of the work in this chapter were to study the WW domain of medaka TAZ 
and characterise structural features and peptide-binding properties from the tandem 
WW domain of medaka YAP. An Ile residue N-terminal to the core WW domain has 
been implicated in stabilising the structure of WW1 (Macias et al. 1996). In order to 
determine if this residue played the same role in medaka YAP WW1, both long and 
short WW1 constructs, WW1 and WW1(s), which contained or lacked the N-terminal 
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Ile, were created. During the course of this research a second isoform of TAZ (TAZ2) 
that contains two WW domains was discovered. Structural features and dynamics of the 
WW domains from medaka YAP and TAZ (Figure 4.2) were characterised by NMR 
spectroscopy. Functional interactions between the YAP/TAZ tandem WW domain 
fragments and PPxY motif containing peptides were also revealed by NMR titration 
experiments. 
 
 
Figure 4.2 Representation of medaka YAP/TAZ domains studied in this chapter. The 
numbering for YAP and TAZ corresponds to the constructs that were most frequently used. 
Each individual WW domain is approx. 40 residues in length. The YAP inter-WW linker is 
approx. 35 residues and the TAZ linker approx. 45 residues. Domains that do not feature in this 
chapter are unlabelled and do not contain colour. 
 
4.2 Materials and methods 
 
4.2.1 Production of template cDNA and cloning of DNA fragments 
Production of TAZ cDNA. The full-length TAZ cDNA plasmids were produced in 
the same way as TEAD cDNA (section 3.2.1). The first round of PCR was carried out 
using an annealing temperature of 56°C with the forward and reverse primers ‘TAZ 3F’ 
and ‘TAZ 3R’ (Appendix I-c). The primers for the nested PCR were ‘TAZ 4F’ and 
‘TAZ1 innerR’ (Appendix I-c), and the annealing temperature was 50°C. 
 
Cloning of WW domains into Vanderbilt vectors. YAP and TAZ WW domain DNA 
was amplified using Phusion HF DNA polymerase following cloning procedures 
described in Chapter 2. YAP and TAZ DNA fragments were cloned into the EcoRI and 
HindIII sites of vectors pSV281, pBG100 and pBG101. Constructs and primers are 
shown in Table 4.1 and Appendix I. 
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Table 4.1 YAP and TAZ WW domain cloning information 
Protein Domain Forward primer Reverse primer 
YAP WW1  
(S119-L162) 
CGGAATTCCTCCTACGA
GATTCCCGAC 
CCCAAGCTTCTATTAGAG
CAGGGCTTTGCG 
YAP WW1(s)  
(D124-L162) 
CGGAATTCCGACGACGT
GCCCCTG 
CCCAAGCTTCTATTAGAG
CAGGGCTTTGCG 
YAP WW1-WW2 
(S119-R222) 
CGGAATTCCTCCTACGA
GATTCCCGAC 
CCCAAGCTTCTATTAGCG
AGTCTCAAGTCG 
YAP WW1(s)-WW2  
(D124-R222) 
CGGAATTCCGACGACGT
GCCCCTG 
CCCAAGCTTCTATTAGCG
AGTCTCAAGTCG 
YAP WW2  
(S182-R222) 
CGGAATTCCAGCCCAGC
TAGTGGAC 
CCCAAGCTTCTATTAGCG
AGTCTCAAGTCG 
TAZ WW1  
(A103-L147) 
CGGAATTCCGCGACATC
GATCATACCTGA 
CCCAAGCTTCTATTAGAG
CTGCGAGAGACGAGG 
TAZ WW1-WW2 
(A103-M218) 
CGGAATTCCGCGACATC
GATCATACCTGA 
CCCAAGCTTCTATTACAT
TTTCTGAGCTAGACGCG 
TAZ WW2  
(N177-M218) 
CGGAATTCCAACCCGGA
GTCAGGTCCAC 
CCCAAGCTTCTATTACAT
TTTCTGAGCTAGACGCG 
 
 
4.2.2 Expression and purification of WW domains from YAP and TAZ 
Induction and purification trials were carried out as described in Chapter 2. All YAP 
and TAZ WW domain constructs were expressed in BL21 (DE3) cells with 0.5 mM 
IPTG for 3 hours at 37°C, with the exception of YAP WW1 and YAP WW1(s) in 
pSV281 which were expressed at 12°C overnight in Arctic Express (RP) and BL21 
(DE3) cells. 15N and 15N/13C labelled preparations were inoculated as described for 
YAP (TBD-WW1) in Chapter 2. In general, cells were resuspended in His-buffer A 
with 2% Triton X-100 and one ‘Complete mini protease inhibitor cocktail’ tablet per 50 
ml buffer. Proteins were initially purified by affinity chromatography using a HisTrap 
FF column (GE Healthcare). The His-tag from pBG100 and the His-GST tag from 
pBG101 were cleaved overnight at 4°C using 3C protease in 50 mM Tris, 150 mM 
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NaCl, 1 mM DTT, pH 7.5. Proteins were separated from the cleaved tags by a second 
affinity purification.   
15N and 15N/13C labelled YAP WW1-WW2 and TAZ WW1-WW2 were further 
purified by ion exchange chromatography using a pre-packed QFF Sepharose column 
(GE Healthcare). The wash buffer for YAP was 10 mM potassium phosphate pH 7, and 
for TAZ was 20 mM Tris pH 7.5. Proteins were eluted in the wash buffer conditions 
with a salt gradient up to 0.5 M NaCl. All WW domain constructs were buffer 
exchanged by concentration/dilution (Table 4.2) and prepared for NMR experiments as 
previously described (Chapter 2). 
 
 
Table 4.2 NMR buffer conditions and parameters for YAP and TAZ WW domains 
Protein 
construct 
Buffer Temperature 15N SW 15N carrier 
frequency 
YAP WW1 
pSV281 
50 mM potassium 
phosphate pH 5.5, 200 
mM NaCl, 5 mM 
EDTA 
18 °C 1519 Hz 120.5 ppm 
YAP WW1(s) 
pSV281 
50 mM potassium 
phosphate pH 5.5, 200 
mM NaCl, 5 mM 
EDTA 
25 °C 1519 Hz 120.5 ppm 
YAP WW1-
WW2 pBG101 
(cleaved) 
50 mM potassium 
phosphate pH 5.5, 100 
mM NaCl, 0.5 mM 
EDTA 
18 °C 1519 Hz 120.5 ppm 
YAP WW1(s)-
WW2 pSV281 
50 mM potassium 
phosphate pH 5.5, 200 
mM NaCl, 5 mM 
EDTA 
25 °C 1519 Hz 120.5 ppm 
YAP WW2 
pSV281 
50 mM potassium 
phosphate pH 5.5, 200 
mM NaCl, 5 mM 
EDTA 
30 °C 1519 Hz 120.5 ppm 
TAZ WW1 
pBG101 
(cleaved) 
20 mM Tris pH 7.5, 
100 mM NaCl, 5 mM 
EDTA, 2 mM NaN3 
20 °C 1640.9 Hz 120 ppm 
TAZ WW1-
WW2 pBG101 
(cleaved) 
20 mM Tris pH 7.5, 
100 mM NaCl 
27.5 °C 1640.9 Hz 120 ppm 
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4.2.3 YAP and TAZ WW domain HSQC backbone assignments 
Initially 2D 1H-15N- HSQC spectra were recorded at different temperatures in order 
to obtain the best quality HSQC. When the optimal temperature was identified an NH2-
only spectrum was recorded identify NH2 side chain peaks. In order to make sequence 
specific backbone assignments, 3D HNCO, HNCACO, HNCACB and CBCACONH 
data sets were recorded on 13C/15N-labelled proteins. The double and triple resonance 
data sets were acquired using Varian BioPack pulse sequences. Spectra were processed 
using NMRPipe/NMRDraw (Delaglio et al. 1995) and analysed with CCPN Analysis 
(Vranken et al. 2005). 1H, 15N and 13C chemical shifts were referenced to DSS (Wishart 
et al. 1995). 
 
4.2.4 YAP WW2 solution structure determination 
NMR data were acquired and processed as described in section 4.2.3. Additional 3D 
data sets were acquired and analysed for the assignment of side chain resonances (15N-
TOCSY, CCONH, HCCH-TOCSY and HCCH-COSY) and to obtain NOE distance 
restraints (15N-NOESY HSQC spectra with mixing times of 50 and 200 ms, 13C-
NOESY HSQC with a mixing time of 170 ms). Backbone dihedral torsion angles ϕ and 
Ψ were predicted using TALOS+ (Shen et al. 2009) within the NMRPipe system. 
Hydrogen bond distance restraints were predicted from the published YAP WW1 
structure (Macias et al. 1996); the NH-O distance was assigned lower and upper values 
of 1.5 and 2.5 Å, and the N-O distance assigned lower and upper values of 2.5 and 3.5 
Å. 
Structures were calculated using Xplor-NIH (Schwieters et al. 2006) to perform 
simulated annealing starting from random extended structures. The VMD-Xplor 
(Schwieters et al. 2001) visualization package was used to scrutinise ensembles of 
structures for violated restraints. The final structures were obtained after iterative 
refinement by removal of consistently violated restraints and using standard Xplor-NIH 
refinement protocols. Structure quality was assessed using PROCHECK-NMR 
(Laskowski et al. 1996). 
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4.2.5 NMR titrations with PPxY peptides 
The peptide GTPPPPYTVG was synthesised by Dr Francesca Giuntini (Department 
of Pharmacy and Pharmacology, University of Bath) and the dual PPxY peptide 
GTPPPPYTVGGGGGGGTPPPPYTVG was purchased from Thermo Fisher Scientific. 
Titration data were acquired at the temperatures shown in Table 4.2. In order to monitor 
WW-peptide binding, 1H-15N-HSQC spectra of YAP and TAZ tandem WW domains 
were recorded as a function of increasing peptide concentration. The spectra, from each 
titration point, were overlaid using Sparky (Goddard et al.) or CCPN Analysis (Vranken 
et al. 2005) to monitor changes in backbone NH chemical shifts. The average chemical 
shift change of each NH peak was calculated using Equation 4.1. Rieko Ishima 
(University of Pittsburgh, U. S. A.) calculated the affinities of WW domains for 
peptides as previously described (Webb et al. 2011).  
 
 
Equation 4.1:  Δδav (ppm) = [(Δδ2HN + Δδ2N/25)/2]1/2 
Where δ is the standard symbol for the chemical shift in parts per million (ppm); δ is calculated 
using the resonance frequencies (Hz) of the atom of interest and a reference substance (which in 
this case is DSS), and the frequency of the spectrometer (which in this case is 600 MHz). 
 
A two tailed t-test was carried out to determine whether peptide binding affected one 
of the WW domains within the WW1-WW2 fragment significantly more than the other. 
In order to assess the potential multimerisation effect of dual PPxY peptide binding to 
the tandem WW domain fragments, native-PAGE was carried out in a similar manner to 
SDS-PAGE (described in Chapter 2), but SDS and β-mercaptoethanol were omitted 
from all buffers, the current was reduced to 40mA and the tank was placed on ice to 
avoid heat denaturation of the protein. 
 
4.2.6 NMR relaxation and dynamics 
15N YAP and TAZ WW1-WW2 domains were buffer exchanged into water by 
dialysis and freeze dried prior to shipping. Rieko Ishima (University of Pittsburgh, U. S. 
A.) acquired and analysed the 15N NOE, R1 and R2 and relaxation dispersion data on the 
unbound tandem WW domain protein fragments as described in Appendix IV on pages 
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3301 and 3302 of the article (Webb et al. 2011). Equivalent data for dual PPxY peptide-
titrated WW1-WW2 fragments were collected on the in-house Varian INOVA 600 
spectrometer. 
 
4.3 Results 
 
4.3.1 TAZ cDNA isoforms 
Several full-length TAZ cDNA plasmids were sequenced (Appendix II-e) and two 
splice forms were identified. The single WW domain isoform, now called TAZ1, was 
previously known to exist. The identification of a tandem WW domain isoform, TAZ2 
is novel, but perhaps not surprising given the existence of the two YAP splice forms 
(YAP1 and YAP2). Comparison of medaka YAP2 and TAZ2 WW domains reveals a 
difference in the length of the inter-domain linker of 10 residues (35 residues for YAP2 
and 45 residues for TAZ2). The tandem WW fragments shown in Figure 4.3 are 59% 
identical and 70% similar. The individual WW1 domains of YAP and TAZ have 75% 
identity and 86% similarity. The individual WW2 domains of YAP and TAZ are 75% 
identical and 90% similar.  
 
Figure 4.3. YAP2 and TAZ2 tandem WW domain alignment made using ClustalW (Thompson 
et al. 1994). The panel was generated in Boxshade.  YAP residues start at S119 and end at 
R222. TAZ residues start at T104 and end at K217. 
 
4.3.2 Expression and purification of YAP and TAZ WW domains 
YAP WW1 was induced overnight at 12°C in Arctic Express (RIL) cells, as 
expression was unsuccessful in BL21 (DE3) cells at 37°C. All other YAP and TAZ 
WW domains were expressed in BL21 (DE3) cells at 37°C for 3 hours. Individual YAP 
WW domains were generally expressed in the pSV281 vector and purified by affinity 
chromatography using the N-terminal 6His-tag, which was not usually removed. YAP 
WW1-WW2 was purified as illustrated in Figure 4.4 and TAZ was purified in the same 
way. Individual TAZ WW domains were expressed in the pBG101 vector. The His-
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GST tag was cleaved and the TAZ proteins purified with similar elution profiles to 
those shown in Figure 4.4a and 4.4b. 
 
Figure 4.4 Purification profiles of 15N YAP WW1-WW2 from a 0.75 L culture used in NMR 
experiments. Nickel ion affinity chromatograms of (A) pre- (10 runs using a 1 ml His-Trap FF 
column) and (B) post- (3 runs using q 5 ml His-Trap FF column) His-GST tag cleaved protein. 
(C) Ion exchange chromatogram (4 runs using a 5 ml QFF column in KH2PO4 pH7 buffer and 
eluted in the same buffer with the addition of up to 0.5 M NaCl) of post-cleaved, post-affinity 
purified sample. (D) Coomassie stained SDS-PAGE gel containing the 1 µl of the final NMR 
sample, with an expected size of ~12 kDa. The pure YAP WW1-WW2 fraction is highlighted in 
each frame by an arrow. 
 
4.3.3 YAP WW1(s) vs. YAP WW1  
It was previously reported that an Ile residue N-terminal to the human YAP WW1 
domain was essential to folding (Macias et al. 1996). We also observed this when 
comparing medaka WW1(s) and WW1 HSQC spectra (Figure 4.5a). The YAP WW1(s) 
construct starts 4 amino acids after this key Ile and the spectrum shows many peaks 
around 7.5-8.5 ppm in the 1H dimension but none further upfield or downfield. In 
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contrast, the WW1 construct that starts two residues N-terminal to I121 produces a 1H-
15N-HSQC with well dispersed peaks, suggestive of a folded domain. 
 
 
Figure 4.5 1H-15N-HSQC spectra of (A) WW1 (blue) and (B) WW1-WW2 (blue), which both 
contain I121, overlaid onto (A) WW1(s) (orange) and (B) WW1(s)-WW2 (orange), which both 
lack I121, spectra to emphasise the effect of I121 on the structure of YAP WW1 (A) alone and 
(B) within WW1-WW2. Data were acquired at 25°C at pH 5.5 (buffer conditions in Table 4.2 in 
section 4.2.2).  
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4.3.4 Assignment of YAP WW1, WW1-WW2 and WW2 NMR spectra 
Making assignments. In order to make sequence specific backbone assignments, a 
range of 3D NMR spectra were recorded on double labelled protein (15N and 13C) 
including (Figure 4.6): HNCACB which detects the chemical shift of the Cα and Cβ; 
CBCACONH which detects the Cα and Cβ of the preceding residue in the sequence; 
HNCACO which detects the C=O chemical shift; and HNCO which detects the C=O of 
the preceding residue in the sequence. The 13C backbone C=O chemical shifts are in a 
different region to those of the side chain carbon atoms. Typically the C=O chemical 
shifts are around 166-182 ppm, Cα and Cβ chemical shifts are 15-75 ppm; The atoms of 
each amino acid have characteristic chemical shifts within these ranges (which can be 
found on the website of the Biological Magnetic Resonance Data Bank-BMRB) and so 
can often be identified.  
 
WW domain NMR spectra assignments. WW1-WW2 backbone NH peak 
assignments (Figure 4.7) required the individual WW1 chemical shift assignments 
(Figure 4.8) for completion, due to weak/undetectable WW1 (within WW1-WW2) 
cross-peaks in 3D spectra. NMR experiments on constructs containing WW1 (Figures 
4.7, 4.8) were recorded at a lower temperature than those of individual WW2 (Figure 
4.9) because there were fewer WW peaks at temperatures higher than 18°C, whereas the 
best quality WW2 1H-15N HSQC spectra were obtained at 30°C. WW1 peaks around 9-
10 ppm, in the 2D 1H-15N-HSQC of WW1 and WW1-WW2, are less intense than the 
other peaks in the spectrum indicating some heterogeneity within the population. The 
equivalent WW2 peaks around 9-10 ppm are more intense than the WW1 peaks, and are 
of similar intensity to the rest of the spectrum, thus suggesting that WW2 adopts a 
stable folded conformation. Individual WW1 and WW2 chemical shifts are very similar 
to those within WW1-WW2 (Figures 4.7-4.9), thus implying that the two domains do 
not interact. 
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Figure 4.6 Example of cross peak connections for sequence-specific chemical shift assignment. 
(A) HNCACB and (B) HNCACO show Cα (blue), Cβ (orange) and CO (purple) chemical shifts 
of the residue of interest (Q194 in the central strip, E193 to the left and A195 to the right). (A) 
CBCACONH and (B) HNCO show Cα (maroon), Cβ (maroon) and CO (green) chemical shifts 
of the preceding residue in the sequence. Smaller signals corresponding to the chemical shift of 
the preceding residue in the sequence are also visible in the HNCACB and HNCACO spectra. 
13C chemical shift values are in the y-axes, 1H chemical shifts are in the x-axes, and 15N 
chemical shifts are in the bottom left corner of each strip. Dotted red lines illustrate the 
connectivity between residues. 
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Initial analysis of the assigned YAP WW1-WW2 HSQC indicates that the WW 
domains contain structural elements and the linker region is natively unfolded. The 
linker residue peaks are not located in well dispersed areas of the HSQC spectrum, they 
are clustered around 8-8.5 ppm in the 1H dimension. Conversely, many WW1 and 
WW2 peaks are dispersed beyond this central region of the HSQC spectrum. 
 
 
 
Figure 4.7 YAP WW1-WW2 1H-15N-HSQC at 18°C with NH backbone peak assignments 
labelled. In order to facilitate label visualisation, Trp indole NH peaks at 10-11 ppm are not 
shown. Chemical shifts from WW1 are labelled in blue, linker chemical shifts have black labels, 
and WW2 peaks have purple labels. All linker residues are located in the centre of the spectrum 
indicating that the linker is intrinsically unstructured. 
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Figure 4.8 His-tagged YAP WW1 1H-15N-HSQC at 18°C with labelled NH backbone peak 
assignments. 
 
 
 
Figure 4.9 His-tagged YAP WW2 1H-15N-HSQC at 30°C with NH backbone peak assignments 
labelled. 
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4.3.5 Solution structure of YAP WW2 
The 3D solution structure of WW2 was determined using NMR data (as described in 
section 4.2) in order to confirm the presence of a typical WW domain fold. That WW2 
proved to be more stable than WW1 and WW1-WW2 enabled completion of the task. 
WW1 alone and within WW1-WW2 was not stable enough to allow the structures of 
these constructs to be solved.  The calculated structure ensemble (Figure 4.10, Table 
4.3) verifies that the domain consists of a triple-stranded, twisted β-sheet with two short 
flexible loops, which is characteristic of WW domains. The root mean squared 
deviation (r.m.s.d.) in Table 4.3 shows the average distance between the atoms of the 20 
superimposed structures. As expected, the flexible regions N- and C-terminal to the β-
sheet arch around the hydrophobic face of the WW domain in a ‘buckle’-like manner. 
Opposite the hydrophobic face lies the anticipated peptide-binding site, the activity of 
which is reportedly dependent upon the presence of the Trp residue in the third β-strand 
(Koepf et al. 1999).  
 
Figure 4.10 Solution structure of medaka YAP WW2 (PDB ID: 2L4J). (A) Superimposition 
and (B) average structure of the 20 lowest energy structures coloured from blue at the N-
terminus to orange at the C-terminus. The figure was taken from Webb et al (2011). The core 
WW domain contains the canonical triple-stranded β-sheet fold; the N-terminus, which 
corresponds to the end of the inter-WW linker, in (B) appears to be almost helical, however the 
orientation of this coiled region is not superimposed within the ensemble. The beginning of the 
WW linker (C-terminal to WW1) is not shown in any WW1-peptide structures within the PDB 
and the 35 residue YAP linker region is also not shown in any structures within the PDB. 
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4.3.6 Assignment of TAZ WW domain NMR spectra  
TAZ WW domain 1H-15N-HSQC spectra display more heterogeneous signal patterns 
than YAP spectra, such as broader line widths and at least one extra Trp side chain NH 
peak around 10 ppm that indicates a certain degree of chemical exchange. Like YAP, 
TAZ also required the assignment of WW1 peaks (Figure 4.11) in order to obtain the 
full complement of WW1-WW2 backbone NH peaks (Figure 4.12). Another similarity 
to the YAP tandem WW domain spectrum is the apparent lack of structure in the linker 
region. NMR data were not acquired for TAZ WW2. 
Table 4.3. Structural statistics summary for the 20 lowest energy structures of YAP 
WW2. Adapted from Webb et al (2011). 
Total number of NOE restraints 358 
 Intra-residue 108 
 Sequential and medium range (i+1 to i+4) 113 
 Long range 137 
Number of dihedral angle restraints 46 
Number of hydrogen bond restraints 20 
Mean r.m.s.d. of backbone atoms* 0.34 Å 
Mean r.m.s.d. of non-hydrogen atoms* 1.04 Å 
Average number of NOE violations 1.8 
Average number of dihedral angle violations 0 
Ramachandran plot regions (% residues)+  
 Most favoured 81.8 
 Additionally allowed 18.2 
 Generously allowed 0 
 Disallowed 0 
*
 The r.m.s.d. from the mean structure calculated over residues 190-197, 201-207 and 
210-214. 
+
 Calculated using PROCHECK-NMR (Laskowski et al. 1996) over residues 190-
214 
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1H, 15N and 13C chemical shift based structure prediction was carried out for TAZ 
WW1 and WW1-WW2 using TALOS+ (Shen et al. 2009). WW1 alone and WW2 
within WW1-WW2 retain the three β−strands of the WW domain fold as described for 
the YAP WW2 structure. Due to incomplete Cα and Cβ assignments for WW1 within 
WW1-WW2 only the presence of the second β-strand was confirmed. However, NH 
chemical shifts are conserved between the individual and tandem WW1 HSQC spectra 
and TAZ WW1 has high sequence homology to YAP WW1, therefore TAZ WW1 
within the tandem domain is also likely to fold in a similar manner. 
 
 
 
 
Figure 4.11 TAZ WW1 (103-147) 1H-15N-HSQC spectrum with backbone NH peak 
assignments. Data were acquired at 20°C. Trp indole peaks around 10 ppm have been omitted to 
facilitate labelling. 
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Figure 4.12 TAZ WW1-WW2 (103-218) 1H-15N-HSQC spectrum with backbone NH peak 
assignments. Data were acquired at 27.5°C. Trp indole peaks around 10 ppm are not shown. 
 
4.3.7 WW1-WW2 NMR titrations with single and dual PPxY peptides 
Both YAP and TAZ tandem WW domains were titrated with the single PPxY 
containing peptide GTPPPPYTVG that has been used in previous interaction studies 
with human YAP WW1 (Macias et al. 1996), and a tandem repeat version 
GTPPPPYTVGGGGGGGTPPPPYTVG. Both WW domains of both proteins have the 
ability to bind both peptides as evidenced by the movement of WW domain peaks in the 
1H-15N-HSQC spectra recorded at each titration point (Figures 4.13 and 4.14). Peaks 
that underwent large chemical shift changes often broadened to the point where 
identification was difficult. Also, a number of peaks split into two during the dual PPxY 
titration, indicating slow chemical exchange. Linker peaks underwent little to no 
movement, suggesting that this region does not interact with, and remains structurally 
unaffected by, the presence of either peptide.  
	   82	  
 
Figure 4.13 Titration of (A) YAP WW1-WW2 and (B) TAZ WW1-WW2 with dual PPxY 
peptide. Overlaid 1H-15N-HSQC spectra illustrate peak movements of the tandem WW domains 
without peptide (red) through to the final addition of peptide (magenta). A red line illustrates 
peak movement in the cases where intermediate titration point peaks have broadened to 
invisibility. NMR spectra with single PPxY peptide were similar to the dual PPxY titration 
spectra, but fewer peaks disappeared during the course of the titration. 
 
WW1 peaks exhibit larger chemical shift changes upon binding to peptide than those 
of WW2 (Figure 4.14). The intensity of WW1 peaks in the 9-10 ppm proton chemical 
shift region of the 1H-15N-HSQC spectra also increase upon binding to peptide. A paired 
two-tailed t-test was performed on the overall chemical shift changes in the individual 
WW domains within the tandem domain constructs. A significant difference is revealed 
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in overall peak movement between WW1 and WW2 for both YAP and TAZ WW1-
WW2 when binding to each peptide. To determine whether the difference in chemical 
shift movements were related to affinities of the WW domains for peptide, Kd values 
were calculated using the average chemical shift movement at each titration point for 
residues within the known binding site.  
 
 
Figure 4.14 Average chemical shift movement of each assigned peak after the final addition of 
single PPxY peptide (top) and dual PPxY peptide (bottom) to (A, C) YAP and (B, D) TAZ 
WW1-WW2. Figure taken from Webb et al (2011). 
 
The two WW domains within WW1-WW2 have similar affinities for single PPxY 
peptide in YAP and TAZ, with TAZ having a slightly lower affinity for the peptide than 
YAP. YAP has WW1 and WW2 Kd values of 284 +/- 52 µM and 281 +/- 55 µM, and 
TAZ has WW1 and WW2 Kd values of 330 +/- 116 µM and 273 +/- 116 µM. The 
similarity between WW1 and WW2 Kd values indicates that the more significant change 
in the chemical environment of WW1 is not due to a difference in affinity, but a larger 
effect on the overall structure of the WW1 domain.  
Titration of WW1-WW2 constructs with the dual PPxY peptide resulted in chemical 
shift changes at much lower peptide concentrations than the titration with single PPxY 
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peptide. For TAZ the Kd was calculated to be at least 6 times higher (48.5 +/- 12 µM) 
than that for the single PPxY peptide, and the YAP Kd could not be accurately 
calculated with confidence but is estimated to be similar to that of TAZ. The pattern of 
WW domain chemical shift changes was similar for single and dual PPxY peptides 
(Figure 4.14 and 4.15), suggesting identical binding mechanisms with both ligands. 
 
Figure 4.15 Average chemical shift movement of binding site residues from YAP/TAZ tandem 
WW domains upon interaction with: (A) single and (B) dual PPxY peptide. Figure taken from 
Webb et al (2011). 
 
If the equipment and an excess of peptide had been available, the affinities of YAP 
and TAZ tandem WW domains for the peptides would have been measured by 
isothermal titration calorimetry to confirm the NMR calculations. Attempts were made 
to monitor the WW-peptide interactions through fluorescence spectroscopy; both by 
monitoring Trp fluorescence which would, in theory, change upon the interaction 
between the second W and the PPxY, and also using 1-anilinonaphthalene-8-sulfonic 
acid (ANS). Unfortunately the fluorescence experiments were unsuccessful as very little 
difference was observed between WW with peptide and without. 
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4.3.8 NMR relaxation and dynamics of tandem WW domains from YAP and TAZ 
Most of the relaxation and dynamics data were acquired and analysed by Rieko 
Ishima (University of Pittsburgh, U. S. A.). The exception being relaxation data 
acquired in-house on the post-titration dual PPxY-YAP WW1-WW2 sample. The 
results of the unbound tandem WW domain (Figure 4.16) and YAP WW1-WW2-dual 
PPxY relaxation (Figure 4.17) experiments are included here to present the whole 
picture as described in Webb et al (2011) (Appendix IV).  
 
  
Figure 4.16 (A-D) YAP and (E-G) TAZ tandem WW domain backbone dynamics and 
relaxation data, adapted from Webb et al (2011). The β-strands shown for YAP are from 
published WW domain structures (Macias et al. 1996; Webb et al. 2011) and those shown for 
TAZ were predicted in TALOS+ using chemical shift values.  
The relaxation rates R1 and R2 are calculated from the relaxation times T1 and T2, 
which measure the time taken (µs-ms) for an excited atom to decay back to thermal 
equilibrium (T1) and to lose spin coherence (T2). Large and fluctuating R2 values signify 
conformational and/or solvent exchange in a dynamic region of a protein. Additional 
dynamic information can be elucidated on the ps-ns timescale using {1H}-15N-NOE 
data, which indicate the degree of movement in the backbone NH bond. High values 
indicate restricted movement characteristic of a rigid folded region and low values 
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suggest a higher degree of flexibility. Relaxation and dynamics experiments required 
15N labelled protein and detected the chemical shifts of the backbone amides. 
The YAP R2 dispersion i.e. the transverse relaxation rate, R2, measured as a function 
of the effective field using a Carr-Purcell-Meiboom-Gill (CPMG) pulse train (Figure 
4.15), indicates that YAP WW1 undergoes significant conformational exchange. The 
side chains of the residues involved in chemical exchange, as determined by R2 RMSD, 
lie on the opposite face of the β-sheet to the peptide-binding site and comprise D125, 
W132, M134, A135, K136, R142, F144, T151 and D156. This correlates with the weak 
WW1 1H-15N-HSQC peak intensities observed in Figures 4.7-4.8. Both WW domains of 
TAZ display signs of conformational instability with high CPMG R2 values, consistent 
with the signs of heterogeneity observed in 1H-15N-HSQC spectra. Due to the high R2 
values in the tandem WW domain constructs, rotational correlation times (τm) using 
R2/R1 could not be obtained and relative orientations of the WW domains and so 
restrictions on the movement of the linker could not be estimated by 15N relaxation. 
The {1H}-15N-NOE data (Figure 4.16d, 4.16g) suggest that the individual WW 
domains within WW1-WW2 exhibit restricted movement, with the backbone NH bond 
vectors on the ps to ns timeframe showing values above 0.7. This is consistent with the 
rigid folded structure of WW domains. Conversely, a high degree of flexibility within 
the inter-domain linker of both YAP and TAZ is evident. Values obtained from {1H}-
15N-NOE experiments for YAP linker residues were close to zero, and for TAZ were 
negative, with average values of 0.064 and -0.207, respectively. The missing NOE 
values in the TAZ linker arise from a lack of NH assignments. The location of YAP and 
TAZ WW domain linker residue peaks in the central area of the HSQC gave an initial 
indication that this region is unstructured. Taken together, the data indicate that the 
linker contains no residual secondary structural elements.   
Relaxation data were acquired on the post-titration (2PPxY) YAP tandem WW 
domain sample (Figure 4.17). The larger R1 values and more uniform distribution of R2 
relaxation rates indicate the existence of a more stable WW1 conformation in the 
presence of peptide. This is consistent with the increased intensity of WW1 1H-15N-
HSQC peaks in the proton chemical shift region of 9-10 ppm during the titration 
experiment, which also suggests enhanced stability of the domain. The backbone 
dynamics of YAP WW1-WW2 are remarkably similar in both bound and unbound 
states (Figure 4.17c). The two WW domains remain rigid and the linker retains the high 
level of flexibility in the presence of 2PPxY peptide. 
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Figure 4.17 YAP WW1-WW2 (A, B) relaxation rates and (C) backbone dynamics: in the 
absence (black) and presence of dual PPxY peptide (grey).  
 
4.4 Discussion  
4.4.1 Identification of TAZ2 
In all previously published studies of TAZ, only a single WW domain isoform 
containing WW1 has been reported (TAZ1). Both the single and tandem WW domain 
isoforms of YAP, YAP1 and YAP2 had been identified by the mid ‘90s (Sudol 1994; 
Sudol et al. 1995). A tandem WW domain isoform of TAZ was identified in medaka 
fish during the course of this project. YAP has been more extensively studied than 
TAZ; therefore it is not inconceivable that TAZ2 exists in vertebrate organisms other 
than medaka but has not yet been found. Differences in the biological roles of YAP1 
and YAP2 are currently unclear.  
It was previously thought that YAP1 might be anti-apoptotic and YAP2 pro-
apoptotic but more recent evidence suggests that the biological activity is dependent on 
cellular context.  The extra WW domain might act to strengthen interactions with a 
partner protein containing two PPxY motifs, or alternatively recruit two molecules of a 
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ligand. YAP2 exhibits stronger binding and increased transcriptional activation with the 
C-terminal fragment of the EGF protein tyrosine kinase ErbB-4 than YAP1 (Komuro et 
al. 2003). In the same study, YAP2 was shown to be more prevalent than YAP1 to the 
extent that YAP1 could not be detected, perhaps indicating a context-dependent 
spatiotemporal requirement for YAP2 rather than YAP1. 
 
4.4.2 Structural analysis of YAP and TAZ WW domains 
The structure of human YAP WW1 in complex with the GTPPPPYTVG peptide was 
first published in 1996 (Macias et al. 1996). The structure of medaka YAP WW2 was 
determined as part of this project to confirm that the domain contains the three-stranded 
twisted β-sheet fold typical of other WW domains including YAP WW1. YAP WW2 
does fit this description. As observed in WW1, the regions N- and C- terminal to the 
folded core wrap around the opposite face to the peptide-binding site and interact with a 
cluster of hydrophobic side chains. Comparison of the rigid region of the YAP WW2 
structure (G191-W214) with a range of other group I WW domains (Figure 4.18) yields 
RMSD values of around 1.5 Å (calculated using Pymol). The most inconsistent area 
between the WW domains is the flexible loop that links β-strands 1 and 2. This loop is 
known to tailor the specificity of WW domain binding to partner proteins (Verdecia et 
al. 2000).  
 
Figure 4.18 Comparison of medaka WW2 (green) with human YAP WW1-N-(n-octyl)-
GPPPY-NH2 (cyan), human YAP WW1 L30K mutant-GTPPPPYTVG (magenta), murine-Sav1 
WW1 (orange), human WWOX WW1 (blue), and human Magi1 WW1 (purple). The image was 
made and superimposition carried out using PyMol (MacPyMOL 2009-2010). 
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Chemical shift-based secondary structure prediction of the TAZ WW domains 
indicated that they too contain the classical WW domain fold. This is not particularly 
surprising given the similarities between YAP and TAZ WW domain HSQC spectra. 
Interpretation of the {1H}-15N NOE data confirm that YAP and TAZ WW1 and WW2 
domains within WW1-WW2 are rigid with average values above 0.7, which indicate 
restricted movement in the NH bond vectors and are consistent with the presence of 
secondary structural elements. 
 
4.4.3 Conformational stability of YAP WW domains  
Loss of the unstructured region N-terminal to YAP WW1 destabilises the WW 
domain fold as reported previously (Macias et al. 1996), leading to HSQC spectra 
representative of a disordered or unstructured polypeptide. This is likely to be an effect 
of losing a portion of the protein that, although unstructured, is usually in close 
proximity to the hydrophobic non-binding site of the domain and that forms one half of 
the ‘buckle’ that loops around the domain (Figure 1.9a). However, the exact mechanism 
of this stabilisation is unclear and the Ile is not conserved within WW domains from 
other proteins, or even YAP WW2 so it seems to be a specific requirement of YAP 
WW1. 
All published structures of YAP WW1 have involved interactions with PPxY 
containing ligands (Macias et al. 1996; Pires et al. 2001; Aragon et al. 2011). The lack 
of an unbound YAP WW1 structure could arise from conformational instability of the 
domain. Another early indicator in this study that WW1 is not as stable as WW2 was 
the difficulty experienced when assigning WW1 backbone peaks in the WW1-WW2 
1H-15N-HSQC spectrum, which meant that triple resonance data and assignments for 
isolated WW1 were required to assign equivalent WW1 peaks in the tandem domain. 
Many cross-peaks for isolated WW1 were weak but detectable whereas the 
corresponding WW1 signals in the tandem WW domain were not detectable. This is at 
least partly due to the smaller size of isolated WW1, which is able to undergo faster 
tumbling than WW1-WW2, leading to the formation of sharper peaks.  
Conformational exchange in the non-binding face of YAP WW1 was observed 
during analysis of 15N relaxation dispersion and R2 data (Figure 4.15). YAP WW2 is 
not subject to chemical exchange on the µs-ms timescale (Figure 4.15). A comparison 
of YAP WW1 and WW2 primary sequences reveals a difference that may potentially 
contribute to stabilising WW2. In WW2 two hydrophobic residues (I196 and I202) are 
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located either side of loop 1, adjacent to the hydrophobic core, as compared to the 
positively charged residues in corresponding WW1 locations (K136 and R142) (Figure 
4.19). It is possible that the conformational exchange in WW1 represents equilibrium 
between folded and unfolded/partially unfolded states. This theory is supported by the 
fact that the residues involved in chemical exchange contribute to the structural integrity 
and stability of the domain as part of its hydrophobic core. 
 
Figure 4.19 Medaka fish YAP (A) (peptide-bound) WW1 (PDB ID: 1K9R Pires et al (2001)), 
and (B) WW2. (A) The positively charged K136 and R142 residues of WW1 that could repel 
each other and destabilise the core are highlighted in blue. (B) The hydrophobic I196 and I202 
of WW2 that could enhance the stability of the hydrophobic core are in red. I121 is not shown 
in this image. The figure was made using PyMol (MacPyMOL 2009-2010). 
 
4.4.4 Conformational instability of TAZ WW domains  
TAZ WW1-WW2 (Figure 4.11) exhibited more heterogeneous and overall weaker 
1H-15N-HSQC signal intensities than YAP WW1-WW2 (Figure 4.7).  This is consistent 
with the elevated 15N R2 values seen in both TAZ WW domains, which are due to 
chemical exchange. The chemical exchange would suggest that, as for YAP WW1, both 
TAZ WW domains are in equilibrium between folded and unfolded/partially folded 
states. Differences in both R1 and R2 indicate that overall molecular motion is greater in 
TAZ WW1-WW2 than in YAP WW1-WW2. Whilst the difference in R2 could be 
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explained by the higher temperature (27.5°C) used for TAZ data acquisition than for 
YAP (18°C), the difference in R1 can only be partially ascribed to temperature. The 
additional dynamics that occur in TAZ WW1-WW2 as compared to YAP WW1-WW2 
could be attributed to more marked motions of the two domains, perhaps due to the 
longer linker, in combination with conformational exchange of the WW domains. 
 
4.4.5 Lack of structure and rigidity in the inter-WW linker  
Chemical shift and {1H}-15N NOE data suggest that the inter-WW domain linker in 
both YAP and TAZ lacks secondary structure and is extremely flexible with average 
{1H}-15N NOE values close to or below 0. Negative values reflect fully disordered 
regions with no restriction to internal motion. Tandem WW domains from several other 
proteins have previously been studied, some of which also contain linkers without 
secondary structure (Su(dx) (Fedoroff et al. 2004), FBP21 (Huang et al. 2009), Smurf2 
(Chong et al. 2010)) and one that has a rigid α-helical linker that restricts the orientation 
of the WW domains (Prp40 (Wiesner et al. 2002)).  
The unstructured inter-WW domain linkers of Su(dx), FBP21 and Smurf2 are shorter 
than the YAP and TAZ linkers (35 and 45 residues) at 20, 12, and 20 residues in length. 
Although these three tandem WW domain linkers are unstructured, they are all subject 
to some degree of restriction with regard to inter-domain movement and orientation, as 
determined by {1H}-15N NOE data, the presence of medium range NOEs, RDC data, 
and R2/R1 ratios that indicated the two WW domains tumble together in solution 
(Fedoroff et al. 2004; Huang et al. 2009).  
The YAP linker has an average {1H}-15N NOE value of 0.064 suggesting little or no 
restriction on the movement of NH bond vectors. No medium range NOEs were 
detected within the inter-domain region indicating that YAP WW domains have more 
freedom of movement than the aforementioned proteins. The TAZ linker is more 
disordered and flexible than YAP with negative {1H}-15N NOE values, which is 
probably due to the extra 10 residues; this supports the statement made in section 4.4.4 
regarding a higher degree of movement between the two domains than in YAP. 
Although we acquired R2 and R1 values from the dynamics data, the conformational 
exchange that most likely caused the large R2 values meant that an estimation of 
motional independence of the WW domains, as was done for FBP21, was not possible. 
 
	   92	  
 
4.4.6 Conformational significance of peptide binding 
Relaxation and backbone dynamics data were acquired for YAP WW1-WW2 bound 
to dual-PPxY peptide. The R1 and R2 data for the peptide-bound form suggest that 
WW1 exists in a more stable conformation than the unbound form; this is in agreement 
with 1H-15N-HSQC titration spectra that show increased peak intensities in the 9-10 
ppm region and previous observations that YAP WW1 is less stable than other WW 
domains (Ibragimova et al. 1999).  
A recently published study of YAP WW1-WW2 interactions with a phospho-Ser-
PPxY peptide derived from Smad1 revealed that WW1 preferentially binds the 
phospho-Ser and WW2 binds the PPxY motif (Aragon et al. 2011). A comparison of 
four YAP WW1 domains in complex with either PPxY (Pires et al. 2001) or phospho-
Ser (Aragon et al. 2011) peptides revealed RMSD values of  more than 2 Å; clear 
differences in domain conformation and peptide orientation can be seen (Figure 4.20). 
The YAP-phospho-Ser WW1 structure is in a wider, more open conformation than the 
YAP-PPxY WW1 structure. There is also a noticeable difference in the specificity loop 
between the β1 and β2 strands. As WW1 can bind two different motifs and WW2 is 
only known to bind one motif, it is possible that the conformational instability of WW1 
contributes to the altered specificity.  
No significant differences in the backbone dynamics of the bound and unbound 
forms of YAP WW1-WW2 were observed. In the peptide-bound form the linker still 
displayed all the hallmarks of an unstructured, flexible region. The solution structure of 
YAP WW1-WW2 in complex with the Smad1 phospho-Ser-PPxY peptide revealed an 
inter-domain linker with a helix-loop-helix structure (Aragon et al. 2011). The tandem 
WW domain structure was not deposited in the PDB and the residue numbers are not 
disclosed, therefore it is difficult to make a comparison with our data. The {1H}-15N 
NOE values for the YAP and TAZ WW1-WW2 gradually approach 0 over 
approximately ten residues at either end of the linker, which could account for the 
presence of potential helices flanking the unstructured flexible region and the region N-
terminal to WW2 also appeared to contain a potential helix/coil (Figure 4.10). 
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Figure 4.20 YAP WW1 solution structures in complex with various peptide ligands. (A) WW 
domain conformations and (B) peptide orientations are illustrated in colour. Green represents 
WW1-N-octyl-GPPPY-NH2 (PDB ID: 1K9Q); cyan represents WW1-acetyl-PLPPY (PDB ID: 
1K9R); magenta represents WW1-diphospho-Ser (PDB ID: 2LAX); yellow represents WW1-
monophospho-Ser (PDB ID: 2LAY). 
   
4.4.7 Mechanism of WW1-WW2 interaction with PPxY peptides 
Titrations of YAP and TAZ WW1-WW2 with single and dual PPxY peptides 
(GTPPPPYTVG and GTPPPPYTVGGGGGGGTPPPPYTVG) revealed that both WW 
domains of both proteins bind to both ligands. The pattern of chemical shift changes is 
very similar between YAP and TAZ, and also between the titrations with the two 
peptides (Figure 4.14). At each titration point, peaks from both WW1 and WW2 
residues moved consistently and when represented graphically the shapes of the curves 
were similar. Therefore it is highly likely that peptide binding to the two WW domains 
within WW1-WW2 occurs simultaneously, not sequentially, and that the affinity of 
WW domains for peptide are similar. 
 
Titrations with single PPxY peptide. The calculated Kd values for the two domains in 
each protein construct for single PPxY peptide were not vastly different, in the range of 
273 ± 116 µM to 330 ± 116 µM. In both YAP and TAZ WW1 peaks exhibited 
significantly larger shifts overall than WW2 residues; the similarity of Kd values 
suggests that the larger effect of ligand binding upon the chemical environment of 
WW1 nuclei is not due to higher affinity. All evidence suggests that the unbound WW2 
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population exists in one stable conformation, whereas WW1 samples at least two 
conformations. The WW2 conformation appears to undergo minor structural alterations 
during interactions with PPxY peptide. One or more of the multiple WW1 
conformations may be less similar to the bound state and undergo larger binding-
induced conformational changes to produce one stable peptide bound conformation. 
Binding to peptide would thus have a larger impact on the chemical environment of 
WW1 than WW2 nuclei. 
 
Implications of tandem WW domains. That YAP and TAZ both contain a WW 
domain repeat might imply the presence of a second domain confers an advantage over 
the single WW isoform, or alternatively the second WW domain might be a redundant 
feature. The latter is less likely as the second WW domain is present in both proteins, at 
least in medaka fish. As the two WW domains in WW1-WW2 bind the same partner 
simultaneously and with equal affinity, and also the inter-domain linker is flexible and 
long enough to allow for various geometries, YAP and TAZ may be able to bind two 
separate partner molecules or two PPxY motifs on one target protein. Binding two 
proteins might be prevented due to steric hindrance, unless the two partner molecules 
also interacted with each other and formed a trimeric complex. It is quite possible that 
YAP/TAZ WW1-WW2 could interact with two binding motifs on a single partner 
molecule if the sites were in close enough proximity. Such binding would presumably 
increase the strength and specificity of the interaction. 
Previous studies have noted more than a doubling in affinity of tandem WW domains 
for certain binding partner molecules and in many of these cases the domains are 
thought to act cooperatively. The affinity of Smurf WW2-WW3 for a Smad single 
PPxY peptide is significantly higher than that of YAP/TAZ WW1-WW2 for single 
PPxY, with a Kd value of 1.7 ± 0.4 µM as compared to ~300 µM. In this Smurf-Smad 
scenario, Smurf WW2 alone cannot bind peptide but the tandem WW Smurf-Smad 
peptide interaction is enhanced relative to WW3 alone (Chong et al. 2010). In the case 
of the group III tandem WW domains of FBP21, a 30-60 fold increase in affinity was 
observed for peptide containing two proline-rich motifs in comparison to peptide 
containing one binding motif (Huang et al. 2009). The initial affinity of FBP21 tandem 
WW domains for a single-PPR binding motif was, however, much lower than we have 
calculated for YAP and TAZ WW1-WW2 for single PPxY peptide, with FBP21-single-
PPR peptide Kd values of 1-3 mM compared to around 300 µM for YAP/TAZ. 
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Titrations with dual PPxY peptide. During the titrations of YAP and TAZ with dual 
PPxY peptide, peak movements were observed at much lower peptide/protein ratios (5-
10 times) than in the single PPxY experiments. TAZ binds the dual PPxY peptide with 
higher affinity (48.5 ± 12 µM) than single PPxY peptide. Based on the chemical shift 
changes, YAP affinity with the dual PPxY peptide was estimated to be similar to that of 
TAZ. The Kd could not be calculated for YAP with confidence; typically the lower Kd 
calculation limit using NMR is 10-100 µM (Fielding 2007). The TAZ and YAP dual-
PPxY interaction is close to or perhaps beyond the sensitivity limit of NMR 
spectroscopy. Unlike the FBP21 tandem WW-dual PPR peptide binding, the 6-fold 
enhancement of YAP and TAZ WW1-WW2 affinity with dual PPxY peptide over 
single PPxY peptide is not likely to be attributed to inter-WW cooperativity. Ideally 
other methods of affinity determination would have been employed, but unfortunately 
fluorescence spectroscopy was unsuccessful and access to large amounts of peptide and 
ITC equipment were unavailable. The linker residue backbone NH chemical shifts were 
relatively unaffected during titration with dual PPxY peptide (Figure 4.13) and, 
consistent with this, little effect on {1H}-15N NOE values was observed (Figure 4.16).  
 
Effect of peptide interactions on inter-WW linker. Chemical shift changes within the 
WW domain and linker residues were similar in both dual and single PPxY titrations. 
The evidence indicates that the linker remains largely unstructured and flexible; 
therefore this particular dual PPxY peptide does not induce allosteric conformational 
change in YAP and TAZ WW1-WW2. An avidity-based mechanism in which binding 
of one PPxY motif to one WW domain brings the other PPxY motif into proximity to 
the other WW domain, thereby limiting the spatial search required for the second WW-
PPxY binding event to occur is a more probable explanation for the > 2-fold increase in 
affinity. Based on the small effects on linker residues and the lower Kd of dual PPxY 
binding, it is possible that the two domain-bound form inter-converts between one 
domain-bound forms.  
 
Implications of dual PPxY peptide interactions with tandem WW domains. Enhanced 
dual PPxY binding by tandem YAP and TAZ WW domains over single PPxY peptide 
has been clearly established. Such enhanced affinity of dual PPxY binding may be 
important in YAP2 or TAZ2 interaction with binding partners such as LATS1, ErbB4 
and AMOT that contain multiple PPxY motifs. The two PPxY motifs in LATS1, a 
kinase that is part of the core Hippo pathway cassette and that phosphorylates YAP and 
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TAZ, are separated by about 180 amino acids but it is possible that these PPxY motifs 
are spatially close enough to bind to tandem WW domains in a single molecule of 
YAP2 or TAZ2. Evidence suggests that both LATS1 PPxY motifs and both YAP WWs 
are necessary for full strength YAP-LATS1 binding as determined by transcriptional 
reporter assays (Oka et al. 2008). In the case of ErbB4, in which two of the PPxY motifs 
are seventeen amino acids apart, YAP2 (two WW domains) co-activates ErbB4-
regulated genes more strongly than YAP1 (one WW domain) (Komuro et al. 2003). 
Recently the YAP tandem WW domain was found to bind a Smad1 peptide containing a 
phospho-Ser and a single PPxY motif (Aragon et al. 2011); the presence of both 
domains of YAP was necessary for the interaction, further compounding the importance 
of WW domain repeats in enhancing interactions and specificity. 
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CHAPTER 5: WW DOMAINS OF THE UPSTREAM 
HIPPO PATHWAY PROTEINS SALVADOR AND KIBRA 
 
 
Figure 5.1 Location of Sav (magenta) and Kibra (purple) within the Hippo pathway. Core 
Hippo pathway components are located within the orange box. 
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5.1 Introduction  
Sav and Kibra are both Hippo pathway proteins (Figure 5.1) that contain a pair of 
WW domains (Figure 5.2). There is no inter-WW linker in these proteins, unlike in the 
tandem WW domains of YAP and TAZ (which have linker lengths of 35 and 45 
residues, respectively). Both Sav and Kibra also contain an atypical WW domain 
whereby non-Trp residues are present at the site of the second conserved Trp (Figure 
5.3). Mouse Sav WW2 forms a homodimer (Ohnishi et al. 2007). Human Sav WW2 has 
the same primary structure as mouse Sav WW2, but Drosophila Sav WW2 differs 
(Figure 5.3). To date, no structural studies of Kibra WW domains have been published. 
Kibra contains a Trp C-terminal to the WW domain that may or may not affect the 
structure or function of the domain. 
 
Figure 5.2 Modular domains of Sav and Kibra. The typical WW1 domains are shown in pink 
and the atypical WW2 (or ‘Wx’) domains are in purple. Domains and linker regions are to 
relative scale. Domains that are not studied in this chapter are unlabelled and uncoloured. 
 
Figure 5.3 Multiple sequence alignment of atypical WW domains (made using ClustalW2). The 
locations of the first conserved Trp residue and replacement of the second conserved Trp are 
highlighted in red. 
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The aims of the work in this chapter were to characterise the tandem WW domains 
from the Hippo pathway proteins Sav and Kibra using NMR spectroscopy. Recent 
collaborators provided the cDNA plasmids for these proteins (N. Tapon and J. 
Kremerskothen). These collaborators do not work with medaka models and so the 
proteins are from different organisms (Drosophila melanogaster and human) to the 
previous work. The results presented here provide hints as to the stability and binding 
capabilities of the WW domains from Drosophila Sav and human Kibra but there are 
still many unanswered questions regarding the structure and function of the tandem 
WW domains from these proteins. 
 
5.2 Materials and methods 
5.2.1 Cloning of DNA fragments  
Using the Sav and Kibra cDNA plasmids as template for PCR, WW domain 
containing DNA fragments were amplified using Phusion DNA polymerase and cloned 
into Vanderbilt vectors as described in Chapter 2. Primers and constructs can be found 
in Appendix I. Constructs were designed so that the equivalent residues to I121 of YAP 
were present (which is not conserved throughout WW domains) to provide a sufficient 
length of peptide to flank the WW domain core 
 
5.2.2 Expression and purification of Sav WW domain protein constructs 
Drosophila Sav WW1 and WW2 expression and purification. Drosophila Sav WW1 
and WW2 domains were expressed using the pSV281 and pBG101 Vanderbilt vectors, 
respectively, in Arctic Express (RIL) chemically competent cells. The cells were grown 
to OD600 of 0.6-0.9 at 37°C and induced overnight at 12°C using 0.5 mM IPTG. 15N-
labelled preparations were inoculated as described in Chapter 2, with the exception of 
the primary culture, which was always started from an agar plate rather than a glycerol 
stock.  Cells were harvested by centrifugation and the cell pellet was resuspended in 
His-buffer A with one ‘Complete mini protease inhibitor cocktail’ tablet/50 ml buffer. 
Protein was purified using nickel affinity chromatography as described in Chapter 2. 
The His-GST tag was cleaved overnight from WW2 using 3C protease in 
approximately 5 ml buffer (50 mM Tris pH 7.5, 150 mM NaCl, 2% glycerol, and 1mM 
DTT) rocking at 4°C. 5 ml His-buffer A was added to the post-cut protein, which was 
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separated from the tag using a 5 ml HisTrap FF column (GE Healthcare) with an elution 
gradient of at least 16 column volumes up to a concentration of 0.5 M imidazole. Cut 
WW2 was present in the flow-through and the first two elution-fractions. The 
effectiveness of the protease and purity of the WW domains were verified by SDS-
PAGE as described in Chapter 2. 
 
Purification of human and Drosophila Salvador WW1-WW2 tandem domain 
constructs. Tandem WW domains from Salvador were expressed in the same manner as 
the individual WW domains. The only deviation from the individual Salvador WW 
domain protocol was the buffer content. A solubility screen found Tris-buffers and high 
salt concentrations to be unfavourable. Therefore, the His-buffers were replaced with 50 
mM HEPES pH 7.5 and 100 mM NaCl, with 20 mM (buffer A) and 500 mM (buffer B) 
imidazole for the initial purification. If a GST-tag was to be removed (i.e. when using 
protein from the pBG101 vector), the WW1-WW2 was separated from the tag using a 
GST-trap FF column. 
 
5.2.3 Expression and purification of human Kibra WW domain protein constructs 
Joachim Kremerskothen (Universitat Münster) sent individual and tandem Kibra 
WW domain plasmids, which were transformed into BL21 (DE3) cells but protein 
expression and purification trials were unsuccessful (proteins either did not express or 
were insoluble). Both short and long Kibra tandem WW domain constructs were re-
cloned into the Vanderbilt vector pSV281 (kanR) and expressed in BL21 (DE3) cells at 
37°C for 4 hours. The long construct contains an extra Trp residue C-terminal to the 
core atypical WW2 domain. 15N-labelled cultures were inoculated as described in 
Chapter 2. The proteins were purified by nickel ion chelating chromatography as 
previously described (Chapter 2). 
 
5.2.4 Glutaraldehyde cross-linking experiment with Drosophila Sav WW domains 
The pure proteins (WW1, WW2 and WW1-WW2) were exchanged into PBS using a 
PD10 desalting column and incubated with a final concentration of 0.1% v/v 
glutaraldehyde. The incubations took place at room temperature for 0, 1 and 30 min, 
and 4°C for 0, 5 and 30 min. The 20 µl reactions were terminated by the addition of 2 µl 
1 M Tris-HCl pH 7.5. The samples were analysed by SDS-PAGE as described in 
Chapter 2. 
	   101	  
   
5.2.5 2D NMR conditions and experiments with Sav WW domains  
Sample preparation. Pure 15N-labelled Drosophila Sav WW1 and WW2 without tags 
were buffer exchanged (into 50 mM MES pH 6.5, 50 mM NaCl) by repeated dilution 
and concentration as previously described. 10% D2O was added to the final samples 
which were transferred to standard NMR tubes. Several buffers were used for the 
human and Drosophila WW1-WW2 proteins in an attempt to improve the HSQC 
spectra (Table 5.1).   
 
Table 5.1 Buffer conditions used for Sav WW1-WW2 NMR experiments 
Construct Buffer Salt Additives pH 
Drosophila 50 mM MES 50 mM NaCl  6.5 
Drosophila 50 mM MES 150 mM NaCl  6.5 
Human 50 mM KH2PO4 200 mM NaCl 5 mM EDTA 5.5 
Drosophila 50 mM HEPES 50 mM NaCl 1 mM EDTA 6.8 
 
 
NMR experiments. The experimental parameters for all Salvador WW domains 
included an optimal temperature of 12°C, nitrogen spectral width of 1640.9 Hz and 
nitrogen carrier frequency of 120 ppm. Experimental procedures and data 
processing/analysis were carried out as described in Chapter 2. In addition to varying 
the buffers and temperatures to obtain the best HSQC spectrum for each construct, 
experiments were carried out to assess the interaction of the WW domains with each 
other and with the GTPPPPYTVG peptide. 
In order to determine whether the presence of Drosophila Sav WW1 affects the 
secondary structure of Sav WW2, an NMR ‘mixing experiment’ was conducted, 
whereby unlabelled lyophilised WW1 was added to a known concentration (~250 µM) 
of 15N-labelled WW2 incrementally. NH chemical shifts were monitored in 1H-15N-
HSQC spectra as described in Chapter 4. 
The single PPxY peptide GTPPPPYTVG was dissolved in the relevant NMR buffer 
and titrated into known concentrations of Drosophila Sav WW1, WW2 and WW1-
WW2 in order to assess the effects of peptide binding. The titration experiments were 
monitored as described previously (Chapter 4). 
 
	   102	  
 
5.2.6 2D NMR conditions and experiments with Kibra tandem WW domains 
Both 15N-labelled human Kibra WW1-WW2 proteins (WW1-WW2(s) and WW1-
WW2(l)) with His-tag were exchanged into 50% PBS and 10% D2O. Experimental 
procedures and data processing/analysis were carried out as described in Chapter 2. The 
optimal temperature for both tandem WW domain constructs was 20°C, the nitrogen 
spectral width was 1884 Hz and nitrogen carrier frequency 120 ppm. The 
GTPPPPYTVG peptide was titrated into 15N-labelled Kibra tandem WW domain 
proteins as described in Chapter 4. 
 
5.3 Results 
5.3.1 Expression and purification of Sav protein constructs 
Drosophila Sav WW1 was grown in 15N-labelled M9 medium, and induced, purified 
(Figure 5.4), and characterised with a His-tag from the pSV281 vector. Fraction ‘3’ 
shown in Figure 5.4 was used to make the WW1 NMR sample. Fractions 1 and 2 were 
discarded because they appeared to be of a lower molecular weight and so may have 
introduced an element of heterogeneity into the sample. Cleaved Salvador WW2 has 
residual affinity for nickel columns. During the separation of WW2 from the His-GST 
tag, a long elution gradient (16 column volumes in a 5 ml His-Trap FF column) was 
used to successfully purify the protein (Figure 5.5).   
 
Optimisation of buffer conditions. Sav WW1-WW2 purification conditions were 
optimised using micro-drop solubility screens (Lepre et al. 1998). Tris based buffers 
were avoided, as they increased protein precipitation. The best buffer condition for the 
initial affinity purification for tandem Sav WW domains was HEPES pH 7.5 with 100 
mM NaCl and 20 mM/500 mM imidazole (buffer A/B). For Sav WW1-WW2 pBG101, 
a glutathione sepharose column (GSTrap FF, GE Healthcare) was used to separate the 
protein from the His-GST tag (Figure 5.6). 
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Figure 5.4 Drosophila Sav WW1 (A) His-affinity elution profile from a 5 ml His-Trap FF 
column; the blue line represents the A280 and the green line is the imidazole gradient. (B) 
Coomassie stained SDS-PAGE analysis; 5 µl marker was loaded (on the left with the band 
MWs labelled) and 10 µl each fraction diluted 1:1 with 2X sample buffer (Appendix III-c) were 
loaded in lanes 1-3. Fractions 1 and 2 have a slightly lower MW than fraction 3 and may be 
partially degraded. Fraction 3 was used to make the NMR samples. 
 
 
Figure 5.5 (A) The initial and (B) post-cut His-GST-tagged 15N-labelled Drosophila Sav WW2 
nickel affinity (5 ml His-Trap FF column) purification profiles. the blue line represents the A280 
and the green line is the imidazole gradient. 
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Figure 5.6 15N-labelled Drosophila Sav WW1-WW2 purification; the blue line represents the 
A280 and the green line is the imidazole gradient. (A) The His-GST tagged WW1-WW2 was 
initially purified using a 5 ml HisTrap FF column (GE Healthcare). (B) 3C protease cleaved 
WW1-WW2 was separated from the His-GST tag using a 5 ml GSTrapFF column (GE 
Healthcare). 
 
5.3.2 Glutaraldehyde cross-linking experiment with Sav WW2 
A glutaraldehyde cross-linking experiment was conducted in an attempt to discover 
whether Drosophila Sav WW2 dimerises in a similar manner to murine Sav WW2. 
Glutaraldehyde would covalently link Arg and Lys side chains that were in close 
proximity to each other. The presence of a covalently linked dimer could then be 
detected using Coomassie stained SDS-PAGE. Arg and Lys residues are present in the 
proposed Sav WW2 dimer interface. The result of this glutaraldehyde cross-linking 
experiment suggests that Drosophila Sav WW2 does not dimerise as no increase in the 
molecular weight of WW2 is observed by SDS-PAGE (Figure 5.7). Another method 
that could have been utilised to answer this question is gel filtration chromatography 
(GFC), however the WW domain is very small at around 4 kDa and the GFC columns 
available had previously undergone some degree of resin packing such that detecting 
such a doubling in MW would be unlikely. If the domain was much larger than 4 kDa 
then light scattering methods might also have been used. 
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Figure 5.7 Glutaraldehyde cross-linking experiment. Drosophila Sav WW1 and WW2 were 
incubated with 0.1% glutaraldehyde and electrophoresed in a 20% polyacrylamide gel. No 
increase in molecular weight was observed for either protein fragment. 
 
5.3.3 2D NMR conditions and experiments with Sav WW domains 
The Drosophila Sav WW1 1H-15N-HSQC spectrum  (Figure 5.8a) exhibits only 11 
backbone NH peaks, significantly fewer than the expected 32 non-Pro and non-NH2 
peaks (or 50 non-Pro peaks including His-tag residues). The low number of peaks 
observed suggests broadening of the line widths and is consistent with a protein in 
equilibrium between two states. It is probable that WW1 exists in unfolded/partially 
unfolded and completely folded conformations. WW1 undergoes binding-induced 
folding upon titration with single PPxY peptide, as evidenced by the appearance of the 
expected number of well dispersed peaks (Figure 5.8). The PPxY-bound WW1 peaks 
around 9-10 ppm in the proton dimension disappear as temperatures increase from 12°C 
to 20°C. An extra indole peak is present around 1H 10 ppm in the peptide bound WW1, 
which indicates that at least one of the Trp side chains undergoes chemical exchange. 
The extra indole peak becomes more intense with the increase in temperature from 
12°C to 20°C (Figure 5.9). 
	   106	  
 
Figure 5.8 Drosophila Sav WW1 1H-15N-HSQC spectra in (A) the absence (red) and (B) the 
presence (purple) of PPxY peptide at 12°C.  Very few peaks are observed in (A) indicating that 
the domain exists in two states (possibly unfolded and folded). (B) Peptide binding induces 
conformational stability in Drosophila Sav WW1. 
 
The 1H-15N-HSQC spectrum for WW2 (Figure 5.9) suggests the domain is folded but 
the peaks between 9 and 10 ppm are weaker than the majority of other peaks, as was 
observed for YAP and TAZ. Like Sav WW1, Sav WW2 is more stable at lower 
temperatures (Figure 5.9). NMR titrations were conducted on 15N Drosophila Sav 
WW2 with single PPxY peptide and no changes were observed in 1H-15N chemical 
shifts; therefore WW2 is not capable of binding this PPxY peptide.  This result is not 
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entirely unexpected as an Arg residue replaces the second conserved Trp in WW2 and 
this Trp normally plays a key role in PPxY binding.  
Lyophilised unlabelled Sav WW1 was added to 15N-labelled Drosophila Sav WW2 
in an NMR mixing experiment in order to assess potential interactions between the two 
WW domains. No visible changes were observed in the 1H-15N-HSQC spectrum of 
WW2; therefore it is unlikely that Drosophila Sav WW1 and WW2 interact within the 
tandem WW domain. As Sav WW2 is unaffected by the presence of single PPxY 
peptide and is also unaffected by WW1, it is unlikely that the tandem WW1-WW2 
binds peptide in a cooperative manner. 
 
Figure 5.9 Drosophila Sav (A) peptide-bound WW1 and (B) native WW2 1H-15N-HSQC 
spectra at a range of temperatures. (A) WW1 peaks at 12°C are purple and at 20°C are orange. 
(B) WW2 peaks are shown in blue at 12°C, green at 16°C, yellow at 20°C and finally in orange 
at 25°C. 
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The Drosophila Sav WW1-WW2 NMR sample was difficult to make as the protein 
precipitated easily, particularly upon concentration. The 1H-15N-HSQC spectra (Figures 
5.10 and 5.11) display peaks of different intensities, which is a sign of conformational 
instability. Also there are many small peaks present, particularly around 15N and 1H 
shifts of 130 ppm and 8 ppm, suggesting proteolytic degradation of the sample. The 
well dispersed peaks in the region of 9-10 ppm belong to WW2 within the tandem WW 
domain, as demonstrated by overlaying the spectra (Figure 5.10). The quality of the 
WW1-WW2 1H-15N-HSQC spectrum is not improved by varying temperature or 
titrating the sample with single PPxY peptide, providing further evidence that the 
labelled protein is subject to degradation. Adding peptide does, however, induce the 
appearance of weak peaks around 9-10 ppm, which is consistent with the binding-
induced folding of WW1 (Figure 5.11). Human Sav WW1-WW2 was also difficult to 
work with and produced a similar (and perhaps worse) 1H-15N-HSQC to Drosophila 
Sav WW1-WW2. 
 
 
Figure 5.10 1H-15N-HSQC spectra of Drosophila Sav WW2 recorded at 12°C with 8 scans 
(blue) and WW1-WW2 recorded with 240 scans (red). A longer acquisition time was necessary 
for WW1-WW2 because of the low protein concentration (~100 µM) as compared with a 
protein concentration of ~500 µM WW2. 
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Figure 5.11 Overlaid 1H-15N-HSQC spectra of Drosophila Sav WW1-WW2 without (red), and 
with (orange) 1.PPxY peptide (as was used in Chapter 4). Both spectra were recorded at 12°C 
with 240 scans (overnight). WW1-WW2 with peptide displayed more peaks in a better-
dispersed distribution, but the heterogeneity in the sample was not reduced (i.e. many peaks are 
still overlapped in the centre of the spectrum and many small degradation peaks are present) 
 
5.3.4 Expression and purification of Kibra WW domain constructs 
Expression trials of individual Kibra WW domains (WW1 and WW2) in the vectors 
sent by Joachim Kremerskothen (Universität Münster) in BL21 (DE3) cells were 
unsuccessful. Kibra WW1-WW2(s) and WW1-WW2(l) were successfully re-cloned 
into the pSV281 vector and expressed in BL21 (DE3) cells at 37°C. Kibra tandem WW 
domains were purified using nickel ion affinity chromatography with a 5 ml His-Trap 
FF column (Figure 5.12). 
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Figure 5.12 (A, B) Elution profiles from a 5 ml His-Trap FF column; the blue line represents 
A280 and the green line indicates the imidazole gradient. (C) Coomassie stained SDS-PAGE 
analysis of His-tagged human Kibra; 5 µl marker (with band sizes indicated) was loaded in lane 
M; 10 µl of pooled elution peak fractions diluted 1:1 with 2X sample buffer (Appendix III-c) 
were run in lanes A and B, which contained 15N-labelled (CA) WW1-WW2(s) and (CB) WW1-
WW2(l) both of which are around 17 kDa. Lower MW bands are likely to be His-rich 
contamination from the bacterial cell lysates. 
 
5.3.5 2D NMR conditions and experiments with Kibra WW domains 
Tandem WW domains of Kibra exhibit signs of a heterogeneous population in 1H-
15N-HSQC spectra with peaks of different intensities and poor dispersion around 9-10 
ppm. The spectra also indicate some degree of sample instability/degradation with the 
appearance of many small peaks. Both short and long constructs interact with single 
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PPxY peptide. Upon titration with peptide at least four peaks around 9-10 ppm appear 
in the WW1-WW2(s/l) 1H-15N-HSQC spectra and the intensity of several other peaks 
increases (Figure 5.13). The evidence indicates that a significant fraction of one WW 
domain within the protein population undergoes binding-induced folding. The presence 
of a second Trp residue seven residues C-terminal to the consensus Trp position in 
WW1-WW2(l) does not appear to change the native structure or affect peptide binding. 
 
 
Figure 5.13 (A) Kibra WW1-WW2(s) and (B) WW1-WW2(l) titrations with GTPPPPYTVG 
peptide; red peaks represent the unbound proteins and the final titration point is shown in blue. 
Also shown is a comparison of WW1-WW2(s) in magenta with WW1-WW2(l) in blue, (C) 
without  and (D) with PPxY peptide. Native WW1-WW2 appears to be largely unfolded as the 
peaks are not particularly well dispersed. The peptide induces the appearance of around 6 peaks 
at 8.5-9.5 ppm which is likely to be representative of only one folded WW domain. 
 
5.4 Discussion  
5.4.1 Atypical WW domains of Sav and Kibra 
Mouse Sav1 WW2 is unusual as, unlike all other WW domains reported to date, it 
forms a homodimer (Ohnishi et al. 2007). WW1 from human Magi1, which has a very 
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similar sequence to Sav1 WW2, does not form a dimer. The homodimerisation of 
mouse Sav WW2 is thought to be due to the presence of a Ser residue in the first β-
strand of the domain, whereas in Magi1 WW1 the Ser is replaced by an Arg residue 
(Ohnishi et al. 2008). Like mouse Sav1 WW2, Drosophila Sav WW2 contains this Ser, 
however unlike mouse Sav1 WW2, three residues before the Ser a positively charged 
Arg replaces a negatively charged Glu that is also thought to contribute to the 
dimerisation. Therefore an attempt to determine whether Drosophila Sav WW2 is a 
monomer or dimer was made. 
Glutaraldehyde cross-linking did not indicate that Drosophila Sav WW2 forms a 
dimer. Glutaraldehyde, which is approximately 7.5 Å long, is known to cross-link side 
chains in Lys-Lys and Lys-Arg pairs (Salem et al. 2010). The structure of Drosophila 
Sav WW2 was modelled upon chains A and B of the mouse Sav1 WW2 dimer (Figure 
5.14b,c) using Swiss-Model (Arnold et al. 2006; Kiefer et al. 2009), and PyMol 
(MacPyMOL 2009-2010) was used to determine the distances between Lys-Arg side 
chains in the theoretical dimer interface. The shortest distance between Lys-Arg side 
chains, based on the model, is 7.4 Å (Figure 5.14c). It is possible that the glutaraldehyde 
could bridge the gap between side chains during dimerisation, so the non-dimerisation 
observed for Drosophila Sav WW2 could be attributed to existing in a monomeric state. 
However, the structural model is theoretical and if the Lys-Arg side chains were a 
fraction further apart the glutaraldehyde could not cross link the two molecules of 
WW2; therefore the possibility that WW2 exists in a dimeric state cannot be ruled out. 
Ideally mouse Sav1 WW2 would have been used as a positive (dimeric) control, but 
unfortunately this protein was not available at the time of the experiment. 
The replacement of the negatively charged Glu by the positively charged Arg might 
still be capable of forming a weak salt bridge with the Ser, if this was the only 
substitution. However, Mouse/human Sav WW2 contains four core aromatic residues, 
whereas Drosophila Sav WW2 only contains two; therefore it is very unlikely that 
Drosophila Sav WW2 forms a dimeric complex. 
Mouse Sav1 WW2, which is identical to human Sav1 WW2 in sequence, is also 
atypical because a Tyr residue replaces the second Trp that is generally conserved 
within WW domains (and so it could be considered as a ‘WY’ domain). The 
replacement of the second Trp is not unique to mouse Sav1 WW2 (Figure 5.3). In 
Drosophila Sav WW2 this residue is replaced by Arg (‘WR’ domain), in human Kibra 
WW2 Ile is present (‘WI’ domain). The NMR titration of Drosophila Sav WW2 with 
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the single generic PPxY peptide (WBP1) revealed no interaction between the atypical 
WW domain and peptide.  
 
Figure 5.14 (A) Mouse/human Sav WW2 and (B, C) Drosophila Sav WW2 models made using 
Swiss-Model (Arnold et al. 2006; Kiefer et al. 2009) based on the structure of the dimeric 
mouse Sav1 WW2 (PDB ID: 2DWV (Ohnishi et al. 2007)). (A) Mouse Sav WW2; the polar 
residues Glu (negative charges shown) and Ser that are located at the N- and C- termini, 
respectively, of the WW2 β1 strand contribute to the dimerisation and are shown in thick lines. 
The four aromatic residues (F, Y, H, Y) that also play a role in dimerisation are shown in thin 
lines.  (B) Drosophila Sav WW2 dimer model showing Arg (positive charges shown) and Ser 
residues that are equivalent to the ‘dimerisation’ residues of mouse Sav WW2. There are fewer 
aromatic residues in (B) Drosophila Sav WW2 compared with (A) mouse Sav WW2. (C) 
Model of Lys (green) and Arg (cyan) residues that could potentially cross-link with 
glutaraldehyde and the distance between side chains in the theoretical dimer interface. PyMol 
(MacPyMOL 2009-2010) was used to make the images. 
 
In the mouse Sav WW2 dimer, the peptide-binding site is obscured. This might 
prevent protein-protein interactions, or alternatively the as yet unidentified ligand might 
competitively inhibit homodimerisation. It has frequently been observed that WW 
domains with replacement residues at the second conserved W are incapable of binding 
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peptides containing the known WW-binding motifs (Kremerskothen et al. 2003; 
Fedoroff et al. 2004; Ludes-Meyers et al. 2004). Perhaps because mouse/human Sav 
WW2 was redundant in terms of normal WW domain functionality, WW1 fulfils this 
role, it developed the ability to homodimerise to enhance the formation of multi-protein 
complexes thereby improving the function of Sav as a scaffolding protein.  
 
In addition to the replacement of the conserved Trp by Ile, Kibra WW2 also contains 
a Trp residue 7 amino acids C-terminal to the WW core. The presence of the C-terminal 
Trp is not likely to be a splicing/insertion event because the characteristic WW domain 
conserved Pro is present 3 residues after the Ile (substituted for the second W) and there 
is not a Pro residue 3 residues after the C-terminal Trp. The presence of the C-terminal 
Trp does not affect the structure of Kibra WW1-WW2 (Figure 5.13), which might 
suggest that its proximity to WW2 is coincidental.  
As individual Kibra WW domains were not purified it was not possible to investigate 
the effect of PPxY peptide on the atypical WW2. The titration of Kibra WW1-WW2 
with PPxY peptide induced the appearance of four peaks in the 9-10 ppm 1H region, 
which suggests that only one domain was affected. As it was previously established that 
WW2 cannot bind a range of peptides with the PPxY motif (Kremerskothen et al. 
2003), it is likely that WW1 alone interacted with the peptide and WW2 exists in an 
unfolded/conformationally dynamic state. Binding motifs for ‘Wx’ domains (like Kibra 
and Sav WW2) have been demonstrated for the ‘WF’ domains of Su(dx) and Smurf2. In 
the former case, WW4 (WF) of Su(dx) interacts with the AKQPPSYEDC peptide 
derived from Notch with higher affinity than the other typical WW domains in Su(dx) 
(45 µM as compared to around 200 µM), but with lower affinity than a ‘WF4’ to 
‘WW4’ mutant (15 µM) (Jennings et al. 2007). Smurf2 WW3 (WF) was found to bind 
the ELESPPPPYSRYPMD peptide with a Kd of 40 µM; the six residues C-terminal to 
the PPxY motif are essential for binding (Chong et al. 2006). 
 
5.4.2 Binding induced folding/stabilisation of Sav and Kibra WW domains 
The native Drosophila Sav WW1 1H-15N-HSQC displayed significantly fewer 
visible NH peaks than expected, probably due to line broadening caused by the domain 
existing in an equilibrium between folded and partially/completely unfolded states. 
Upon titration with the single PPxY peptide the Drosophila Sav WW1 1H-15N-HSQC 
spectrum exhibits well dispersed peaks of similar intensity, characteristic of a folded 
domain. The binding of peptide by Drosophila Sav WW1 probably involves the 
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population of WW1 molecules that adopt the folded conformation and as the 
equilibrium shifts, all of the population is brought into the more stable bound folded 
state. The instability of native Drosophila Sav WW1 is further compounded by the 
presence of lower molecular weight fractions in the purification profile (Figure 5.4a), 
which are probably caused by degradation or incomplete translation. The latter is less 
likely as the fragment is very small and a cell strain (Arctic Express (RIL)) was 
specifically selected to cope with the rare codons. 
Binding-induced folding also appears to occur for Kibra WW1-WW2. Equilibrium is 
also likely to exist between folded and partially folded conformations in this protein. As 
Kibra WW2 cannot bind a range of PPxY peptides (Kremerskothen et al. 2003) it is 
highly likely that interactions between PPxY peptide and WW1 are responsible for the 
extra peaks observed in the 1H-15N-HSQC. As WW1 is almost certainly the domain that 
undergoes binding induced folding, the lack of well dispersed peaks in the native Kibra 
WW1-WW2 spectra suggest that WW2 is probably natively unfolded or in equilibrium 
between conformations. Previously the consensus sequence observed to have the 
greatest affinity with Kibra WW1 was RxPPxY, however our peptide of TxPPxY was 
evidently capable of interacting with the WW domain.  
Another case where titration of PPxY peptide was necessary for complete WW 
domain folding was that of Su(dx) (Fedoroff et al. 2004). Native Su(dx) WW3-WW4 
does not adopt a stable folded conformation, WW4 is a ‘WF’ domain and does not bind 
peptide. WW3-PPxY binding stabilised the whole tandem domain structure thus 
allowing for NH backbone assignments and subsequent structure calculations. Only 5 
weak peaks appeared around 9-10 ppm during the Kibra WW1-WW2 titration, 
indicating the presence of only one fully folded WW domain. As only one WW domain 
is stabilised by peptide, Kibra does not appear to behave in a similar manner to Su(dx), 
it is more like Drosophila Sav with independent functional WW1 domains and WW2 
domains. The function of the atypical Kibra WW2 is undetermined. Kibra WW1-WW2, 
like Sav WW1-WW2, exhibits signs of degradation indicated by the presence of many 
small peaks in the 1H-15N-HSQC spectra. Proteolysis is more prevalent in unfolded 
proteins, so the possible conformational instability in Sav and Kibra WW1-WW2 could 
be promoting degradation of the recombinant proteins. 
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CHAPTER 6: FINAL DISCUSSION AND CONCLUSIONS 
 
 
Figure 6.1 Location within the Hippo pathway of all proteins studied i.e. TEAD (blue), 
YAP/TAZ (pink), Sav1 (magenta), and Kibra (purple). Core Hippo pathway components are 
located within the orange box. 
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6.1 Discussion 
Nuclear targets of the Hippo pathway: TEAD-YAP/TAZ. The TEAD transcription 
factors form an active complex with the Hippo pathway target proteins YAP and TAZ 
to mediate transcription of genes that promote cell proliferation, survival and 
differentiation. Our attempts to characterise the two functional domains of TEAD were 
ultimately unsuccessful, though given more time success might have been achieved. 
The crystal structures of YBDs from several TEAD proteins both alone and in complex 
with fragments of YAP are now known. The structures will enable more detailed 
analysis of the TEAD family of transcription factors and their binding partners. 
 
Alternative isoforms and repeat regions. In the attempt to generate cDNA for 
subsequent cloning of medaka fish TEAD protein domains, alternate isoforms of 
medaka TEAD1, 2/3 and 4 were identified.  The TEAD4 variant has a stop codon 
between the DBD and the YBD, potentially leading to transcription of a truncated non-
YAP-binding protein. TEAD1 and TEAD 2/3 variants contain a 20 residue insertion C-
terminal to the DBD. This insertion is highly similar to the H3 helix that contains the 
NLS and mediates DNA binding. Due to this similarity the insertion is probably α-
helical in structure. Cooperativity between multiple NLSs to enhance transportation into 
the nucleus has been observed in the human mismatch repair protein MSH6 (Gassman 
et al. 2011). It is conceivable that the role of the insertion in these TEAD variants is to 
enhance nuclear localisation, particularly as the transcription factors are also responsible 
for the nuclear transport of their co-activators YAP and TAZ. With the extra region 
being in such close proximity to the conserved DBD, it would be interesting to assess 
the effect on TEAD-DNA interactions. 
Regional repeats appear frequently in proteins of the Hippo pathway. In addition to 
the identification of TEAD variants during cDNA generation, a second TAZ isoform 
was also found. Like its paralogue YAP, the second splice form of TAZ contains a 
second WW domain. One difference between the tandem domains of YAP and TAZ is 
that the newly discovered TAZ2 has a longer linker by around 10 residues. When repeat 
regions have a known function, the question of potential cooperativity often arises (as 
was speculated on for the TEAD insertion). Often the distance between domains and the 
structural features of the inter-domain linker has a marked effect on such cooperativity. 
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NMR spectroscopy was used to investigate structural features of the YAP and TAZ 
tandem WW domains and potential inter-WW domain cooperation. 
 
NMR studies of tandem WW domains. The inter-WW domain linker was found to be 
unstructured and flexible in both YAP and TAZ. Perhaps unsurprisingly there was more 
freedom of movement in TAZ, with the longer linker, than YAP. Other NMR-based 
studies of tandem WW domains with unstructured linkers found more restriction of 
internal motion than we observed, however the linkers of YAP and TAZ are 
significantly longer than in any of the other characterised proteins so again this 
observation is not particularly unexpected.  
A recently published solution structure of YAP WW1-WW2 in complex with a 
phospho-Ser-PPxY peptide confirmed our finding that the inter-domain linker was a 
flexible loop, however the structure also contained an α-helix at either end of the linker 
(Aragon et al. 2011). The {1H}-15N-NOE values for YAP and TAZ observed in Chapter 
4 reached the minimum level (close to or below 0) approximately 10 residues after the 
core of the first WW domain and began increasing approximately 10 residues before the 
second WW. This gradual decrease/increase in NOE values could be consistent with 
restricted movement imposed by helices. The structure of medaka YAP WW2 appeared 
to contain a helical coil N-terminal to the core WW domain, though the orientation was 
not superimposed on all 20 of the models. This may also be an indication the C-
terminus of the inter WW-linker contains some residual structure. Individual YAP 
WW1 domains in the PDB do not contain enough linker residues to determine if a 
similar effect is observed C-terminal to the WW1 core (i.e. the beginning of the linker). 
The dual PPxY peptide did not affect the inter-WW linker meaning potential helices 
connecting the WW domains to the linker are likely to also be present in the native 
protein. The dual PPxY peptide did not induce the formation of extra structural changes 
in comparison to the single PPxY peptide, indicating that the linker plays no active role 
in peptide binding. The possibility that other dual WW-binding site peptides could 
induce allosteric conformational changes in the tandem WW domains of YAP and TAZ 
cannot be excluded. Although the linker region of YAP and TAZ WW1-WW2 plays no 
active role in peptide binding, at least six-fold increased affinity for dual PPxY peptide 
was observed over single PPxY peptide. This is a smaller effect than the thirty-fold 
increase in affinity observed for FBP21 binding to dual Pro-rich peptide (Huang et al. 
2009). FBP21 contains a shorter linker (12 residues) than YAP and TAZ; we did 
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observe a slightly higher affinity in YAP than TAZ for single PPxY peptide, which may 
be an effect caused by the shorter YAP linker.  
 
Enhanced and cooperative binding through tandem WW domains. Su(dx) WW3 and 
WW4 exhibit cooperativity whereby WW3-WW4 affinity for a WW3-binding peptide 
is higher than WW3 alone (Jennings et al. 2007). Binding of peptide to Su(dx) WW3 
(within WW3-WW4) leads to folding of WW4, which subsequently increases the 
affinity of WW4 for its peptide. The cooperative effects of ligand binding to Su(dx) are 
due to interactions between the native unbound WW3 and WW4 (Jennings et al. 2007).  
Evidence indicated that YAP/TAZ WW1 and WW2 do not interact and Aragon et al 
(2011) also reported a lack of YAP inter-WW contacts. Cooperativity is not likely to 
contribute to enhanced binding in the dual PPxY peptide as chemical shift changes 
occurred concurrently in the two WW domains, rather than sequentially. One 
explanation for the observed affinity effect is an avidity-based mechanism, whereby 
binding to one WW domain brings the second PPxY into close proximity with the 
second WW domain. This theory would also apply to the increased affinity observed in 
the case of FPB21 (Huang et al. 2009).  
 
Atypical WW domains. The upstream Hippo pathway proteins Sav and Kibra contain 
tandem WW domains without linker regions. The C-terminal WW domains of both Sav 
and Kibra are atypical ‘Wx’ domains, like Su(dx) WW4. Unfortunately canonical 
binding motifs for the ‘Wx’ domains of Sav and Kibra WW2 have not been identified, 
and in the case of the potentially dimeric mouse Sav WW2 might not exist. Drosophila 
Sav WW2 contains several differences in key ‘dimerisation’ residues compared with 
mouse Sav, and based upon these differences Drosophila Sav WW2 is predicted to be 
monomeric, though this has not been definitively proven.   
Due to the lack of known ‘Wx’ binding motifs it is not possible to assess the 
structural impact of peptide binding using experiments such as those used for Su(dx) to 
assess the potential effects of cooperativity between two different ligands and the two 
WW domains. A second limitation of studying these tandem WW domains is sample 
instability. The poor 1H-15N-HSQC spectra seem to indicate that the atypical Kibra 
WW2 within WW1-WW2 is unfolded and the major population of Drosophila Sav 
WW2 domain within WW1-WW2 is natively folded. In both Sav and Kibra the typical 
group I N-terminal WW domains may be partially unfolded and undergo 
conformational exchange. The instability of the Sav and Kibra WW1-WW2 samples 
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makes it difficult to draw any definite conclusions about the conformation of the 
atypical tandem WW domains. Mixing experiments with the individual 15N labelled Sav 
WW2 and unlabelled Sav WW1 revealed no chemical shift changes, indicating that the 
two domains do not interact. 
 
Conformational flexibility. Besides the general instability of the tandem WW domain 
samples (Sav and Kibra in particular), most of the Hippo pathway WW domains studied 
exhibited some degree of conformational exchange. YAP (WW1), TAZ (WW1), Sav 
(WW1, WW1-WW2, WW2) and Kibra (WW1-WW2) all display weak peaks around 
proton chemical shift values of 9-10 ppm in 1H-15N-HSQC spectra; the difference in 
intensity to other peaks suggests that the whole population is not in one fully folded 
conformation. In the case of YAP WW1, 15N R2 transverse relaxation data and RMSD 
within R2 dispersion data indicated that the domain undergoes significant 
conformational exchange with residues facing the stabilizing ‘buckle’ opposite the 
peptide-binding face being affected. The TAZ WW1-WW2 1H-15N-HSQC spectrum 
displayed broad line widths and relaxation experiments (15N R1 and 15N R2) showed that 
both WW domains are subject to conformational instability. 
The low number of NH peaks in the Drosophila Sav WW1 1H-15N-HSQC spectrum 
suggests that the domain is in equilibrium between unfolded/partially folded and fully 
folded conformations. Presumably, as the structure of mouse Sav WW1 (which has the 
same sequence as human Sav WW1) is present in the PDB it is more stable than its 
Drosophila counterpart.  The Kibra WW1-WW2 1H-15N-HSQC spectrum also displays 
signs of heterogeneity with variable peak intensities. The 1H-15N-HSQC spectra from 
Sav WW1, Kibra WW1-WW2, YAP WW1-WW2, and TAZ WW1-WW2 all improve 
by varying degrees upon the addition of PPxY peptide. The most obvious improvement 
was for Sav WW1 where a few peaks in the centre of the spectrum were transformed 
upon the addition of peptide into a well dispersed pattern consistent with a 
homogeneous folded domain.  
It would appear that the WW domains undergoing conformational exchange are 
subject to a certain degree of binding-induced folding. The most likely scenario is 
conformational selection where peptide binds to the folded fraction, shifting the 
equilibrium until the whole population is folded. Binding-induced folding of WW 
domains is likely to have functional implications for Hippo pathway proteins. It is 
possible that the conformational instability of the WW domains contributes to binding 
specificity. For example YAP WW1, which is dynamic in terms of conformation, binds 
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the phospho-Ser site of the Smad1 peptide (Figure 4.17) and WW2, which exists in a 
single conformation, preferentially binds to the PPxY site on the same peptide (Aragon 
et al. 2011). WW domain interactions of YAP, TAZ, Sav and Kibra mediate cross-talk 
between signalling pathways; conformational exchange to alter binding partner 
specificity may be one mechanism that enables switching between pathways. 
 
The mechanisms of WW domain folding and general stability are perhaps not yet 
completely predictable despite a large number of experimental and theoretical studies. 
One molecular dynamics simulation found that the stability of WW domains is affected 
by various factors including electrostatic interactions, side-chain packing, 
conformational entropy of the flexible regions either end of the WW core, and the 
binding of cognate ligand (Ibragimova et al. 1999). Given the small size of these 
domains it is not surprising that minor differences can significantly affect the structural 
stability and binding preferences. However, the prevalence of WW domains in 
intracellular proteins involved in transcriptional regulation highlights them as essential 
protein modules worthy of detailed investigation. 
 
 
6.2 Conclusions  
6.2.1 TEAD domains and TBDs of YAP and TAZ. 
Variant isoforms of medaka fish TEAD mRNA were identified, though the 
biological relevance of these isoforms remains undetermined. TEAD domains (DBD 
and YBD) are intrinsically structured, though mostly insoluble when expressed in E. 
coli and therefore difficult to work with. TBDs of YAP and TAZ are natively 
unstructured and are also insoluble in the absence of the C-terminal WW domain. 
 
6.2.2 YAP and TAZ WW domains  
A second isoform of medaka TAZ was discovered, TAZ2, which contains a second 
WW domain much like YAP2. The medaka YAP WW2 structure is similar to other 
WW domains. WW1 of YAP and both WW domains of TAZ undergo conformational 
exchange but appear to retain the classical WW domain structure in the predominant 
folded states. YAP and TAZ WW domains, within WW1-WW2 pairs, are capable of 
binding PPxY peptide with similar affinity. The presence of a second PPxY motif 
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within a titrated peptide increases the affinity of the tandem WW domain pairs for 
ligand by at least 6-times. The WW domain linker in TAZ2 is longer than in YAP2 by 
10 amino acids. The linker region is highly flexible in the two proteins, in both free and 
ligand bound states. 
 
6.2.3 Sav and Kibra WW domains 
Drosophila Sav WW2 is stable, natively folded, and cannot bind PPxY peptide. 
Drosophila Sav WW1 appears to be in equilibrium between folded and unfolded states 
but the domain retains its stable secondary structure when bound to PPxY peptide. The 
tandem WW domain constructs of Drosophila and human Sav and human Kibra are 
unstable, heterogeneous, and partially unfolded in their native state. Drosophila Sav 
WW1-WW2 undergoes partial folding (which involves WW1 only) upon titration with 
PPxY peptide but heterogeneity within the NMR sample remains. WW1 within Kibra 
WW1-WW2 seems to gain more stability by binding induced folding during ligand 
titration, however the samples do not appear to become completely homogeneous and 
WW2 does not appear to be folded. 
 
 
6.3 Future directions 
Our intended short-term outcomes of the TEAD-YAP studies have been thoroughly 
covered by three publications as well as relevant reviews. Although it would be 
interesting to further study the intricacies of the various TEAD proteins, perhaps by 
modelling them using the available structures, and studying how interactions with YAP 
and TAZ differ, it would not be efficient to pursue this avenue of investigation at the 
current time. As for long-term goals, an ambitious but worthwhile task would be to 
study ternary DNA-TEAD-YAP and DNA-TEAD-TAZ complexes and elucidate the 
exact role of the C-terminal transactivation domain from YAP/TAZ. As both TEAD and 
YAP/TAZ are required for transcriptional activation, it would also be interesting to 
determine whether cooperativity between the DBD and YBD of TEAD is involved in 
binding YAP/TAZ and DNA. The WW domains of YAP/TAZ are known to be 
promiscuous; another area of investigation could be to determine whether they interact 
with transcriptional machinery to form an intra-nuclear multi-protein complex. 
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Our publication of the YAP and TAZ WW domain data shows that this study 
reached a satisfactory outcome, though it has raised more questions about the 
conformational stability of WW domains and their numerous roles within various cell-
signalling networks. Several studies have highlighted the importance of residues 
flanking the PPxY motif with regard to affinity; it would therefore be interesting to 
assess the effect of varying the peptide sequence on the YAP/TAZ WW domain pair. 
Altering the linker length between PPxY motifs and WW domains would also increase 
understanding of the mechanisms of enhanced binding via multiple WW domain 
activity. 
There are many questions to be answered about the content of Chapter 4, but there 
are also many difficulties to overcome with the solubility and general stability of the 
Sav and Kibra WW domains. In order to make the Sav and Kibra work truly 
comparable in terms of Hippo pathway function, the constructs should be derived from 
the same organism. Therefore, it would be useful to clone, express and purify the 
individual WW domains of human Sav to assess whether they behave in the same 
manner as their Drosophila counterparts. It would also be useful to produce individual 
WW domain constructs for Kibra and to optimise buffer systems for all of the protein 
fragments for further characterisation by NMR. A long-term goal would be to identify 
binding motifs for the atypical ‘Wx’ domains of Sav and Kibra, compare the interaction 
of such partners with typical WW domains, and further explore the possibilities of inter-
WW domain cooperation. 
Clearly the proteins of the Hippo pathway contain multiple protein-protein 
interaction domains that could potentially mediate the formation of huge multi-protein 
complexes. We have used the most practical approach of ‘divide and conquer’ with 
regard to characterising the various interaction modules. Ultimately the goal would be 
to build up a larger picture of the proteins involved in the formation of such complexes 
at any given time and assess the interactions that regulate them to gain a systems level 
understanding of the processes involved in organ growth, tumour suppression and other 
physiological processes that the Hippo pathway impacts upon.  
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CHAPTER 8: APPENDICES 
Appendix I: Constructs, primers, restriction sites, and vectors 
I-a TEAD constructs 
Table 7.1 TEAD1 primers 
Primer name/ 
region 
Primer Restriction 
site 
Vectors 
TEAD1 outerF/ 
pre-N-terminal 
TAGCTTGGAGAGCCCGACT 
 
Blunt pBlueScript 
SK- 
TEAD1 innerF/ N-
terminal -> 
AGAGCCCGACTGCCAAGAT 
 
Blunt pBlueScript 
SK- 
TEAD1 innerR/ C-
terminal <- 
tgtTCATTCTTTAACCAGTCTGTAGAT Blunt pBlueScript 
SK- 
TEAD1 outerR/ 
post-C-terminal 
ggtgtTCATTCTTTAACCAGTCTGT 
 
Blunt pBlueScript 
SK- 
Med-TEAD1-for/ 
(133) pre-YBD 
CGGAATTCCGCCAGAAGAAAATCT
CGTGAG 
EcoRI Vanderbilt 
G246F/ -> YBD CGGAATTCGGGCCGCTCCATCGGTA
CTTC 
EcoRI Vanderbilt 
Med-TEAD1-rev/ 
YBD <- 
CCGCTCGAGCTATCATTCTTTAACC
AGTCTGTAGAT 
XhoI Vanderbilt 
TEAD1_13f/ -> 
DBD 
CGGGATCCGTGGACAATGATGCTG
AAGG 
BamHI Vanderbilt 
TEAD1_92r/ 
DBDα3 <- 
GGAATTCCTATTAAGCTTGGATTTC
TCGAACTTTC 
EcoRI Vanderbilt 
TEAD1_121r/ 
DBDα4 <- 
GGAATTCCTATTAGTCCATACTTGT
AACCTTTAGC 
EcoRI Vanderbilt 
TEAD1(1-2) 
_V12f/ -> DBD 
AGGAGATATACCATGGTGGACAAT
GATGCTGAAGGGGT 
N/A - LIC pOPIN-E 
TEAD1_S113r/ 
DBD <- 
GTGATGGTGATGTTTGGAATGAAA
CTCACGAGATTTTCTTCTTTCAAG 
N/A - LIC pOPIN-E 
TEAD1(1-2) 
_R88f/ -> DBDα4 
AGGAGATATACCATGCGAGAAATC
CAAGCTGCCATTAAGGTG 
N/A - LIC pOPIN-E 
TEAD1(1-2) 
_T211f/ ->YBD 
AGGAGATATACCATGACAGCACCA
GCATGGCAGGGC 
N/A - LIC pOPIN-E 
TEAD1_E435r/ 
YBD <- 
GTGATGGTGATGTTTTTCTTTAACC
AGTCTGTAGATATGATGCTGG 
N/A - LIC pOPIN-E 
 
TEAD1 plasmids: 
TEAD1_1-2fl: pBlueScript SK-   (full length TEAD1 with DBDα4 cDNA) 
TEAD1_1-1fl: pBlueScript SK-   (f-l TEAD1 with expected DBD cDNA) 
TEAD1 (13-92): pSV281, pBG101 (DBD) 
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TEAD1 (12-92): pOPIN-E   (DBD) 
TEAD1 (12-113): pOPIN-E  (DBD with α4) 
TEAD1 (133-464): pSV281  (YBD and unstructured N-terminal region) 
TEAD1 (246-464): pSV281, pBG101 (YBD) 
 
Table 7.2 TEAD2/3 primers 
Primer name/ 
region 
Primer Restriction 
site 
Vectors 
Medaka tead3F/ 
pre-N-terminal 
CACCATTGCGTCCAACGA Blunt pBlueScript 
SK- 
TEAD3 innerF/ N-
terminal -> 
GCGTCCAACGAGTGGAGT Blunt pBlueScript 
SK- 
TEAD3 innerR/ C-
terminal <- 
tccctggcaagctgTTAGTC Blunt pBlueScript 
SK- 
TEAD3 outerR/ 
post-C-terminal 
AGAAGCTCCCTGGCAAGC Blunt pBlueScript 
SK- 
Med-TEAD2-for/ 
pre-YBD -> 
CGGAATTCCGCACGGAAGAAAGTG
CGTGAA 
EcoRI Vanderbilt 
mTEAD3_V239F/ 
-> YBD 
CGGAATTCGGTTCCAGTATGGCAG
GATCG 
EcoRI Vanderbilt 
Med-TEAD2-rev/ 
YBD (464) <- 
CCGCTCGAGCTATTAGTCTTTAACA
AGTCTGTAGAC 
XhoI Vanderbilt 
TEAD3_1f/ -> 
DBD 
CGGGATCCATGGATGGGGACGCAG
AGG 
BamHI Vanderbilt 
TEAD3_107r_4-1b 
/ DBDα3 <- 
GGAATTCCTATTATTGAGCAGACGA
CAGCGCT 
EcoRI Vanderbilt 
TEAD3_116r_3-1a 
/ DBDα4 <- 
GGAATTCCTATTATTTGTCTTTGGA
TGCCTGATC 
EcoRI Vanderbilt 
TEAD3_M1f/ -> 
DBD 
AAGTTCTGTTTCAGGGCCCGATGGA
TGGGGACGCAGAGGGG 
N/A - LIC pOPIN-F 
TEAD3_G82r/ 
DBDα3 <- 
ATGGTCTAGAAAGCTTTAGCCCGCC
TGGTATTCACGCAC 
N/A - LIC pOPIN-F 
TEAD3_K105r/ 
DBD <- 
ATGGTCTAGAAAGCTTTACTTTAGC
TTTGACTGGATCTCGCGAGA 
N/A - LIC pOPIN-F 
TEAD3_E78f/ -> 
DBDα4 
AAGTTCTGTTTCAGGGCCCGGAATA
CCAGGCCGGCATAAAG 
N/A - LIC pOPIN-F 
TEAD3_T201f/     
->YBD 
AAGTTCTGTTTCAGGGCCCGACCGC
AGTTCCAGTATGGCAGGAT 
N/A - LIC pOPIN-F 
TEAD3_D247r/ 
YBD <- 
ATGGTCTAGAAAGCTTTAGTCTTTA
ACAAGTCTGTAGACGTGCTCTTG 
N/A - LIC pOPIN-F 
 
TEAD2/3 plasmids: 
TEAD3_3-1a_fl: pBlueScript SK-    (full length TEAD2/3 with DBDα4 cDNA) 
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TEAD3_4-1b_fl: pBlueScript SK-  (f-l TEAD2/3 with expected DBD cDNA) 
TEAD3 (1-82): pOPIN-F/-J  (DBD) 
TEAD3 (1-105): pOPIN-F/-J  (DBD with α4) 
TEAD3 (1-107): pSV281   (DBD with α4) 
TEAD2 (239-462): pSV281, pBG101 (YBD) 
TEAD3 (201-427): pOPIN-F/-J  (YBD) 
 
Table 7.3 TEAD4 primers 
Primer name/ 
region 
Primer Restriction 
site 
Vectors 
Medaka tead4F/ 
pre-N-terminal 
AGAGGTTCCCTCTCCATCGT Blunt pBlueScript 
SK- 
TEAD4 innerF/ N-
terminal -> 
CATCGTCCCACCACGTCT Blunt pBlueScript 
SK- 
TEAD4 innerR/ C-
terminal <- 
TCAGTCTTTGACCAGCCTGT Blunt pBlueScript 
SK- 
Medaka TEAD4R/ 
post-C-terminal 
CACCAGTGCCTCTGTGTCAG Blunt pBlueScript 
SK- 
TEAD4_Y222f/ -> 
YBD 
CGGAATTCGTATGCTATGCAAGCG
ACTGG 
EcoRI Vanderbilt 
TEAD4_D470r/ 
YBD <- 
CCGCTCGAGCTATCAGTCTTTGACC
AGCCTGTAAAT 
XhoI Vanderbilt 
TEAD4_194f/ -> 
YBD 
CGGGATCCGGTAGAAGTATTGCCA
GCTC 
BamHI Vanderbilt 
TEAD4_216f/ -> 
YBD 
CGGGATCCGACCCAGAGACTTTCA
ACAAG 
BamHI Vanderbilt 
TEAD4_239f/ -> 
YBD 
CGGGATCCTATCTGGAGTCGGTGG
ACAT 
BamHI Vanderbilt 
TEAD4_A2for/ -> 
DBD 
AAGTTCTGTTTCAGGGCCCGGCAGA
GGGTGTGTGGAGCCCT 
N/A - LIC pOPIN-F/J 
TEAD4_Q77rev/ 
DBD <- 
ATGGTCTAGAAAGCTTTACTGGATC
TCCCGGGCCTTACG 
N/A - LIC pOPIN-F/J 
TEAD4_M171for/     
->YBD 
AAGTTCTGTTTCAGGGCCCGATGTC
TCCTGGTGCCCCCCCT 
N/A - LIC pOPIN-F/J 
TEAD4_D398rev/ 
YBD <- 
ATGGTCTAGAAAGCTTTAGTCTTTG
ACCAGCCTGTAAATATGGTGC 
N/A - LIC pOPIN-F/J 
 
TEAD4 plasmids: 
TEAD4-1 fl: pBlueScript SK-   (TEAD4 full length cDNA) 
TEAD4 (222-470): pBG100/101, pSV281 (YBD) 
TEAD4 (194-470): pBG100/101, pSV281           (YBD and unstructured N-terminus) 
TEAD4 (171-398): pOPIN-F/-J   (YBD) 
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I-b YAP constructs 
Table 7.4 YAP primers 
Primer name/ 
region 
Primer Restriction 
site 
Vectors 
YAP_M1f/ N-
terminal -> 
CGGAATTCCATGGATCCGAGCCAGCAC
AAC 
EcoRI Vanderbilt 
YAP_V10f/  
TBD -> 
CGGAATTCCGTCGGACACCAGATTGTT
CAC 
EcoRI Vanderbilt 
YAP_M105f/ 
pre-WW1 -> 
CGGAATTCCATGGCCTCAGCAGGCGCC
TC 
EcoRI Vanderbilt 
YAP_S119f/ 
WW1 -> 
CGGAATTCCTCCTACGAGATTCCCGAC EcoRI Vanderbilt 
YAP_D124f/ 
short WW1 -> 
CGGAATTCCGACGACGTGCCCCTG EcoRI Vanderbilt 
YAP S171f/ 
pre-WW2 -> 
CGGAATTCCAGTACCGTTCCAGTTCAGC
AG 
EcoRI Vanderbilt 
YAP S182f/ 
WW2 -> 
CGGAATTCCAGCCCAGCTAGTGGAC EcoRI Vanderbilt 
YAP S65r/ 
short TBD <- 
CCCAAGCTTCTATTAGGAATGGGACTT
GGGCTC 
HindIII Vanderbilt 
YAP L94r/ 
TBD <- 
CCCAAGCTTCTATTACAGCTGCAGGGA
AGCTGG 
HindIII Vanderbilt 
YAP G109r/ 
post-TBD <- 
CCCAAGCTTCTATTAGCCTGCTGAGGCC
ATCC 
HindIII Vanderbilt 
YAP L162r/ 
WW1 <- 
CCCAAGCTTCTATTAGAGCAGGGCTTTG
CG 
HindIII Vanderbilt 
YAP T168r/ 
post-WW1 <- 
CCCAAGCTTCTATTAGGTAGCCTGGTTC
AACTG 
HindIII Vanderbilt 
YAP R222r/ 
WW2 <- 
CCCAAGCTTCTATTAGCGAGTCTCAAGT
CG 
HindIII Vanderbilt 
YAP A240r/ 
post-WW2 <- 
CCCAAGCTTCTATTAAGCGCTTTGGGTG
ATCCT 
HindIII Vanderbilt 
YAP L440r/ C-
terminal <- 
CCCAAGCTTCTATTATAACCATGTGAGG
AAGCTCTCCTT 
HindIII Vanderbilt 
YAP_V10F 
pOPINF/TBD-> 
AAGTTCTGTTTCAGGGCCCGGTCGGAC
ACCAGATTGTTCACGTT 
N/A-LIC pOPIN-F/J 
YAP_Q67R 
pOPINF/TBD<- 
ATGGTCTAGAAAGCTTTATTGTCTGGAA
TGGGACTTGGGCTC 
N/A-LIC pOPIN-F/J 
YAP_G100R 
pOPINF/TBD<- 
ATGGTCTAGAAAGCTTTAGCCACCCGA
AACGGCGCC 
N/A-LIC pOPIN-F/J 
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YAP plasmids: 
YAP (10-65): pSV281, pBG101  (minimal TBD) 
YAP (10-94): pSV281, pBG101  (TBD) 
YAP (1-109): pSV281/282, pBG101 (TBD) 
YAP (1-100): pOPIN-F/-J   (TBD) 
YAP (10-67): pOPIN-F/-J   (minimal TBD) 
YAP (1-168): pSV281, pBG100   (TBD-WW1) 
YAP (1-234): pSV281, pBG100  (TBD-WW1-WW2) 
YAP (105-168): pSV281, pBG101 (long WW1 with unstructured termini) 
YAP (119-162): pSV281, pBG101 (WW1) 
YAP (124-162): pSV281, pBG101 (short, partially unfolded WW1) 
YAP (105-234): pSV281, pBG101 (long WW1-long WW2) 
YAP (119-222): pSV281, pBG101 (WW1-WW2) 
YAP (124-222): pSV281, pBG101 (short WW1-WW2) 
YAP (171-234): pSV281, pBG100/101 (long WW2) 
YAP (182-222): pSV281, pBG101 (WW2) 
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I-c TAZ constructs 
Table 7.5 TAZ primers 
Primer name/ 
region 
Primer Restriction 
site 
Vectors 
TAZ 3F/ pre-N-
terminal -> 
TGGAGATTTGCTTCGACTCTG Blunt pBluescript 
SK- 
TAZ 4F/ N-
terminal -> 
GACTCTGACTTCTGGCGACAT Blunt pBluescript 
SK- 
TAZ1 innerR/ 
C-terminal <- 
GGTGAGCAGATTGTCCCTGT Blunt pBluescript 
SK- 
TAZ 3R/ post-
C-terminal <- 
GCCTATAGCCAGGTGAGCAG Blunt pBluescript 
SK- 
TAZ G7f/ TBD 
-> 
CGGAATTCCGGACGGCAGGTCGTGCAC EcoRI Vanderbilt 
TAZ A103f/ 
WW1 -> 
CGGAATTCCGCGACATCGATCATACCTG
A 
EcoRI Vanderbilt 
TAZ N177f/ 
WW2 -> 
CGGAATTCCAACCCGGAGTCAGGTCCA
C 
EcoRI Vanderbilt 
TAZ L147r/ 
WW1 <- 
CCCAAGCTTCTATTAGAGCTGCGAGAGA
CGAGG 
HindIII Vanderbilt 
TAZ M218r/ 
WW2 <- 
CCCAAGCTTCTATTACATTTTCTGAGCT
AGACGCG 
HindIII Vanderbilt 
TAZ_R5f_pOPI
N/ TBD -> 
AAGTTCTGTTTCAGGGCCCGCGGAGCGG
ACGGCAGGTC 
N/A-LIC pOPIN-F/J 
TAZ_R63r_pO
PIN/ TBD <- 
ATGGTCTAGAAAGCTTTATCTAGAGTGT
CCGCGGGGCTC 
N/A-LIC pOPIN-F/J 
TAZ_T96r_pO
PIN/ TBD <- 
ATGGTCTAGAAAGCTTTAGGTGGAGAG
GGAGTTGACGGG 
N/A-LIC pOPIN-F/J 
 
TAZ plasmids: 
TAZ (5-63): pOPIN-F/-J    (minimal TBD) 
TAZ (5-96): pOPIN-F/-J    (TBD) 
TAZ (7-147): pSV281, pBG100/101  (TBD-WW1) 
TAZ (7-218): pSV281, pBG100/101  (TBD-WW1-WW2) 
TAZ (103-147): pSV281, pBG100/101  (WW1) 
TAZ (103-218): pSV281, pBG100/101  (WW1-WW2) 
TAZ (177-218): pSV281, pBG100/101  (WW2) 
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I-d Sav constructs 
Table 7.6 Sav primers 
Primer name/ 
region 
Primer Restriction 
site 
Vectors 
DrosSav_E421f/ 
WW1 ->  
CGGGATCCGAGGAGCTGCCTCTGCCG BamHI Vanderbilt 
DrosSav_L455f/ 
WW2 -> 
CGGGATCCTTGGAGCGCGAAGGTCTG BamHI Vanderbilt 
DrosSav_R457r/ 
WW1 <- 
GGAATTCTTATTAGCGCTCCAACGGAT
GATTC 
EcoRI Vanderbilt 
DrosSav_P489r/ 
WW2 <- 
GGAATTCCTATTATGGATGCTGACGTTG
GCTC 
EcoRI Vanderbilt 
DrosSav_Q608r/ 
SARAH <- 
GGAATTCCTATCACTGGTTTTGGTTCTG
GTTC 
EcoRI Vanderbilt 
hWW45_E197f/ 
WW1 -> 
CGGGATCCGAAGATTTACCCCTTCCTCC BamHI Vanderbilt 
hWW45_P265r/ 
WW2 <- 
GGAATTCCTATTAGGGATGCCTGTATTG
GGC 
EcoRI Vanderbilt 
hWW45_G380r/ 
SARAH <-  
GGAATTCCTATCATCCATGTTGTTGGGC
ATACC 
EcoRI Vanderbilt 
 
Drosophila Sav plasmids: 
dSav WW1: pSV281, pBG101   (E421-R457) 
dSav WW1-WW2: pSV281, pBG101  (E421-P489)  
dSav WW1–WW2–SARAH: pSV281, pBG101 (E421-Q608) 
dSav WW2: pSV281, pBG101    (L455-P489) 
dSav WW2-SARAH: pSV281, pBG101  (L455-Q608) 
 
Human Sav1 (WW45) plasmids: 
hSav WW1-WW2: pSV281, pBG101  (E197-P265) 
hSav WW1-WW2-SARAH: pSV281, pBG101 (E197-G380) 
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I-e Kibra constructs 
Table 7.7 Kibra primers 
Primer name/ 
region 
Primer Restriction 
site 
Vectors 
Kibra_E5f/ 
WW1 -> 
CGGAATTCCGAGCTGCCCCTGCCGGA EcoRI Vanderbilt 
Kibra_A48f/ 
WW2 -> 
CGGAATTCCGCTGACTGCATTAGTGATG
A 
EcoRI Vanderbilt 
Kibra_K43r/ 
WW1 <- 
CCCAAGCTTCTATTATTTGGTGTACCTGT
CCCG 
HindIII Vanderbilt 
Kibra_Q87r/ 
WW2 <- 
CCCAAGCTTCTATTATTGTACTCGAGGAT
CCTCAAT 
HindIII Vanderbilt 
Kibra_K97r/ 
WW2(l) <- 
CCCAAGCTTCTATTACTTCAGCATATGTT
CCTGCT 
HindIII Vanderbilt 
 
Kibra plasmids: 
Kibra (5-87): pSV281, pBG101   (WW1-WW2) 
Kibra (5-97): pSV281, pBG101   (WW1-WW2 long) 
Kibra WW1+WW2 WT: pGEX42  (from J. Kremerskothen) 
Kibra WW1(P37A)+WW2(P84A): pGEX42 (from J. Kremerskothen) 
Kibra WW1(P37A)+WW2: pGEX42  (from J. Kremerskothen) 
Kibra WW1 WT: pGEX-2TK-KG  (from J. Kremerskothen) 
Kibra WW1(P37A): pGEX-2TK-KG  (from J. Kremerskothen) 
Kibra WW2 WT: pGEX-2TK-KG  (from J. Kremerskothen) 
Kibra WW2(P84A): pGEX-2TK-KG  (from J. Kremerskothen) 
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I-f Vanderbilt vectors  
The Vanderbilt vector maps for pSV281, pBG100, and pBG101 used during this 
project are shown below. 
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I-g pOPIN vectors 
Details of pOPIN vectors used for ligation independent cloning are shown below. 
The vectors used in Chapter 3 have been highlighted with a red asterisk. 
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Appendix II: DNA sequencing results and protein sequences 
Only the longest sequenced constructs for each protein are included here. All shorter 
constructs were sequenced successfully and encompass shorter sections of the 
sequences shown below. Grey sequences represent a His-tag. Rare codon analysis was 
carried out using the UCLA Rare codon calculator (RaCC) for TEAD proteins (Tables 
7.8-7.10) due to difficulties in protein expression and purification.  
 
II-a Medaka TEAD1 full-length sequences 
TEAD1_1-2fl (TEAD1_1-1fl lacks the DBDα4 and the penultimate K residue): 
atggagaggatgagtgattcagcagacaagcctgtggacaatgatgctgaaggggtgtgg 
 M  E  R  M  S  D  S  A  D  K  P  V  D  N  D  A  E  G  V  W  
agccccgacattgaacaaagctttcaagaagctctggccatctaccctccatgtggtcga 
 S  P  D  I  E  Q  S  F  Q  E  A  L  A  I  Y  P  P  C  G  R  
aggaagatcatcctttctgatgagggaaagatgtatggtcgaaatgaactgatagccaga 
 R  K  I  I  L  S  D  E  G  K  M  Y  G  R  N  E  L  I  A  R  
tacatcaagctccgtaccggaaagacgaggacccggaagcaggtgtctagtcacatacag 
 Y  I  K  L  R  T  G  K  T  R  T  R  K  Q  V  S  S  H  I  Q  
gtcttagcaagaaagaaagttcgagaaatccaagctgccattaaggtgtctagtcacatt 
 V  L  A  R  K  K  V  R  E  I  Q  A  A  I  K  V  S  S  H  I  
caggttcttgccagaagaaaatctcgtgagtttcattccaagctaaaggttacaagtatg 
 Q  V  L  A  R  R  K  S  R  E  F  H  S  K  L  K  V  T  S  M  
gaccaagctgtgaaagacaaagccctccagagcatggcctccatgtcctcggctcagatc 
 D  Q  A  V  K  D  K  A  L  Q  S  M  A  S  M  S  S  A  Q  I  
gtctctgccacggcgattcacaataagctgggtctgccgggcatccctcgtccagccttt 
 V  S  A  T  A  I  H  N  K  L  G  L  P  G  I  P  R  P  A  F  
cctggagcagggttatggcagggtatgatatcagctggtcaaccaggatcctcacaagac 
 P  G  A  G  L  W  Q  G  M  I  S  A  G  Q  P  G  S  S  Q  D  
attaagcctttcacccagcaaccctatcccatccagccagcagtcacaacaaccatttca 
 I  K  P  F  T  Q  Q  P  Y  P  I  Q  P  A  V  T  T  T  I  S  
agttatgatccctcagcggctccgacacccacagcaccagcatggcagggccgctccatc 
 S  Y  D  P  S  A  A  P  T  P  T  A  P  A  W  Q  G  R  S  I  
ggtacttctaaactccggctggtggagttctccgccttcttggaacaacagagagaccca 
 G  T  S  K  L  R  L  V  E  F  S  A  F  L  E  Q  Q  R  D  P  
gactcttaccataagcatctgtttgtacatattggacagataaatcattcctacagtgac 
 D  S  Y  H  K  H  L  F  V  H  I  G  Q  I  N  H  S  Y  S  D  
gccctgctggagtcagtggacattcgtcagatttatgacaaattccctgaaaagaaaggg 
 A  L  L  E  S  V  D  I  R  Q  I  Y  D  K  F  P  E  K  K  G  
ggcctgaaagagctttatggaagaggaccccagaactccttcttcctcatcaaattctgg 
 G  L  K  E  L  Y  G  R  G  P  Q  N  S  F  F  L  I  K  F  W  
gctgacttgaactgcaatattcaggatgagaccggatctttctacagagtcaccagtcag 
 A  D  L  N  C  N  I  Q  D  E  T  G  S  F  Y  R  V  T  S  Q  
tatgaaagttcagagaacatgaccattacatgctcaacaaaggtctgctcctttggcaaa 
 Y  E  S  S  E  N  M  T  I  T  C  S  T  K  V  C  S  F  G  K  
caagtggtggagaaggttgagacggaatatgctcgctttgagaacggacgattcgtctac 
 Q  V  V  E  K  V  E  T  E  Y  A  R  F  E  N  G  R  F  V  Y  
cggataagtcggtctccgatgtgtgaatacatgatcaacttcatccacaagcttaagcat 
 R  I  S  R  S  P  M  C  E  Y  M  I  N  F  I  H  K  L  K  H  
ctgcccgagaaatacatgatgaacagcgtgctggagaacttcaccatcttattggtggta 
 L  P  E  K  Y  M  M  N  S  V  L  E  N  F  T  I  L  L  V  V  
acaaacagggacacccaggagacgctgctgtgcatggcgtgtgtgtttgaagtctcaaac 
 T  N  R  D  T  Q  E  T  L  L  C  M  A  C  V  F  E  V  S  N  
agtgagcacggggcccagcatcatatctacagactggttaaagaatga 
 S  E  H  G  A  Q  H  H  I  Y  R  L  V  K  E  -   
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Table 7.8 Rare codon analysis of TEAD1  (RaCC) 
Rare codons Rare codon positions (rare codon doublets are highlighted) 
Arg: agg/aga/cga 3, 40, 41, 54, 60, 70, 84, 88, 105, 106, 238, 288, 316, 357, 
403, 431 
Leu: cta 115 
Ile: ata 58, 79, 170, 254, 362 
Pro: ccc 22, 188, 190, 204, 210, 290, 382 
 
II-b Medaka TEAD2/3 full-length sequences 
TEAD 3-1a fl: 
atggatggggacgcagagggggtttggagcccagatatcgagcagagcttccaggaggcc 
 M  D  G  D  A  E  G  V  W  S  P  D  I  E  Q  S  F  Q  E  A  
cttgccatctaccctccatgtggtaggaggaaaatcatactgtccgacgagggaaagatg 
 L  A  I  Y  P  P  C  G  R  R  K  I  I  L  S  D  E  G  K  M  
tacggtcgtaatgaactgattgcaagatatatcaagctgaggacaggcaaaacccgcaca 
 Y  G  R  N  E  L  I  A  R  Y  I  K  L  R  T  G  K  T  R  T  
agaaagcaggtgtctagtcacatacaggtgttagcacggaagaaagtgcgtgaataccag 
 R  K  Q  V  S  S  H  I  Q  V  L  A  R  K  K  V  R  E  Y  Q  
gcgggcataaaggtttctagccacttgcaggttctcgcccggagaaaatctcgcgagatc 
 A  G  I  K  V  S  S  H  L  Q  V  L  A  R  R  K  S  R  E  I  
cagtcaaagctaaaggcaatgaatttggatcaggcatccaaagacaaagctctacagaac 
 Q  S  K  L  K  A  M  N  L  D  Q  A  S  K  D  K  A  L  Q  N  
atggcagcgctgtcgtctgctcaaatcgtctccccgagtatgataaagaatcatcttcca 
 M  A  A  L  S  S  A  Q  I  V  S  P  S  M  I  K  N  H  L  P  
ccaatgtctccagccccatatcagcctcccagattctggcctggtccaatctctgtgcag 
 P  M  S  P  A  P  Y  Q  P  P  R  F  W  P  G  P  I  S  V  Q  
cctggaccctctcaggacataaaaccatttgtacagcccccataccaaagccttcaaggc 
 P  G  P  S  Q  D  I  K  P  F  V  Q  P  P  Y  Q  S  L  Q  G  
cccgtacaaccagctataccagcctatgagcctttagcgcctcctccggcaccaacagcc 
 P  V  Q  P  A  I  P  A  Y  E  P  L  A  P  P  P  A  P  T  A  
accgcagttccagtatggcaggatcgaacgattgcttcctccaagctgcggatgttggag 
 T  A  V  P  V  W  Q  D  R  T  I  A  S  S  K  L  R  M  L  E  
tactctgcctttatggaggtccagagagaccccgacaactacagcaaacacttgtttgtc 
 Y  S  A  F  M  E  V  Q  R  D  P  D  N  Y  S  K  H  L  F  V  
cacattggacagacgaatccctcatacagtgatccactccttgaagctgtggacatccgg 
 H  I  G  Q  T  N  P  S  Y  S  D  P  L  L  E  A  V  D  I  R  
cagatttacgacaagttccctgagaagaaaggaggcctaaaagagctttatgagaaaggc 
 Q  I  Y  D  K  F  P  E  K  K  G  G  L  K  E  L  Y  E  K  G  
ccccagaatgctttcttcttagtaaagttctgggctgacctgaacagcagcgggatgcca 
 P  Q  N  A  F  F  L  V  K  F  W  A  D  L  N  S  S  G  M  P  
gatgggcccggctcattctacggggtcagcagccagtacagcagcgccgaaaatatgaca 
 D  G  P  G  S  F  Y  G  V  S  S  Q  Y  S  S  A  E  N  M  T  
atcactgtttccaccaaggtgtgctcctttggcaagcaggttgtcgagaaagttgagaca 
 I  T  V  S  T  K  V  C  S  F  G  K  Q  V  V  E  K  V  E  T  
gagtacgcccggctggagggaggaaagtgcgtttacaggatccaccgctcgccaatgtgc 
 E  Y  A  R  L  E  G  G  K  C  V  Y  R  I  H  R  S  P  M  C  
gagtacatgatcaactttatccacaagctcaaacacctgccggaaaaatacatgatgaac 
 E  Y  M  I  N  F  I  H  K  L  K  H  L  P  E  K  Y  M  M  N  
agtgttctggaaaactttacaattctacaggtggtgacaaatcgcgacacccaggagacc 
 S  V  L  E  N  F  T  I  L  Q  V  V  T  N  R  D  T  Q  E  T  
ttgctttgtatagcatttgtgtttgaggtttccaatagtgagcacggagctcaatatcac 
 L  L  C  I  A  F  V  F  E  V  S  N  S  E  H  G  A  Q  Y  H  
gtctacagacttgttaaagactaa 
 V  Y  R  L  V  K  D  - 
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Table 7.9 Rare codon analysis of TEAD2/3  (RaCC) 
Rare codons Rare codon positions (rare codon doublets are highlighted) 
Arg: agg/aga/cga 29, 30, 49, 54, 61, 95, 151, 209, 229, 353, 423 
Leu: cta 104, 118, 273, 389 
Ile: ata 33, 68, 83, 135, 167, 186, 404 
Pro: ccc 150, 163, 173, 181, 231, 247, 281, 303 
 
II-c Medaka TEAD4 full-length sequences 
TEAD4-1fl (a start codon could not be identified for medaka TEAD4) 
aagcttgatcatcgtcccaccacgtctgcggagtgggtgccggctccctcccccaggggt 
 K  L  D  H  R  P  T  T  S  A  E  W  V  P  A  P  S  P  R  G  
gggagtgaggagctgggggatggacttgacaaacccctggagaacgatgcagagggtgtg 
 G  S  E  E  L  G  D  G  L  D  K  P  L  E  N  D  A  E  G  V  
tggagccctgacattgagcagagttttcaggaggctctggccatctatccaccctgcggc 
 W  S  P  D  I  E  Q  S  F  Q  E  A  L  A  I  Y  P  P  C  G  
cgccgcaagatcatcctctctgatgagggcaagatgtacggacggaatgagctgattgca 
 R  R  K  I  I  L  S  D  E  G  K  M  Y  G  R  N  E  L  I  A  
cggtacatcaaacttcgtacggggaagacacgaaccaggaagcaggtatctagtcatatc 
 R  Y  I  K  L  R  T  G  K  T  R  T  R  K  Q  V  S  S  H  I  
caggtccttgcccggcgtaaggcccgggagatccaggtgaagctgaaggaccaagctgcc 
 Q  V  L  A  R  R  K  A  R  E  I  Q  V  K  L  K  D  Q  A  A  
aaggacaaggctctccagagtatggccaccatgtcctcagcccagatcatctcccccaca 
 K  D  K  A  L  Q  S  M  A  T  M  S  S  A  Q  I  I  S  P  T  
gccttccagaacaagatgactctccagggcctctctagaccggtttaccccactgctggt 
 A  F  Q  N  K  M  T  L  Q  G  L  S  R  P  V  Y  P  T  A  G  
gggttctggcatggggctcttcccggacagccaggaagccatgaagacattaagcccttc 
 G  F  W  H  G  A  L  P  G  Q  P  G  S  H  E  D  I  K  P  F  
tcccaccagagttatgctatgcaagcgactggcccggccccaatagcaggctatgaaagt 
 S  H  Q  S  Y  A  M  Q  A  T  G  P  A  P  I  A  G  Y  E  S  
acagcagggctgtccatgtctcctggtgcccccccttggcaaggtagaagtattgccagc 
 T  A  G  L  S  M  S  P  G  A  P  P  W  Q  G  R  S  I  A  S  
tccaagctgcgaatgctggagttctccgccttcttggagcaacctcaagacccagagact 
 S  K  L  R  M  L  E  F  S  A  F  L  E  Q  P  Q  D  P  E  T  
ttcaacaagcacttatttgttcacatcggacagtccaacccgacctacagcgacccctat 
 F  N  K  H  L  F  V  H  I  G  Q  S  N  P  T  Y  S  D  P  Y  
ctggagtcggtggacatcaggcagatctatgacaaattccctgagaagaaagggggcctc 
 L  E  S  V  D  I  R  Q  I  Y  D  K  F  P  E  K  K  G  G  L  
aaggagcttttcgacaaagggccccacaatgctttctttcttgtcaagttttgggcggac 
 K  E  L  F  D  K  G  P  H  N  A  F  F  L  V  K  F  W  A  D  
ctgagtgtaaacctgcaagacgacagcaacttcttttatggcgtgtccagccagtatgag 
 L  S  V  N  L  Q  D  D  S  N  F  F  Y  G  V  S  S  Q  Y  E  
agctctgacaacatggttatcacctcatccaccaaagtgtgctcctttggcaaacaggtt 
 S  S  D  N  M  V  I  T  S  S  T  K  V  C  S  F  G  K  Q  V  
gttgagaaagtggagacggagtacgcgcgcttcgagaacgggcgctacgtgttccggatc 
 V  E  K  V  E  T  E  Y  A  R  F  E  N  G  R  Y  V  F  R  I  
cacagatccccgttgtgtgaatacatgatcaacttcattcacaagctgaagcatctgccg 
 H  R  S  P  L  C  E  Y  M  I  N  F  I  H  K  L  K  H  L  P  
gagaagtacatgatgaacagcgtactggaaaacttcaccatcctacaggtggtgactaac 
 E  K  Y  M  M  N  S  V  L  E  N  F  T  I  L  Q  V  V  T  N  
agggacacactggagaccctgctgtgcatagcatacgtcttcgaggtgtccaccagcgag 
 R  D  T  L  E  T  L  L  C  I  A  Y  V  F  E  V  S  T  S  E  
cacggcgcacagcaccatatttacaggctggtcaaagactga 
 H  G  A  Q  H  H  I  Y  R  L  V  K  D  -  
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Table 7.10 Rare codon analysis of TEAD4 (RaCC) 
Rare codons Rare codon positions  
Arg: agg/aga/cga 13, 85, 87, 147, 210, 218, 261, 356, 395, 423 
Leu: cta 389 
Ile: ata 189, 404 
Pro: ccc 10, 12, 26, 52, 133, 151, 162, 173, 205, 253, 282 
 
 
 
 
II-d Medaka YAP 1-234 (TBD-WW1-WW2) sequences 
atggatccgagccagcacaaccctcctgtcggacaccagatcgttcacgttcggggcgac 
 M  D  P  S  Q  H  N  P  P  V  G  H  Q  I  V  H  V  R  G  D  
tcggaaacggacctggaggcgcttttcaacgccgtgatgaacccaaagggcgccgtcgtg 
 S  E  T  D  L  E  A  L  F  N  A  V  M  N  P  K  G  A  V  V  
ccccagtccgtgcccatgaggatgaggaagctgccggactccttcttcaagcccccggag 
 P  Q  S  V  P  M  R  M  R  K  L  P  D  S  F  F  K  P  P  E  
cccaagtcccattccagacaagctagcactgatgctgggagtggcggcgtgctcaccccc 
 P  K  S  H  S  R  Q  A  S  T  D  A  G  S  G  G  V  L  T  P  
caccacgtacgcgcacactcgtctccagcttccctgcagctgggcgccgtttcgggtggc 
 H  H  V  R  A  H  S  S  P  A  S  L  Q  L  G  A  V  S  G  G  
tccctgtctgggatggcctcagcaggcgcctccccccaacatctccggcagtcgtcctac 
 S  L  S  G  M  A  S  A  G  A  S  P  Q  H  L  R  Q  S  S  Y  
gagattcccgacgacgtgcccctgccgccaggctgggagatggccaagaccagctccggc 
 E  I  P  D  D  V  P  L  P  P  G  W  E  M  A  K  T  S  S  G  
cagagatactttctcaaccacattgatcaaaccaccacttggcaggatccacgcaaagcc 
 Q  R  Y  F  L  N  H  I  D  Q  T  T  T  W  Q  D  P  R  K  A  
ctgctccagttgaaccaggctacccctcccagtaccgttccagttcagcagcagaacctt 
 L  L  Q  L  N  Q  A  T  P  P  S  T  V  P  V  Q  Q  Q  N  L  
ttaagcccagctagtggacctctacctgaaggctgggaacaagccataacaccagaggga 
 L  S  P  A  S  G  P  L  P  E  G  W  E  Q  A  I  T  P  E  G  
gaaatttactacattaaccacaagaacaagactacttcctggctagatcctcgacttgag 
 E  I  Y  Y  I  N  H  K  N  K  T  T  S  W  L  D  P  R  L  E  
actcgctatgcc 
 T  R  Y  A   
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II-e Medaka TAZ full-length sequences 
atggacgcgcaccggagcggacggcaggtcgtgcacgtccgcggggactcgcagaaggag 
 M  D  A  H  R  S  G  R  Q  V  V  H  V  R  G  D  S  Q  K  E  
ctggaggccctgttcagtagggtgatgaaccccagcgaggcgtccaggcagccgtcgtcg 
 L  E  A  L  F  S  R  V  M  N  P  S  E  A  S  R  Q  P  S  S  
gttccgatgaggatgaggaagctgcccgactccttcttcaagcccccggagccccgcgga 
 V  P  M  R  M  R  K  L  P  D  S  F  F  K  P  P  E  P  R  G  
cactctagacaagccagttcggatggaggcgtgtgtggttccctcactccccatcacagc 
 H  S  R  Q  A  S  S  D  G  G  V  C  G  S  L  T  P  H  H  S  
cggacggtttccgcccccgctgcgctccccgtcaactccctctccacccaagcagcagat 
 R  T  V  S  A  P  A  A  L  P  V  N  S  L  S  T  Q  A  A  D  
gtcgcggcgacatcgatcatacctgacgatgtgccactcccccctggttgggaaatggcc 
 V  A  A  T  S  I  I  P  D  D  V  P  L  P  P  G  W  E  M  A  
aaaactcccgctggccagcgatacttcctgaatcacctggataagacaaccacgtggctc 
 K  T  P  A  G  Q  R  Y  F  L  N  H  L  D  K  T  T  T  W  L  
gaccctcgtctctcgcagctccagtcggctcagcatcccatcgccaacgccccggtccat 
 D  P  R  L  S  Q  L  Q  S  A  Q  H  P  I  A  N  A  P  V  H  
tcccactccttcagcaaccctgcgcccaccacacaagcacaaagcgtcaacccggagtca 
 S  H  S  F  S  N  P  A  P  T  T  Q  A  Q  S  V  N  P  E  S  
ggtccactgcctgaaggctgggagcaggctgtgactccagagggagagatgtactacatc 
 G  P  L  P  E  G  W  E  Q  A  V  T  P  E  G  E  M  Y  Y  I  
gatcacataaataagaccaccacatgggtcgacccgcgtctagctcagaaaatgagccct 
 D  H  I  N  K  T  T  T  W  V  D  P  R  L  A  Q  K  M  S  P  
ggtgtcctcagcttggcaatgcaaaggcaggaaaagctcagatgcaagcaaggcgcgccc 
 G  V  L  S  L  A  M  Q  R  Q  E  K  L  R  C  K  Q  G  A  P  
ccacaagccacacaacaggagggagcaggaaggaaccaaatgtctgctggtttggaccac 
 P  Q  A  T  Q  Q  E  G  A  G  R  N  Q  M  S  A  G  L  D  H  
gacaggagcggtcaggtacttgtcccatcagtggatgccaggatccgagccccaaaccat 
 D  R  S  G  Q  V  L  V  P  S  V  D  A  R  I  R  A  P  N  H  
gaaactgcaatgaacggagctcactctcgcaatgagagcacggacagcggtctgagcgtc 
 E  T  A  M  N  G  A  H  S  R  N  E  S  T  D  S  G  L  S  V  
agcagcctgccgcgcacgaacgaccacatgctgagccctgtggatcacatggatactggt 
 S  S  L  P  R  T  N  D  H  M  L  S  P  V  D  H  M  D  T  G  
gaccccagtgaacccccatcgatggccctgcaggagccgatgctccccatgagtgaaggc 
 D  P  S  E  P  P  S  M  A  L  Q  E  P  M  L  P  M  S  E  G  
gaggagctgatgccctgcatccctgaaggtctgagctcagacctcctgatggatatggag 
 E  E  L  M  P  C  I  P  E  G  L  S  S  D  L  L  M  D  M  E  
actgttctctccggctcacacatggacagggacaatctgctcacctggctataggc 
 T  V  L  S  G  S  H  M  D  R  D  N  L  L  T  W  L  - 
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II-f Drosophila Sav (WW1-WW2-SARAH: pSV281) sequences 
atgggttcttctcaccatcaccatcaccatgaaaacctgtacttccagggatccgaggag 
 M  G  S  S  H  H  H  H  H  H  E  N  L  Y  F  Q  G  S  E  E  
ctgcctctgccgcccggctgggccactcagtacacgctacacggtcggaaatactatatt 
 L  P  L  P  P  G  W  A  T  Q  Y  T  L  H  G  R  K  Y  Y  I  
gatcacaatgcgcataccacgcactggaatcatccgttggagcgcgaaggtctgccggtg 
 D  H  N  A  H  T  T  H  W  N  H  P  L  E  R  E  G  L  P  V  
ggctggcggcgggtggtgtccaagatgcatggcacctactatgagaaccagtataccggg 
 G  W  R  R  V  V  S  K  M  H  G  T  Y  Y  E  N  Q  Y  T  G  
cagagccaacgtcagcatccatgcttgacctcctactatgtctacacgacgtctgcggag 
 Q  S  Q  R  Q  H  P  C  L  T  S  Y  Y  V  Y  T  T  S  A  E  
ccaccgaaagcgattcgaccagaggcgtcgctctatgccccacccacgcacactcacaat 
 P  P  K  A  I  R  P  E  A  S  L  Y  A  P  P  T  H  T  H  N  
gcactggtgccggccaatccctatctgctcgaggagatccccaagtggttggccgtctac 
 A  L  V  P  A  N  P  Y  L  L  E  E  I  P  K  W  L  A  V  Y  
tcggaggcggactcgtccaaggaccacctgctgcagttcaacatgtttagcctgccggag 
 S  E  A  D  S  S  K  D  H  L  L  Q  F  N  M  F  S  L  P  E  
ctggagggcttcgacagcatgctggtgcggctcttcaagcaggaactgggcaccatcgtg 
 L  E  G  F  D  S  M  L  V  R  L  F  K  Q  E  L  G  T  I  V  
ggcttctacgagcgctaccgtcgcgctttgatactcgagaagaatcgacgcgccggccag 
 G  F  Y  E  R  Y  R  R  A  L  I  L  E  K  N  R  R  A  G  Q  
aaccagaaccaaaaccagtga 
 N  Q  N  Q  N  Q  -   
 
 
 
II-g Human Sav (WW1-WW2-SARAH: pSV281) sequences 
atgggttcttctcaccatcaccatcaccatgaaaacctgtacttccagggatccgaagat 
 M  G  S  S  H  H  H  H  H  H  E  N  L  Y  F  Q  G  S  E  D  
ttaccccttcctcctggctggtctgtggactggacaatgagagggagaaaatattatata 
 L  P  L  P  P  G  W  S  V  D  W  T  M  R  G  R  K  Y  Y  I  
gatcataacacaaatacaactcactggagccatcctcttgagcgagaaggacttcctcct 
 D  H  N  T  N  T  T  H  W  S  H  P  L  E  R  E  G  L  P  P  
ggatgggaacgagttgagtcatccgaatttggaacctattatgtagatcacacaaataag 
 G  W  E  R  V  E  S  S  E  F  G  T  Y  Y  V  D  H  T  N  K  
aaggcccaatacaggcatccctgtgctcctagtgtacctcggtatgatcaaccacctcct 
 K  A  Q  Y  R  H  P  C  A  P  S  V  P  R  Y  D  Q  P  P  P  
gtcacataccagccacagcaaactgaaagaaatcagtcccttctggtacctgcaaatcca 
 V  T  Y  Q  P  Q  Q  T  E  R  N  Q  S  L  L  V  P  A  N  P  
tatcatactgcagaaattcctgactggcttcaggtttacgcacgagcccctgtgaaatat 
 Y  H  T  A  E  I  P  D  W  L  Q  V  Y  A  R  A  P  V  K  Y  
gaccacattctgaagtgggaactcttccagctggctgacctggatacataccagggaatg 
 D  H  I  L  K  W  E  L  F  Q  L  A  D  L  D  T  Y  Q  G  M  
ctaaagttgctcttcatgaaagaattggagcagattgttaaaatgtatgaagcatacaga 
 L  K  L  L  F  M  K  E  L  E  Q  I  V  K  M  Y  E  A  Y  R  
caagcccttcttacagagttggaaaaccgaaagcagagacagcagtggtatgcccaacaa 
 Q  A  L  L  T  E  L  E  N  R  K  Q  R  Q  Q  W  Y  A  Q  Q  
catggatga 
 H  G  -   
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II-h Human Kibra (WW1-WW2 long: pBG101) sequences 
caccatgaaaacctgtacttccagggatccccgaattccgagctgcccctgccggag 
 H  H  E  N  L  Y  F  Q  G  S  P  N  S  E  L  P  L  P  E  
ggctgggaggaggcgcgcgacttcgacggcaaggtctactacatagaccacacgaaccgc 
 G  W  E  E  A  R  D  F  D  G  K  V  Y  Y  I  D  H  T  N  R  
accaccagctggatcgacccgcgggacaggtacaccaaaccgctcacctttgctgactgc 
 T  T  S  W  I  D  P  R  D  R  Y  T  K  P  L  T  F  A  D  C  
attagtgatgagttgccgctaggatgggaagaggcatatgacccacaggttggagattac 
 I  S  D  E  L  P  L  G  W  E  E  A  Y  D  P  Q  V  G  D  Y  
ttcatagaccacaacaccaaaaccactcagattgaggatcctcgagtacaatggcggcgg 
 F  I  D  H  N  T  K  T  T  Q  I  E  D  P  R  V  Q  W  R  R  
gagcaggaacatatgctgaagtaa 
 E  Q  E  H  M  L  K  -   
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Appendix III: Buffers and solutions  
III-a 100 ml M9 Trace elements 
CaCl2.2H2O  550 mg 
MnSO4.H2O  140 mg 
CuSO4.5H2O  40 mg 
ZnSO4.7H2O  220 mg 
CoSO4.7H2O  45 mg 
Na2MoO4.2H2O  26 mg 
H3BO4   40 mg 
KI    26 mg 
 
-Add 70 ml distilled H2O and adjust to pH8 
-Add 500 mg EDTA and adjust to pH8 
-Add 375 mg FeSO4.7H2O 
Make up to 100 ml with distilled H2O and autoclave   
 
 
III-b 15% acrylamide gel for SDS-PAGE (8 gels) 
Resolving gel 
Tris base 1.5 M pH 8.8    12.5 ml 
H2O     18.5 ml 
40% 29:1 acrylamide/bis-acrylamide  18.7 ml 
10% APS      250 µl 
TEMED      22.5 µl 
-Pipette saturated butanol onto the liquid resolving gel and remove using filter paper 
(Whatman) before pouring the stacking gel. 	  
Stacking gel 
Tris  0.5 M pH6.8     3.125 ml 
H2O     8 ml 
40% 29:1 acrylamide/bis-acrylamide  1.25 ml 
10% APS      62.5 µl 
TEMED      12.5 µl 	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III-c 10 ml 2x SDS-PAGE sample buffer 
H2O   2.25 ml 
0.5 M Tris pH6.8   1.25 ml 
10% (w/v) SDS   3 ml 
50% (v/v) glycerol   2 ml 
2-mercaptoethanol   0.5 ml 
0.15% bromophenol blue  1 ml 
 
 
III-d 1 L 10x Glycine running buffer for SDS-PAGE 
Tris base   30.3 g 
Glycine   143.75 g 
SDS   10 g 
- Make up to 1 L with distilled H2O. The pH is not adjusted but should be around 
pH 8.3. 	  
 
III-e Coomassie Blue stain for acrylamide gels 
40% Methanol 
0.1% (w/v) Brilliant blue R250 
50% H2O 10% Acetic acid 
- Dissolve brilliant blue R250 in methanol before adding the H2O and acetic acid. 	  
III-f Destain for acrylamide gels 
25% Methanol 
65% H2O  
10% Acetic acid 	  
III-g Drying solution for acrylamide gels  
30% Methanol 
10% Glycerol 
50% H2O 
10% Acetic acid 	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III-h 1 L 50x TAE buffer for DNA electrophoresis 
Tris base   242 g 
Acetic acid   57.1 ml 
0.5 M EDTA  100 ml 
- EDTA solution must be adjusted to pH 8 to enhance the solubility of the EDTA 
powder.  
- Make up to 1 L with distilled H2O 
 	  
III-i Buffers for His-affinity purification 
His buffer A (wash buffer) – pH 8 
20 mM Tris base 
300 mM NaCl 
20 mM Imidazole 	  
His buffer B (elution buffer) – pH 8 
20 mM Tris base 
300 mM NaCl 
500 mM Imidazole 	  
